[go: up one dir, main page]

US20210002289A1 - Monofunctional intermediates for ligand-dependent target protein degradation - Google Patents

Monofunctional intermediates for ligand-dependent target protein degradation Download PDF

Info

Publication number
US20210002289A1
US20210002289A1 US17/007,191 US202017007191A US2021002289A1 US 20210002289 A1 US20210002289 A1 US 20210002289A1 US 202017007191 A US202017007191 A US 202017007191A US 2021002289 A1 US2021002289 A1 US 2021002289A1
Authority
US
United States
Prior art keywords
dione
oxoisoindolin
piperidine
amino
dioxopiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/007,191
Inventor
Yangbing Li
Angelo Aguilar
Bing Zhou
Jiantao Hu
Fuming Xu
Chong QIN
Yang Hu
Weiguo Xiang
Rohan Rej
Jiuling Yang
Xin Han
Longchuan Bai
Chao-Yie Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Priority to US17/007,191 priority Critical patent/US20210002289A1/en
Publication of US20210002289A1 publication Critical patent/US20210002289A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • the present disclosure provides compounds that are medically useful, e.g., as immunomodulators for the treatment of cancer, and/or synthetically useful as monofunctional intermediates for the preparation of small-molecule drug conjugates.
  • Coupling the monofunctional synthetic intermediates of this disclosure with an inhibitor of a target protein of interest e.g., an oncogenic protein inhibitor, e.g., a BET bromodomain inhibitor or MDM2 inhibitor, provides a heterobifunctional small-molecule that simultaneously binds the target protein and a ubiquitin ligase, enabling ubiquitination and degradation of the target protein.
  • Phthalimide-based drugs e.g., thalidomide or lenalidomide
  • protein-degradation machinery e.g., cereblon (CRBN; part of an ubiquitin E3 ligase complex). This may promote the recruitment of two transcription factors (IKZF1 and IKZF3) that are essential to disease progression, resulting in drug-induced ubiquitylation and degradation by the proteasome.
  • IKZF1 and IKZF3 two transcription factors
  • VHL ligand may recruit a target protein to an E3 ubiquitin ligase, resulting in drug induced ubiquitination and degradation.
  • Van Hagen et al. Nucleic Acids Research 38: 1922-1931 (2010); Buckley et al., J. Am. Chem. Soc. 134:4465-4468 (2012); Buckley et al., Angew, Chem. Int. Ed. Engl. 51:11463-11467 (2012); Lipkowitz and Weissman, Nat Rev Cancer 11:629-643 (2011); and Zengerle et al., ACS Chem. Biol. 10:1770-1777 (2015).
  • the present disclosure provides compounds having any one of Formulae I-VI, VIa, or VIb below, and the salts or solvates thereof, collectively referred to as “Compounds of the Disclosure.”
  • Compounds of the Disclosure comprise a ligand for an E3 ubiquitin ligase protein and thus can be used as an immunomodulatory drug to treat cancer, e.g., multiple myeloma, and other diseases responsive to inducing, enhancing, or suppressing an immune response, e.g., Crohn's disease, sarcoidosis, graft-versus-host disease, and rheumatoid arthritis, in a subject in need thereof.
  • the present disclosure provides Compounds of the Disclosure as monofunctional synthetic intermediates that can be used to prepare heterobifunctional protein degraders.
  • heterobifunctional protein degraders having any one of Formulae VII-IX or XI-XXXII, below, and the pharmaceutically acceptable salts or solvates thereof.
  • Heterobifunctional protein degraders comprise a target protein inhibitor, a linker, and a ligand for an E3 ubiquitin ligase protein.
  • Compounds of the Disclosure are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare heterobifunctional protein degraders.
  • Compounds of the Disclosure are compounds represented by Formula I:
  • X is selected from the group consisting of —C ⁇ C—, —O—, —N(R 2a )—, —OC( ⁇ O)—,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n —, and —(CH 2 ) r —W—(CH 2 ) u —O—(CH 2 ) v —;
  • A is absent
  • A is heteroarylenyl
  • W is selected from the group consisting of phenylenyl, heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • r 0, 1, 2 or 3;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C ⁇ C—, —CH ⁇ CH—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • B is a monovalent radical of a ligand for an E3 ubiquitin ligase protein.
  • Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein:
  • X is selected from the group consisting of —C ⁇ C—, —O—, —N(R 2a )—,
  • Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein X is selected from the group consisting of —C ⁇ C—, —O—, —N(R 2a )—,
  • Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein X is —OC( ⁇ O)—, wherein the —C( ⁇ O)— of —OC( ⁇ O)— is attached to L.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • B is selected from the group consisting of:
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • G is selected from the group consisting of —C(R 16d ) ⁇ and —N ⁇ ;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16d is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a, B-1b, B-1c, or B-1d, and R 5 is partially or entirely enriched with an isotope of hydrogen, e.g., R 5 is about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% deuterium.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein
  • B is selected from the group consisting of:
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds having Formula I that are not any one of the compounds of Table 6, or any stereoisomer thereof.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein X is —C ⁇ C—.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein X is —N(H)—.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein X is —OC( ⁇ O)—.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein X is
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is C 1-12 alkylenyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 (CH 2 ) 2 CH 2 —, —CH 2 (CH 2 ) 3 CH 2 —, —CH 2 (CH 2 ) 4 CH 2 —, —CH 2 (CH 2 ) 5 CH 2 —, and —CH 2 (CH 2 ) 6 CH 2 —.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is 3- to 12-membered heteroalkylenyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • L is —(CH 2 ) o O—(CH 2 CH 2 O) p —(CH 2 ) q —;
  • o 1, 2, or 3;
  • p 0, 1, 2, 3, 4, or 5;
  • q is 1, 2, or 3.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and A is absent.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is phenylenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is 5-membered heteroarylenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of —O—, —S—, and —N(R 6 )—;
  • R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is 6-membered heteroarylenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is heterocyclenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is cycloalkylenyl. In another embodiment, m is 0.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • L is -A-(CH 2 ) m —W—(CH 2 ) n —;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is phenylenyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is 5-membered heteroarylenyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of —O—, —S—, and —N(R 6 )—;
  • R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is 6-membered heteroarylenyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is heterocyclenyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is cycloalkylenyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and A is a 5-membered heteroarylenyl.
  • A is a 5-membered heteroarylenyl selected from the group consisting of:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and A is a 6-membered heteroarylenyl.
  • A is:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • L is —(CH 2 ) r —W—(CH 2 ) u —O—(CH 2 ) v —;
  • r 0, 1, or 2;
  • u is 1, 2, or 3;
  • v 1, 2, or 3.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is —(CH 2 ) r —W—(CH 2 ) u —O—(CH 2 ) v — and W is selected from the group consisting of phenylenyl and heteroarylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein Y is selected from the group consisting of —C ⁇ C—, —CH ⁇ CH—, —CH 2 —, —O—, and —N(R 2c )—.
  • Y is —C ⁇ C—.
  • Y is —CH 2 —.
  • Y is —O—.
  • Y is —N(H)—. In another embodiment, Y is —CH ⁇ CH—.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • B is B-1a
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen and halo.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • B is B-1a
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • R 16b is selected from the group consisting of hydrogen and halo.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16c is selected from the group consisting of hydrogen and halo.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a and Z is —CH 2 —.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a and Z is —C( ⁇ O)—.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a and R 5 is hydrogen.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-2.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B-3.
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is:
  • Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein embodiment, B is:
  • Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein:
  • B is selected from the group consisting of:
  • X is selected from the group consisting of —N(R 2a )—,
  • X is absent
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH 2 ) m —W—(CH 2 ) n —;
  • W is selected from the group consisting of optionally substituted phenylenyl, optionally substituted 5-membered heteroarylenyl, and optionally substituted 6-membered heteroarylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C ⁇ C—, —CH ⁇ CH—, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein B is B-2a
  • Compounds of the Disclosure are compounds represented by Formula II:
  • R 5 is hydrogen.
  • Z is —CH 2 —.
  • Z is —C( ⁇ O)—.
  • Y is selected from the group consisting of —C ⁇ C—, —O—, —N(H)—, —C( ⁇ O)N(H)—, —N(H)C( ⁇ O)CH 2 O—, and —N(H)C( ⁇ O)CH 2 N(H)—.
  • Y is selected from the group consisting of —C ⁇ C—, —CH ⁇ CH—, —O—, and —N(H)—. In another embodiment, Y is absent. In another embodiment, Y is —C ⁇ C—.
  • Compounds of the Disclosure are compounds represented by Formula III:
  • Compounds of the Disclosure are compounds represented by Formula IIIa:
  • Compounds of the Disclosure are compounds represented by Formula IV:
  • Y is selected from the group consisting of —C ⁇ C—, —CH ⁇ CH—, —O—, —N(H)—, —C( ⁇ O)N(H)—, —N(H)C( ⁇ O)CH 2 O—, and —N(H)C( ⁇ O)CH 2 N(H)—.
  • Y is selected from the group consisting of —C ⁇ C—, —O—, and —N(H)—.
  • Y is absent.
  • Y is —C ⁇ C—.
  • Compounds of the Disclosure are compounds represented by Formula V:
  • B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n — and —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C ⁇ C—, —CH ⁇ CH—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds represented by Formula VI:
  • B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n — and —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C ⁇ C—, —CH ⁇ CH—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds represented by Formula VIa:
  • B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n — and —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —; or
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C ⁇ C—, —CH ⁇ CH—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds represented by Formula VIb:
  • X is selected from the group consisting of —C ⁇ C—, —O—, and —N(R 2a )—:
  • R 2a is selected from the group consisting of hydrogen and C 1-4 alkyl
  • B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n — and —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds represented by any one of Formulae I-IV, and the pharmaceutically acceptable salts or solvates
  • X is selected from the group consisting of —N(H)—,
  • Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is C 1-12 alkylenyl.
  • L is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 (CH 2 ) 2 CH 2 —, —CH 2 (CH 2 ) 3 CH 2 —, —CH 2 (CH 2 ) 4 CH 2 —, —CH 2 (CH 2 ) 5 CH 2 —, and —CH 2 (CH 2 ) 6 CH 2 —.
  • Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is 3- to 20-membered heteroalkylenyl.
  • L is selected from the group consisting of —(CH 2 ) o O—(CH 2 CH 2 O) p —(CH 2 ) q — and —(CH 2 ) r O—(CH 2 ) s —O(CH 2 ) t —; wherein o is 2 or 3; p is 0, 1, 2, 3, 4, 5, 6, or 7; q is 2 or 3;
  • Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is —(CH 2 ) m —W—(CH 2 ) n —.
  • W is phenylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or
  • Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of —O—, —S—, and —N(R 6 )—;
  • R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Compounds of the Disclosure are any one or more of the compounds of Table 1, and salts and solvates thereof.
  • Compounds of the Disclosure are any one or more of the compounds of Table 2, and salts and solvates thereof.
  • Compounds of the Disclosure are any one or more of the compounds of Table 3, and salts and solvents thereof.
  • Compounds of the Disclosure are any one or more of the compounds of Table 4, and salts and solvates thereof.
  • Compounds of the Disclosure are any one or more of the compounds of Table 5, and salts and solvates thereof.
  • the disclosure provides a method of preparing a compound having Formula IX:
  • T is a monovalent radical of a target protein inhibitor
  • X, L, Y, and B are as defined in connection with Formula I.
  • the disclosure provides a method of preparing a compound having Formula IX:
  • T is a monovalent radical of a target protein inhibitor
  • X, L, Y, and B are as defined in connection with Formula I, the method comprising condensing a compound having Formula I, with compound having Formula X:
  • T is a monovalent radical of a target protein inhibitor
  • X 3 is selected from the group consisting of —C( ⁇ O)OH and -LG;
  • LG is a leaving group, e.g., —Cl, —Br, —I, —OTs, —OMs.
  • the disclosure provides a method of preparing a compound having Formula IX, and the pharmaceutically acceptable salts or solvates thereof, comprising:
  • B is selected from the group consisting of:
  • X is selected from the group consisting of —C ⁇ C—, —O—, —N(R 2a )—,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n —, and —(CH 2 ) r —W—(CH 2 ) u —O—(CH 2 ) v —;
  • A is absent
  • A is heteroarylenyl
  • W is selected from the group consisting of phenylenyl, heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • r 0, 1, 2 or 3;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • B is selected from the group consisting of:
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl, with compound having Formula X:
  • T is a monovalent radical of a target protein inhibitor
  • X 3 is selected from the group consisting of —C( ⁇ O)OH and -LG;
  • LG is a leaving group, e.g., —Cl, —Br, —I, —OTs, —OMs,
  • the disclosure provides a method of preparing a compound having Formula IX, and the pharmaceutically acceptable salts or solvates thereof, wherein the compound having Formula I are not any one of the compounds of Table 6, or any stereoisomer thereof.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein X is —C ⁇ C—.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein X is —N(H)—.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein X is
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is C 1-12 alkylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 (CH 2 ) 2 CH 2 —, —CH 2 (CH 2 ) 3 CH 2 —, —CH 2 (CH 2 ) 4 CH 2 —, —CH 2 (CH 2 ) 5 CH 2 —, and —CH 2 (CH 2 ) 6 CH 2 —.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is 3- to 12-membered heteroalkylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is —(CH 2 ) o O—(CH 2 CH 2 O) p —(CH 2 ) q —;
  • o 1, 2, or 3;
  • p 0, 1, 2, 3, 4, or 5;
  • q is 1, 2, or 3.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and A is absent.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is phenylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is 5-membered heteroarylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of —O—, —S—, and —N(R 6 )—;
  • R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is 6-membered heteroarylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is heterocyclenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n —, A is absent, and W is cycloalkylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is -A-(CH 2 ) m —W—(CH 2 ) n —;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is phenylenyl.
  • the disclosure provides a method of preparing a compound having Formula XX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is 5-membered heteroarylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of —O—, —S—, and —N(R 6 )—;
  • R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is 6-membered heternarylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is heterocyclenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and W is cycloalkylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and A is a 5-membered heteroarylenyl.
  • A is a 5-membered heteroarylenyl selected from the group consisting of:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH 2 ) m —W—(CH 2 ) n — and A is a 6-membered heteroarylenyl.
  • A is:
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is —(CH 2 ) r —W—(CH 2 ) u —O—(CH 2 ) v —;
  • r 0, 1, or 2;
  • u is 1, 2, or 3;
  • v 1, 2, or 3.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is —(CH 2 ) r —W—(CH 2 ) u —O—(CH 2 ) v — and W is selected from the group consisting of phenylenyl and heteroarylenyl. In another embodiment, W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein Y is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, and —N(R 2c )—.
  • Y is —C ⁇ C—.
  • Y is —CH 2 —.
  • Y is —O—.
  • Y is —N(H)—.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-1a.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen and halo.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • B is B-1a
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • R 16b is selected from the group consisting of hydrogen and halo.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16c is selected from the group consisting of hydrogen and halo.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-1a and Z is —CH 2 —.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-1a and Z is —C( ⁇ O)—.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-1a and R 5 is hydrogen.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-2.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B-3.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein T is a monovalent radical of an oncogenic protein inhibitor.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein T is a monovalent radical of a MDM2 protein inhibitor.
  • the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein T is a monovalent radical of a BET bromodomain protein inhibitor.
  • the disclosure provides methods of making a compound having Formula VII:
  • T is selected from the group consisting of:
  • X is selected from the group consisting of —N(R 2a )—,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH 2 ) m —W—(CH 2 ) n —;
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C ⁇ C—, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro, the method comprising:
  • R 7 is a leaving group, e.g., R 7 is selected from the group consisting of —Cl and —OH,
  • X is selected from the group consisting of —N(R 2a )—,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH 2 ) m —W—(CH 2 ) n —;
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C ⁇ C—, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 — and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen and fluoro
  • the disclosure provides methods of making a compound having Formula VII, or a pharmaceutically acceptable salt or solvate thereof, the method comprising:
  • R 11a , R 11b , R 11c , and R 11d are independently selected from the group consisting of hydrogen, chloro, and fluoro;
  • R 12a and R 12b are independently selected from the group consisting of hydrogen and C 1-6 alkyl; or
  • R 12a and R 12b taken together with the carbon atom to which they are attached form a 4- to 8-membered optionally substituted cycloalkyl
  • Q is selected from the group consisting of substituted phenylenyl, optionally substituted heteroarylenyl, and optionally substituted cycloalkylenyl,
  • the disclosure provides methods of making a compound having Formula VIII:
  • T is selected from the group consisting of:
  • X is selected from the group consisting of —N(R 2a )—,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH 2 ) m —W—(CH 2 ) n —;
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • R 7 is a leaving group, e.g., R 7 is selected from the group consisting of —Cl and —OH,
  • X is selected from the group consisting of —N(R 2a )—,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH 2 ) m —W—(CH 2 ) n —;
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8
  • the disclosure provides methods of making a compound having Formula VIII, or a pharmaceutically acceptable salt or solvate thereof, the method comprising:
  • R 11a , R 11b , R 11c , and R 11d are independently selected from the group consisting of hydrogen, chloro, and fluoro;
  • R 12a and R 12b are independently selected from the group consisting of hydrogen and C 1-6 alkyl; or
  • R 12a and R 12b taken together with the carbon atom to which they are attached form a 4- to 8-membered optionally substituted cycloalkyl
  • Q is selected from the group consisting of substituted phenylenyl, optionally substituted heteroarylenyl, and optionally substituted cycloalkylenyl,
  • the disclosure provides methods of making a compound having Formula XI:
  • R 1 is selected from the group consisting of hydrogen and optionally substituted C 1-4 alkyl
  • R 2a′ and R 2b′ are each independently selected from the group consisting of hydrogen, optionally substituted C 1-4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R 2a′ and R 2b′ together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl
  • R 3a and R 3b are each independently selected from the group consisting of hydrogen and optionally substituted C 1-4 alkyl; or
  • R 3a and R 3b together with the carbon atom to which they are attached form an optionally substituted 3- to 6-membered cycloalkyl
  • R 4 is selected from the group consisting of hydrogen, halogen, optionally substituted C 1-4 alkyl, optionally substituted C 2-4 alkenyl, optionally substituted C 2-4 alkynyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, —NR 6a R 6b , —OR 7d , —SR 8a , —S( ⁇ O)R 8b , —S( ⁇ O) 2 R 8c , —C( ⁇ O)R 9 , (heteroaryl)alkyl, and alkoxyalkyl;
  • R 6a and R 6b are each independently selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and carboxamido; or
  • R 6a and R 6b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • R 7d is selected from the group consisting of hydrogen, optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, and carboxamido;
  • R 8a is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R 8b is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R 8c is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and amino;
  • R 9 selected from the group consisting of hydrogen, optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkoxy, and amino;
  • Y 1 is selected from the group consisting of —O—, —S—, and —NR 10 —;
  • R 10 is selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, (C 3-6 cycloalkyl)C 1-4 alkyl, aralkyl, (alkoxycarbonyl)alkyl, —C( ⁇ O)R u , —SO 2 R 12 , —C( ⁇ O)—OR 13 , and —C( ⁇ O)—NR 14a R 14b ;
  • R 11 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 12 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 13 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 14a and R 14b are each independently selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl; or
  • R 14a and R 14b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • R 15 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, and alkoxy;
  • B is a monovalent radical of a ligand for an E3 ubiquitin ligase protein, e.g., B is:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n — and —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Y 1 is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y 1 is absent
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • X 1 is selected from the group consisting of Br and I;
  • R 1 is selected from the group consisting of hydrogen and optionally substituted C 1-4 alkyl
  • R 2a′ and R 2b′ are each independently selected from the group consisting of hydrogen, optionally substituted C 1-4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R 2a′ and R 2b′ together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl
  • R 3a and R 3b are each independently selected from the group consisting of hydrogen and optionally substituted C 1-4 alkyl; or
  • R 3a and R 3b together with the carbon atom to which they are attached form an optionally substituted 3- to 6-membered cycloalkyl
  • R 4 is selected from the group consisting of hydrogen, halogen, optionally substituted C 1-4 alkyl, optionally substituted C 2-4 alkenyl, optionally substituted C 2-4 alkynyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, —NR 6a R 6b , —OR 7 , —SR 8a , —S( ⁇ O)R 8b , —S( ⁇ O) 2 R 8c , —C( ⁇ O)R 9 , (heteroaryl)alkyl, and alkoxyalkyl;
  • R 6a and R 6b are each independently selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and carboxamido; or
  • R 6a and R 6b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • R 7 is selected from the group consisting of hydrogen, optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, and carboxamido;
  • R 8a is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R 8b is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R 8c is selected from the group consisting of optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and amino;
  • R 9 selected from the group consisting of hydrogen, optionally substituted C 1-4 alkyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkoxy, and amino;
  • Y 1 is selected from the group consisting of —O—, —S—, and —NR 10 —;
  • R 10 is selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, (C 3-6 cycloalkyl)C 1-4 alkyl, aralkyl, (alkoxycarbonyl)alkyl, —C( ⁇ O)R u , —SO 2 R 12 , —C( ⁇ O)—OR 13 , and —C( ⁇ O)—NR 14a R 14b ;
  • R 11 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 12 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 13 is selected from the group consisting of optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R 14a and R 14b are each independently selected from the group consisting of hydrogen, optionally substituted C 1-6 alkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl; or
  • R 14a and R 14b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • R 15 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, and alkoxy,
  • B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n — and —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl, and
  • the disclosure provides a method for making a compound represented by Formula XIII:
  • the disclosure provides a method for making a compound represented by Formula XI or Formula XIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 3a and R 3b are hydrogen.
  • the disclosure provides a method for making a compound represented by Formula XI or Formula XIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 1 is C 1-4 alkyl. In another embodiment, R 1 is methyl, or a pharmaceutically acceptable salt or hydrate thereof.
  • the disclosure provides a method for making a compound represented by Formula XI or Formula XIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 2a′ and R 2b′ are each independently selected from the group consisting of hydrogen and C 1-4 alkyl.
  • the disclosure provides a method for making a compound represented by Formula XIV:
  • the disclosure provides a method or making a compound represented by Formula XV:
  • R 2a is C 1-4 alkyl
  • R 4 , L, Y, Y 1 , and B are as defined in connection with Formula XI.
  • the disclosure provides a method for making a compound represented by Formula XVI:
  • R 2a is C 1-4 alkyl
  • R 4 , L, Y, Y 1 , and B are as defined in connection with Formula XI.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVI, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 4 is selected from the group consisting of halogen, C 1-4 alkyl, optionally C 2-4 alkenyl, optionally substituted C 2-4 alkynyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl.
  • R 4 is aralkyl.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVI, and the pharmaceutically acceptable salts or hydrates thereof, Y 1 is —O—. In another embodiment, Y 1 is —N(H)—.
  • the disclosure provides a method for making a compound represented by Formula XVII:
  • R 2a is selected from the group consisting of hydrogen and C 1-3 alkyl
  • R 17a and R 17b are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, haloalkyl, C 1-4 alkoxy, and halo
  • L, Y, and B are as defined in connection with Formula XI.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is C 1-12 alkylenyl.
  • L is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 (CH 2 ) 2 CH 2 —, —CH 2 (CH 2 ) 3 CH 2 —, —CH 2 (CH 2 ) 4 CH 2 —, —CH 2 (CH 2 ) 5 CH 2 —, and —CH 2 (CH 2 ) 6 CH 2 —.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein, L is 3- to 12-membered heteroalkylenyl.
  • L is —(CH 2 ) o O—(CH 2 CH 2 O) p —(CH 2 ) q —; o is 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 1, 2, or 3.
  • the disclosure provides methods for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of: —CH 2 OCH 2 CH 2 —, —CH 2 CH 2 OCH 2 CH 2 —, —CH 2 O(CH 2 CH 2 O)CH 2 CH 2 —, —CH 2 O(CH 2 CH 2 O) 2 CH 2 CH 2 —, —CH 2 O(CH 2 CH 2 O) 3 CH 2 CH 2 —, —CH 2 CH 2 O(CH 2 CH 2 O) 6 CH 2 CH 2 —, —CH 2 CH 2 O(CH 2 CH 2 O) 6 CH 2 CH 2 —, —CH 2 CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 OCH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 O(CH 2 CH 2 O) 2 CH 2 CH 2 —, and —CH 2 CH 2 CH 2 O(CH 2 ) 4 OCH 2 CH
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is —(CH 2 ) m —W—(CH 2 ) n —.
  • W is phenylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • m is 0.
  • n is 1, 2, 3, 4, or 5.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is —(CH 2 ) m —W—(CH 2 ) u -0-(CH 2 ) v —.
  • W is phenylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of:
  • n 1, 2, 3, 4, or 5.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of —O—, —S—, and —N(R 6 )—; and R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • m is 0.
  • n is 1, 2, 3, 4, or 5.
  • L is L-3.
  • L is L-4.
  • L is L-5.
  • L is L-6.
  • L is L-7.
  • L is L-8.
  • L is L-9.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of:
  • L is L-10. In another embodiment, L is L-11. In another embodiment, L is L-12. In another embodiment, L is L-13.
  • the disclosure provides a method for making a compound represented by Formula XVIII:
  • the disclosure provides a method for making a compound represented by Formula XIX:
  • the disclosure provides a method for making a compound represented by Formula XX:
  • the disclosure provides a method for making a compound represented by Formulae XVIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein R 2a is hydrogen. In another embodiment, R 2a is methyl.
  • the disclosure provides a method for making a compound represented by Formulae XVIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein Y is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, and —N(H)—.
  • Y is —C ⁇ C—.
  • Y is —CH 2 —.
  • Y is —O—.
  • Y is —N(H)—.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XX, wherein B is B-1a.
  • a 1 is —C(R 16a ) ⁇ and R 16a is selected from the group consisting of hydrogen and halo.
  • a 2 is —C(R 16b ) ⁇ and R 16b is selected from the group consisting of hydrogen and halo.
  • a 3 is —C(R 16c ) ⁇ and R 16c is selected from the group consisting of hydrogen and halo.
  • a 1 is —N ⁇
  • a 2 is —C(R 16b ) ⁇
  • a 3 is —C(R 16c ) ⁇ .
  • a 1 is —C(R 16a ) ⁇
  • a 2 is —N ⁇
  • a 3 is —C(R 16c ) ⁇
  • a 1 is —C(R 16a ) ⁇
  • a 2 is —C(R 16b ) ⁇
  • a 3 is —N ⁇
  • Z is —CH 2 —.
  • Z is —C( ⁇ O)—.
  • R 5 is hydrogen.
  • B-1a is selected from the group consisting of:
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-2.
  • the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-3.
  • the disclosure provides a method of making a compound having Formula XXI:
  • R 1 is selected from the group consisting of hydrogen and optionally substituted C 1-4 alkyl
  • R 2a′ and R 2b′ are each independently selected from the group consisting of hydrogen, optionally substituted C 1-4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R 2a′ and R 2b′ together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl
  • R 3 is selected from the group consisting of optionally substituted C 6-14 aryl and optionally substituted 5- to 14-membered heteroaryl
  • R 4 is selected from the group consisting of hydrogen, halogen, optionally substituted C 1-4 alkyl, optionally substituted C 2-4 alkenyl, optionally substituted C 2-4 alkynyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R 15 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, and alkoxy;
  • B is a monovalent radical of a ligand for an E3 ubiquitin ligase protein, e.g., B is:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n — and —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • X 1 is selected from the group consisting of —Br and —I;
  • R 1 is selected from the group consisting of hydrogen and optionally substituted C 1-4 alkyl
  • R 2a′ and R 2b′ are each independently selected from the group consisting of hydrogen, optionally substituted C 1-4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R 2a′ and R 2b′ together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl
  • R 3 is selected from the group consisting of optionally substituted C 6-14 aryl and optionally substituted 5- to 14-membered heteroaryl;
  • R 4 is selected from the group consisting of hydrogen, halogen, optionally substituted C 1-4 alkyl, optionally substituted C 2-4 alkenyl, optionally substituted C 2-4 alkynyl, aralkyl, optionally substituted C 6-14 aryl, optionally substituted C 3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R 15 is selected from the group consisting of hydrogen, halogen, C 1-4 alkyl, and alkoxy,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH 2 ) m —W—(CH 2 ) n — and —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u 0, 1, 2, or 3;
  • v 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen, methyl, and fluoro
  • a 1 is selected from the group consisting of —C(R 16a ) ⁇ and —N ⁇ ;
  • a 2 is selected from the group consisting of —C(R 16b ) ⁇ and —N ⁇ ;
  • a 3 is selected from the group consisting of —C(R 16c ) ⁇ and —N ⁇ ;
  • R 16a is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16b is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl
  • R 16c is selected from the group consisting of hydrogen, halo, and C 1-4 alkyl, and
  • the disclosure provides a method for making a compound represented by Formula XXIII
  • the disclosure provides a method for making a compound represented by Formula XXI or Formula XXIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 3 is optionally substituted phenyl.
  • the disclosure provides a method for making a compound represented by Formula XXI or Formula XXIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 1 is C 1-4 alkyl. In another embodiment, R 1 is methyl.
  • the disclosure provides a method for making a compound represented by Formula XXI or Formula XXIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 2a′ and R 2b′ are each independently selected from the group consisting of hydrogen and C 1-4 alkyl.
  • the disclosure provides a method for making a compound represented by Formula XXIV:
  • the disclosure provides a method for making a compound represented by Formula XXV:
  • the disclosure provides a method for making a compound represented by Formula XXVI:
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI, or XXIII-XXVI, and the pharmaceutically acceptable salts or hydrates thereof, wherein R 4 is C 1-4 alkyl. In another embodiment, R 4 is methyl. In another embodiment, R 4 is hydrogen.
  • the disclosure provides a method for making a compound represented by Formula XXVII:
  • R 17a and R 17b are each independently selected from the group consisting of hydrogen, C 1-4 alkyl, haloalkyl, C 1-4 alkoxy, and halo; and L, Y, and B are as defined in connection with Formula XXI.
  • R 17a and R 17b are each independently selected from the group consisting of hydrogen and halo.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is C 1-12 alkylenyl.
  • L is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 (CH 2 ) 2 CH 2 —, —CH 2 (CH 2 ) 3 CH 2 —, —CH 2 (CH 2 ) 4 CH 2 —, —CH 2 (CH 2 ) 5 CH 2 —, and —CH 2 (CH 2 ) 6 CH 2 —.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein, L is 3- to 12-membered heteroalkylenyl.
  • L is —(CH 2 ) o O—(CH 2 CH 2 O) p —(CH 2 ) q —; o is 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 1, 2, or 3.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of: —CH 2 OCH 2 CH 2 —, —CH 2 CH 2 OCH 2 CH 2 —, —CH 2 O(CH 2 CH 2 O)CH 2 CH 2 —, CH 2 O(CH 2 CH 2 O) 2 CH 2 CH 2 —, —CH 2 O(CH 2 CH 2 O) 3 CH 2 CH 2 —, —CH 2 CH 2 O(CH 2 CH 2 O) 6 CH 2 CH 2 —, —CH 2 CH 2 O(CH 2 CH 2 O) 6 CH 2 CH 2 —, —CH 2 CH 2 CH 2 OCH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 O(CH 2 CH 2 O) 2 CH 2 CH 2 —, and —CH
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is —(CH 2 ) m —W—(CH 2 ) n —.
  • W is phenylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • m is 0.
  • n is 1, 2, 3, 4, or 5.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —.
  • W is phenylenyl.
  • W is 5-membered heteroarylenyl.
  • W is 6-membered heteroarylenyl.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • n is 1, 2, 3, 4, or 5.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Q 3 is selected from the group consisting of —O—, —S—, and —N(R 6 )—; and R 6 is selected from the group consisting of hydrogen and C 1-4 alkyl.
  • m is 0.
  • n is 1, 2, 3, 4, or 5.
  • n is 2, 3, or 4.
  • L is L-3.
  • L is L-4.
  • L is L-5.
  • L is L-6.
  • L is L-7.
  • L is L-8.
  • L is L-9.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • m is 0. In another embodiment, n is 1, 2, 3, 4, or 5. In another embodiment, n is 2, 3, or 4. In another embodiment, L is L-10. In another embodiment, L is L-11. In another embodiment, L is L-12. In another embodiment, L is L-13.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is —(CH 2 ) m —W—(CH 2 ) u —O—(CH 2 ) v —; W is selected from the group consisting of 5-membered heteroarylenyl and optionally substituted 6-membered heteroarylenyl; m is 0, 1, 2, 3, 4, 5, 6, or 7; u is 0; and v is 1, 2, 3, or 4. In another embodiment, m is 0.
  • the disclosure provides a method for making a compound represented by Formula XXVIII:
  • the disclosure provides a method for making a compound represented by Formula XXIX:
  • the disclosure provides a method for making a compound represented by Formula XXX:
  • the disclosure provides a method for making a compound represented by any one of Formulae XXVIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein R 2a is hydrogen. In another embodiment, R 2a is methyl.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXVIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein Y is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, and —N(H)—.
  • Y is —C ⁇ C—.
  • Y is —CH 2 —.
  • Y is —O—.
  • Y is —N(H)—.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-1a.
  • a 1 is —C(R 16a ) ⁇ and R 16a is selected from the group consisting of hydrogen and halo.
  • a 2 is —C(R 16b ) ⁇ and R 16b is selected from the group consisting of hydrogen and halo.
  • a 3 is —C(R 16c ) ⁇ and R 16c is selected from the group consisting of hydrogen and halo.
  • a 1 is —N ⁇
  • a 2 is —C(R 16b ) ⁇
  • a 3 is —C(R 16c ) ⁇ .
  • a 1 is —C(R 16a ) ⁇
  • a 2 is —N ⁇
  • a 3 is —C(R 16c ) ⁇ .
  • a 1 is —C(R 16a ) ⁇
  • a 2 is —C(R 16b ) ⁇
  • a 3 is —N ⁇ .
  • Z is —CH 2 —.
  • Z is —C( ⁇ O)—.
  • R 5 is hydrogen.
  • B-1a is selected from the group consisting of:
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-2.
  • the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-3.
  • the disclosure provides methods of making a compound having Formula XXXI:
  • B is selected from the group consisting of:
  • R 1a is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and —N(H)R 3c ;
  • Q 1 is ⁇ CH— and Q 2 is —N ⁇ ;
  • Q 1 is ⁇ N— and Q 2 is —CH ⁇ ;
  • Q 1 is ⁇ N— and Q 2 is —N ⁇ ;
  • R 3c is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
  • X 2 is —C( ⁇ O)N(H)—, wherein the nitrogen atom of —C( ⁇ O)N(H)— is attached to L,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH 2 ) m —W—(CH 2 ) n —;
  • W is selected from the group consisting of optionally substituted phenylenyl, optionally substituted 5-membered heteroarylenyl, and optionally substituted 6-membered heteroarylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen and fluoro
  • R 1a is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and —N(H)R 3 ;
  • Q 1 is ⁇ CH— and Q 2 is —N ⁇ ;
  • Q 1 is ⁇ N— and Q 2 is —CH ⁇ ;
  • Q 1 is ⁇ N— and Q 2 is —N ⁇ ;
  • R 3c is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
  • R 7a is a leaving group, e.g., R 7a is selected from the group consisting of chloro and —OR 7b ;
  • R 7b is hydrogen
  • B is selected from the group consisting of:
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH 2 ) m —W—(CH 2 ) n —;
  • W is selected from the group consisting of optionally substituted phenylenyl, optionally substituted 5-membered heteroarylenyl, and optionally substituted 6-membered heteroarylenyl;
  • n 0, 1, 2, 3, 4, 5, 6, or 7;
  • n 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C ⁇ C—, —CH 2 —, —O—, —N(R 2c )—, —C( ⁇ O)N(R 2d )—, —N(R 2e )C( ⁇ O)CH 2 O—, and —N(R 2e )C( ⁇ O)CH 2 N(R 2f )—; or
  • Y is absent
  • R 2c , R 2d , R 2e , and R 2f are each independently selected from the group consisting of hydrogen and C 1-4 alkyl;
  • Z is selected from the group consisting of —CH 2 and —C( ⁇ O)—;
  • R 5 is selected from the group consisting of hydrogen and fluoro
  • a suitable organic solvent e.g., DMF, THF, etc.
  • Salts, hydrates, and solvates of the Compounds of the Disclosure can also be used in the methods disclosed herein.
  • the present disclosure further includes all possible stereoisomers and geometric isomers of Compounds of the Disclosure to include both racemic compounds and optically active isomers.
  • a Compound of the Disclosure When a Compound of the Disclosure is desired as a single enantiomer, it can be obtained either by resolution of the final product or by stereospecific synthesis from either isomerically pure starting material or use of a chiral auxiliary reagent, for example, see Z. Ma et al., Tetrahedron: Asymmetry, 8(6), pages 883-888 (1997). Resolution of the final product, an intermediate, or a starting material can be achieved by any suitable method known in the art. Additionally, in situations where tautomers of the Compounds of the Disclosure are possible, the present disclosure is intended to include all tautomeric forms of the compounds.
  • the present disclosure encompasses the preparation and use of salts of Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure, including pharmaceutically acceptable salts.
  • the pharmaceutical “pharmaceutically acceptable salt” refers to salts or zwitterionic forms of Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure. Salts of Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure can be prepared during the final isolation and purification of the compounds or separately by reacting the compound with an acid having a suitable cation.
  • the pharmaceutically acceptable salts of Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure can be acid addition salts formed with pharmaceutically acceptable acids.
  • acids which can be employed to form pharmaceutically acceptable salts include inorganic acids such as nitric, boric, hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
  • Nonlimiting examples of salts of compounds of the disclosure include, but are not limited to, the hydrochloride, hydrobromide, hydroiodide, sulfate, bi sulfate, 2-hydroxyethansulfonate, phosphate, hydrogen phosphate, acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerolphsphate, hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate, maleate, ascorbate, isethionate, salicylate, methanesulfonate, me sitylene sulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate,
  • available amino groups present in the compounds of the disclosure can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
  • any reference Compounds of the Disclosure appearing herein is intended to include compounds of Compounds of the Disclosure as well as pharmaceutically acceptable salts, hydrates, or solvates thereof.
  • solvates typically do not significantly alter the physiological activity or toxicity of the compounds, and as such may function as pharmacological equivalents.
  • solvate as used herein is a combination, physical association and/or solvation of a compound of the present disclosure with a solvent molecule such as, e.g. a disolvate, mono solvate or hemisolvate, where the ratio of solvent molecule to compound of the present disclosure is about 2:1, about 1:1 or about 1:2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding.
  • solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid.
  • “solvate” encompasses both solution-phase and isolatable solvates.
  • Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure can be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, and ethanol, and it is intended that the disclosure includes both solvated and unsolvated forms of Compounds of the Disclosure.
  • a pharmaceutically acceptable solvent such as water, methanol, and ethanol
  • One type of solvate is a hydrate.
  • a “hydrate” relates to a particular subgroup of solvates where the solvent molecule is water.
  • Solvates typically can function as pharmacological equivalents.
  • solvates Preparation of solvates is known in the art. See, for example, M. Caira et al, J. Pharmaceut. Sci., 93(3):601-611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by E. C. van Tender et al., AAPS Pharm. Sci. Tech., 5(1) Article 12 (2004), and A. L. Bingham et al., Chem Commun. 603-604 (2001).
  • a typical, non-limiting, process of preparing a solvate would involve dissolving a Compound of the Disclosure in a desired solvent (organic, water, or a mixture thereof) at temperatures above 20° C. to about 25° C., then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration.
  • Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
  • heterobifunctional target protein degraders for the treatment of a variety of diseases and conditions wherein degradation of the target proteins has a beneficial effect.
  • Heterobifunctional target protein degraders typically have a binding affinity (IC 50 ) to the target protein of interest of less than 100 ⁇ M, e.g., less than 50 ⁇ M, less than 25 ⁇ M, and less than 5 ⁇ M, less than about 1 ⁇ M, less than about 0.5 ⁇ M, or less than about 0.1 ⁇ M.
  • the present disclosure relates to a method of treating an individual suffering from a disease or condition wherein degradation of a target protein provides a benefit comprising administering a therapeutically effective amount of a heterobifunctional target protein degrader to an individual in need thereof.
  • a “monovalent radical of a target protein inhibitor” is derived from the removal of a hydrogen or other suitable atom, e.g., Br, I, or group, e.g., —OH, from a parent protein inhibitor, e.g., an oncogenic protein inhibitor such as BET bromodomain inhibitor or a MDM2 inhibitor.
  • a hydrogen atom or other suitable atom or group facilitates the linkage of the target protein inhibitor to an E3 ubiquitin ligase protein ligand to give a heterobifunctional compound having Formula IX, as defined above.
  • a hydrogen atom is removed from any suitable —NH 2 group of the target protein inhibitor.
  • a hydrogen atom is removed from any suitable —OH group of the target protein inhibitor.
  • a hydrogen atom is removed from any suitable —N(H)— group of the target protein inhibitor.
  • a hydrogen atom is removed from any suitable —CH 3 , —CH 2 —, —CH ⁇ , or —C ⁇ CH group of the target protein inhibitor.
  • the hydrogen atom is removed from any suitable —OH group of the target protein inhibitor.
  • a Br or I atom is removed from any suitable aryl or heteroaryl group of the target protein inhibitor.
  • target protein inhibitor or “parent target protein inhibitor” and the like refers to a compound that disrupts, interferes with, or inhibits protein activity.
  • oncogenic protein inhibitor or “parent oncogenic protein inhibitor” and the like refers to a compound that disrupts, interferes with, or inhibits oncogenic protein activity.
  • Oncogenic proteins are proteins encoded by oncogenes (dysregulated or activated genes).
  • an “oncogene” is any gene that is a causative factor in the initiation of cancerous growth, e.g., a gene that has a potential to cause cancer.
  • transcription factors, kinases, and growth factors are oncogenic proteins because they are genetically involved in signaling systems leading to cell growth, survival, differentiation, and programmed cell death (apoptosis).
  • Other oncogenic proteins include MDM2 and BET bromodomain proteins.
  • a “monovalent radical of a ligand for an E3 ubiquitin ligase protein” is derived from the removal of a hydrogen or other suitable atom, e.g., Br, I, or group, e.g., —OH, from a parent E3 ubiquitin ligase protein ligand.
  • a hydrogen atom or other suitable atom or group facilitates the linkage of the parent E3 ubiquitin ligase protein ligand to a target protein inhibitor to give a heterobifunctional compound having Formula IX, as defined above.
  • a hydrogen atom is removed from any suitable —NH 2 group of the parent E3 ubiquitin ligase protein ligand.
  • a hydrogen atom is removed from any suitable —OH group of the parent E3 ubiquitin ligase protein ligand. In another embodiment, a hydrogen atom is removed from any suitable —N(H)— group of the parent E3 ubiquitin ligase protein ligand. In another embodiment, a hydrogen atom is removed from any suitable —CH 3 , —CH 2 —, —CH ⁇ group of the parent E3 ubiquitin ligase protein ligand. In another embodiment, the hydrogen atom is removed from any suitable —OH group of the the parent E3 ubiquitin ligase protein ligand.
  • a Br or I atom is removed from any suitable aryl or heteroaryl group of the parent E3 ubiquitin ligase protein ligand.
  • exemplary non-limiting monovalent radicals of E3 ubiquitin ligase protein ligands include:
  • a “ligand for an E3 ubiquitin ligase protein” or “parent ligand for an E3 ubiquitin ligase protein” or “E3 ubiquitin ligase protein ligand” refers to a compound that binds, e.g., inhibits, an E3 ubiquitin ligase protein, including the von Hippel-Lindau protein (VHL).
  • Ligands for E3 ubiquitin ligase proteins are known to those of ordinary skill in the art.
  • Exemplary non-limiting ligands for an E3 ubiquitin ligase protein include phthalimide-based drugs such as thalidomide.
  • a “monovalent radical of a MDM2 inhibitor” is derived from the removal of a hydrogen or other suitable atom, e.g., Br, I, or group, e.g., —OH, from a parent MDM2 inhibitor.
  • the removal of a hydrogen atom or other suitable atom or group facilitates the linkage of the MDM2 inhibitor to an E3 ubiquitin ligase protein ligand to give a heterobifunctional compound having Formula IX, as defined above.
  • a hydrogen atom is removed from any suitable —NH 2 group of the parent MDM2 inhibitor.
  • a hydrogen atom is removed from any suitable —OH group of the parent MDM2 inhibitor.
  • a hydrogen atom is removed from any suitable —N(H)— group of the parent MDM2 inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —CH 3 , —CH 2 —, —CH ⁇ , or —C ⁇ CH group of the parent MDM2 inhibitor. In another embodiment, the hydrogen atom is removed from any suitable —OH group of the parent MDM2 inhibitor. In another embodiment, the —OH group is removed from any suitable —C( ⁇ O)OH group of the parent MDM2 inhibitor. In another embodiment, a Br or I atom is removed from any suitable aryl or heteroaryl group of the parent MDM2 inhibitor.
  • MDM2 inhibitor refers to a compound that disrupts the p53-MDM2 interaction and/or interferes with MDM2 activity.
  • MDM2 inhibitors are known to those of ordinary skill in the art. See, e.g., Shangary. et al., Annual Review Of Pharmacology and Toxicology 49: 223-241 (2009); and Weber, Expert Opinion On Therapeutic Patents 20: 179-191 (2010).
  • the MDM2 inhibitor is a spiro-oxindole compound.
  • spiro-oxindole MDM2 inhibitor refers, for example, to a compound disclosed and/or claimed in U.S. Pat. Nos. 7,759,383; 7,737,174; 8,518,984; 8,680,132; or 8,629,141.
  • the MDM2 inhibitor is a cis-imidazoline compound
  • the term “cis-imidazoline MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Pat. Nos. 6,617,346; 6,734,302; 7,132,421; 7,425,638; or 7,579,368; or U.S. Patent Application Publication Nos. 2005/0288287 or U.S. 2009/0143364.
  • a cis-imidazoline MDM2 inhibitor is commonly referred to as a “nutlin.”
  • the cis-imidazoline is Nutlin-1, Nutlin-2, or Nutlin-3 (Chart 3; see Vassilev, L. T. et al., Science 303:844-848 (2004)).
  • the MDM2 inhibitor is any one of the inhibitors disclosed and/or claimed in U.S. Pat. No. 6,734,302.
  • the MDM2 inhibitor is a compound of Formula III-A:
  • R is —C ⁇ R 1 ;
  • R 1 is selected from C 1 -C 4 alkyl, —C ⁇ CHCOOH, —NHCH 2 CH 2 R 2 , —N(CH 2 CH 2 OH)CH 2 CH 2 OH, —N(CH 3 )CH 2 CH 2 NHCH 3 , —N(CH 3 )CH 2 CH 2 N(CH 3 )CH 3 , saturated 4-, 5- and 6-membered rings, and saturated and unsaturated 5- and 6-membered rings containing at least one hetero atom wherein the hetero atom is selected from S, N and O and being optionally substituted with a group selected from lower alkyl, —C ⁇ O—R 5 , —OH, lower alkyl substituted with hydroxy, lower alkyl substituted with —NH 2 , N-lower alkyl, —SO 2 CH 3 , ⁇ O, —CH 2 C ⁇ OCH 3 , and 5- and 6-membered saturated rings containing at least one hetero atom selected from S, N and O;
  • R 5 is selected from H, lower alkyl, —NH 2 , —N-lower alkyl, lower alkyl substituted with hydroxy, and lower alkyl substituted with NH 2 ;
  • R 2 is selected from —N(CH 3 )CH 3 , —NHCH 2 CH 2 NH 2 , —NH 2 , morpholinyl and piperazinyl;
  • X 1 , X 2 and X 3 are independently selected from —OH, C 1 -C 2 alkyl, C 1 -C 5 alkoxy, —Cl, —Br, —F, —CH 2 OCH 3 , and —CH 2 OCH 2 CH 3 ;
  • X 1 , X 2 or X 3 is H and the other two are independently selected from hydroxy, lower alkyl, lower alkoxy, —Cl, —Br, —F, —CF 3 , —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , —OCH 2 CH 2 R 3 , —OCH 2 CF 3 , and —OR 4 ;
  • X 1 , X 2 or X 3 is H and the other two taken together with the two carbon atoms and the bonds between them from the benzene ring to which they are substituted form a 5- or 6-membered saturated ring that contains at least one hetero atom selected from S, N, and O, wherein R 3 is selected from —F, —OCH 3 , —N(CH 3 )CH 3 , unsaturated 5- and 6-membered rings containing at least one hetero atom wherein the hetero atom is selected from S, N and O;
  • R 4 is a 3- to 5-membered saturated ring
  • Y 1 and Y 2 are each independently selected from —Cl, —Br, —NO 2 , —C ⁇ N, and —C ⁇ CH.
  • the MDM2 inhibitor is a substituted piperidine compound.
  • substituted piperidine MDM2 inhibitor refers, for example, to a compound disclosed and/or claimed in U.S. Pat. Nos. 7,060,713 or 7,553,833.
  • the MDM2 inhibitor is a spiroindolinone compound.
  • spiroindolinone MDM2 inhibitor refers, for example, to a compound disclosed and/or claimed in U.S. Pat. Nos. 6,916,833; 7,495,007; or 7,638,548.
  • the MDM2 inhibitor is an oxindole compound.
  • oxindole MDM2 inhibitor refers, for example, to a compound disclosed and/or claimed in U.S. Pat. No. 7,576,082.
  • the MDM2 inhibitor is a diphenyl-dihydro-imidazopyridinone compound.
  • diphenyl-dihydro-imidazopyridinone MDM2 inhibitor refers, for example, to a compound disclosed and/or claimed in U.S. Pat. No. 7,625,895.
  • the MDM2 inhibitor is an imidazothiazole compound.
  • imidazothiazole MDM2 inhibitor refers, for example, to a compound disclosed and/or claimed in U.S. 2009/0312310.
  • the MDM2 inhibitor is a deazaflavin compound.
  • the term “deazaflavin MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Patent Application Publication Nos. 2006/0211718 or 2010/0048593.
  • the MDM2 inhibitor is a benzodiazapine compound.
  • benzodiazapine MDM2 inhibitor refers, for example, to a compound disclosed and/or claimed in U.S. 2005/0227932.
  • the MDM2 inhibitor is a isoindolin-1-one compound.
  • isoindolin-1-one MDM2 inhibitor refers, for example, to a compound disclosed and/or claimed in U.S. 2008/0261917.
  • the MDM2 inhibitor is a boronic acid.
  • boronic acid MDM2 inhibitor refers, for example, to a compound disclosed and/or claimed in U.S. Patent Application Publication Nos. 2009/0227542 or 2008/0171723.
  • the MDM2 inhibitor is a peptide or polypeptide.
  • the term “peptidic MDM2 inhibitor” refers for example, to a compound disclosed and/or claimed in U.S. Pat. No. 7,083,983; U.S. 2006/0211757 A1; U.S. 2005/0137137; U.S. 2002/0132977; U.S. 2009/0030181; or WO 2008/106507.
  • the MDM2 inhibitor is a compound disclosed and/or claimed in any of Shangary, S, et al., Proc. Natl. Acad. Sci. USA 105:3933-3938 (2008); Vassilev, L. T., Trends Mol. Med. 13:23-31 (2007); Vassilev, L. T. et al., Science 303:844-848 (2004); Ding, K. et al., J. Med. Chem. 49:3432-3435 2006; Shangary, S. et al., Clin. Cancer Res. 14:5318-5324 (2008); Chene, P., Molecular Cancer Research 2:20-28 (2004); Pazgier et al., Proc. Natl.
  • the MDM2 inhibitor is a compound disclosed and/or claimed in any of WO 2009/151069 A1; WO 2009/037343 A1 (U.S. application Ser. No. 12/678,680); WO 2008/125487 A1 (U.S. Pat. No. 7,625,895); WO 2008/119741 A2 (U.S. application Ser. No. 12/593,721); and WO 2009/156735 A2.
  • the MDM2 inhibitor is any one of the inhibitors disclosed and/or claimed in WO 2009/156735 A2.
  • the MDM2 inhibitor is a compound of Formulae IV-F or V-F:
  • X is selected from O, N or S
  • R 1 is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl;
  • R 2 is selected from hydrogen, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted branched hydroxyalkyl, substituted or unsubstituted cycloalkyl having 6 ring carbon atoms or greater, substituted or unsubstituted cycloalkenyl, hydroxyalkylaralkyl, hydroxyalkylhetero aralkyl, and a carboxylic acid-containing group;
  • R 3 is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; and
  • R 4 -R 7 represents groups R 4 , R 5 , R 6 and R 7 which are independently selected from hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaralkyl, substituted or unsubstituted alkylamine, substituted or unsubstituted alkoxy, trifluoromethyl, amino, nitro, carboxyl, carbonylmethylsulfone, trifluoromethylsulfone, cyano and substituted or unsubstituted sulfonamide;
  • R 2 is substituted or unsubstituted branched hydroxyalkyl, X is O or S;
  • R 2 is hydrogen, at least one of R 4 -R 7 is not hydrogen and R 3 is not a benzimidazole derivative or a benzimidazoline derivative; and wherein, in the Formula V, the 6-membered ring may have 0, 1, or 2 C ⁇ C double bonds.
  • the MDM2 inhibitor is any one of the inhibitors disclosed and/or claimed in WO 2009/1511069 A1.
  • the MDM2 inhibitor is a compound of Formula VI-G:
  • Ar 1 and Ar 2 are each independently selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
  • R 1 is selected from the group consisting of hydrogen, optionally substituted alkyl, and —COR 1a ;
  • R 1a is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted aryl;
  • R 2 and R 3 are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; or
  • R 2 and R 3 taken together form a 3- to 6-membered optionally substituted cycloalkyl or heterocyclo;
  • R 4 and R 5 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted aryl;
  • W is selected from the group consisting of:
  • R 6 and R 7 are each independently selected from the group consisting of hydrogen, hydroxy and optionally substituted alkyl; or
  • R 6 and R 7 taken together form a 3- to 6-membered optionally substituted cycloalkyl or an oxo, i.e., C ⁇ O;
  • R 8 is selected from the group consisting of hydrogen or optionally substituted alkyl
  • R 9 and R 10 are each independently selected from the group consisting of hydrogen or optionally substituted alkyl; or
  • R 9 and R 10 taken together form a 3- to 6-membered optionally substituted cycloalkyl or heterocyclo;
  • X is a carbon atom.
  • MDM2 inhibitor is a compound of Formula VI-G wherein possible examples of substituent groups include where:
  • Ar 1 and Ar 2 are each independently selected from the group consisting of optionally substituted phenyl and optionally substituted pyridyl;
  • R 1 is selected from the group consisting of hydrogen, optionally substituted C 1 -C 6 alkyl, and —COR 1a ;
  • R 1a is selected from the group consisting of hydrogen and optionally substituted C 1 -C 6 alkyl
  • R 2 and R 3 are each independently selected from the group consisting of hydrogen and optionally substituted C 1 -C 6 alkyl; or
  • R 2 and R 3 taken together form a 3- to 6-membered optionally substituted cycloalkyl
  • R 4 and R 5 are each independently selected from the group consisting of hydrogen and optionally substituted C 1 -C 6 alkyl;
  • W is:
  • R 6 and R 7 are each independently selected from the group consisting of hydrogen and optionally substituted C 1 -C 6 alkyl; or
  • R 6 and R 7 taken together form a 3- to 6-membered optionally substituted cycloalkyl or an oxo.
  • a “monovalent radical of a BET bromodomain protein inhibitor” is derived from the removal of a hydrogen or other suitable atom, e.g., Br, I, or group, e.g., —OH, from a parent BET bromodomain inhibitor.
  • the removal of a hydrogen atom or other suitable atom or group facilitates the linkage of the BET bromodomain inhibitor to an E3 ubiquitin ligase protein ligand to give a heterobifunctional compound having Formula IX, as defined above.
  • a hydrogen atom is removed from any suitable —NH 2 group of the parent BET bromodomain inhibitor.
  • a hydrogen atom is removed from any suitable —OH group of the parent BET bromodomain inhibitor.
  • a hydrogen atom is removed from any suitable —N(H)— group of the parent BET bromodomain inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —CH 3 , —CH 2 —, —CH ⁇ , or —C ⁇ CH group of the parent BET bromodomain inhibitor. In another embodiment, the hydrogen atom is removed from any suitable —OH group of the parent BET bromodomain inhibitor. In another embodiment, the —OH group is removed from any suitable —C( ⁇ O)OH group of the parent BET bromodomain inhibitor. In another embodiment, a Br or I atom is removed from any suitable aryl or heteroaryl group of the parent BET bromodomain inhibitor.
  • BET bromodomain inhibitor or “parent BET bromodomain inhibitor” refers to a compound that interferes with, e.g., inhibits, BET bromodomain activity.
  • BET bromodomain inhibitors are known to those of ordinary skill in the art.
  • BET bromodomain protein inhibitors are disclosed in the following U.S. patents: U.S. Pat. Nos. 8,044,042, 8,476,260, 8,114,995, 8,557,984, and 8,580,957; the following U.S.
  • LG refers to an atom or group of atoms that becomes detached from an atom or group of atoms in what is considered to be the residual or main part of the molecule in a specified reaction.
  • Non-limiting exemplary leaving groups include —Cl, —I, —Br, —OTf, —OMs, and -OTs.
  • reaction or “reacting” and the like refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product. Reacting can take place in the presence or absence of solvent.
  • halo as used by itself or as part of another group refers to —Cl, —F, —Br, or —I.
  • nitro as used by itself or as part of another group refers to —NO 2 .
  • cyano as used by itself or as part of another group refers to —CN.
  • hydroxy as used by itself or as part of another group refers to —OH.
  • alkyl refers to unsubstituted straight- or branched-chain aliphatic hydrocarbons containing from one to twelve carbon atoms, i.e., C 1-20 alkyl, or the number of carbon atoms designated, e.g., a C 1 alkyl such as methyl, a C 2 alkyl such as ethyl, a C 3 alkyl such as propyl or isopropyl, a C 1-3 alkyl such as methyl, ethyl, propyl, or isopropyl, and so on.
  • the alkyl is a C 1-10 alkyl.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.

Description

    BACKGROUND OF THE INVENTION Field of the Invention
  • The present disclosure provides compounds that are medically useful, e.g., as immunomodulators for the treatment of cancer, and/or synthetically useful as monofunctional intermediates for the preparation of small-molecule drug conjugates. Coupling the monofunctional synthetic intermediates of this disclosure with an inhibitor of a target protein of interest, e.g., an oncogenic protein inhibitor, e.g., a BET bromodomain inhibitor or MDM2 inhibitor, provides a heterobifunctional small-molecule that simultaneously binds the target protein and a ubiquitin ligase, enabling ubiquitination and degradation of the target protein.
    • Background
  • Phthalimide-based drugs, e.g., thalidomide or lenalidomide, bind to protein-degradation machinery, e.g., cereblon (CRBN; part of an ubiquitin E3 ligase complex). This may promote the recruitment of two transcription factors (IKZF1 and IKZF3) that are essential to disease progression, resulting in drug-induced ubiquitylation and degradation by the proteasome. See, e.g., Ito et al., Science 327:1345-1350 (2010) and Winter et al., Science 348:1376-1381 (2015).
  • A high-affinity VHL ligand, see Bondeson et al., Nat. Chem. Biol. 11:611-617 (2015), may recruit a target protein to an E3 ubiquitin ligase, resulting in drug induced ubiquitination and degradation. See, e.g., van Hagen et al., Nucleic Acids Research 38: 1922-1931 (2010); Buckley et al., J. Am. Chem. Soc. 134:4465-4468 (2012); Buckley et al., Angew, Chem. Int. Ed. Engl. 51:11463-11467 (2012); Lipkowitz and Weissman, Nat Rev Cancer 11:629-643 (2011); and Zengerle et al., ACS Chem. Biol. 10:1770-1777 (2015).
  • There is an ongoing need for immunomodulatory drugs. There is also an ongoing need for monofunctional synthetic intermediates comprising a ligand for an E3 ubiquitin ligase protein, e.g., thalidomide, for use in preparing heterobifunctional protein degraders.
    • BRIEF SUMMARY OF THE INVENTION
  • In one aspect, the present disclosure provides compounds having any one of Formulae I-VI, VIa, or VIb below, and the salts or solvates thereof, collectively referred to as “Compounds of the Disclosure.” Compounds of the Disclosure comprise a ligand for an E3 ubiquitin ligase protein and thus can be used as an immunomodulatory drug to treat cancer, e.g., multiple myeloma, and other diseases responsive to inducing, enhancing, or suppressing an immune response, e.g., Crohn's disease, sarcoidosis, graft-versus-host disease, and rheumatoid arthritis, in a subject in need thereof.
  • In another aspect, the present disclosure provides Compounds of the Disclosure as monofunctional synthetic intermediates that can be used to prepare heterobifunctional protein degraders.
  • In another aspect, the present disclosure provides methods of preparing heterobifunctional protein degraders having any one of Formulae VII-IX or XI-XXXII, below, and the pharmaceutically acceptable salts or solvates thereof. Heterobifunctional protein degraders comprise a target protein inhibitor, a linker, and a ligand for an E3 ubiquitin ligase protein.
  • Additional embodiments and advantages of the disclosure will be set forth, in part, in the description that follows, and will flow from the description, or can be learned by practice of the disclosure. The embodiments and advantages of the disclosure will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims.
  • It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only, and are not restrictive of the invention as claimed.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Compounds of the Disclosure are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare heterobifunctional protein degraders.
  • In one embodiment, Compounds of the Disclosure are compounds represented by Formula I:
  • Figure US20210002289A1-20210107-C00002
  • and the salts or solvates thereof, wherein:
  • X is selected from the group consisting of —C≡C—, —O—, —N(R2a)—, —OC(═O)—,
  • Figure US20210002289A1-20210107-C00003
  • wherein the —N(R2b)— of
  • Figure US20210002289A1-20210107-C00004
  • is attached to L;
  • the —O— of
  • Figure US20210002289A1-20210107-C00005
  • is attached to L;
  • the —C(═O)— of —OC(═O)— is attached to L;
  • and the carbon atom of
  • Figure US20210002289A1-20210107-C00006
  • is attached to L;
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n—, and —(CH2)r—W—(CH2)u—O—(CH2)v—;
  • A is absent; or
  • A is heteroarylenyl;
  • W is selected from the group consisting of phenylenyl, heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • r is 0, 1, 2 or 3;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C≡C—, —CH═CH—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2a, R2b, R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl; and
  • B is a monovalent radical of a ligand for an E3 ubiquitin ligase protein.
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein:
  • X is selected from the group consisting of —C≡C—, —O—, —N(R2a)—,
  • Figure US20210002289A1-20210107-C00007
  • wherein the —N(R2b)— of
  • Figure US20210002289A1-20210107-C00008
  • is attached to L and the —O— of
  • Figure US20210002289A1-20210107-C00009
  • is attached to L.
  • In one embodiment, Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein X is selected from the group consisting of —C≡C—, —O—, —N(R2a)—,
  • Figure US20210002289A1-20210107-C00010
  • In one embodiment, Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein X is —OC(═O)—, wherein the —C(═O)— of —OC(═O)— is attached to L.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00011
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • G is selected from the group consisting of —C(R16d)═ and —N═;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16d is selected from the group consisting of hydrogen, halo, and C1-4 alkyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a, B-1b, B-1c, or B-1d, and R5 is partially or entirely enriched with an isotope of hydrogen, e.g., R5 is about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100% deuterium.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00012
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I that are not any one of the compounds of Table 6, or any stereoisomer thereof.
  • TABLE 6
    Figure US20210002289A1-20210107-C00013
    Figure US20210002289A1-20210107-C00014
    Figure US20210002289A1-20210107-C00015
    Figure US20210002289A1-20210107-C00016
    Figure US20210002289A1-20210107-C00017
    Figure US20210002289A1-20210107-C00018
    Figure US20210002289A1-20210107-C00019
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein X is —C≡C—.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein X is —N(H)—.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein X is —OC(═O)—.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein X is
  • Figure US20210002289A1-20210107-C00020
  • and the carbon atom of
  • Figure US20210002289A1-20210107-C00021
  • is attached to L.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is C1-12 alkylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2(CH2)2CH2—, —CH2(CH2)3CH2—, —CH2(CH2)4CH2—, —CH2(CH2)5CH2—, and —CH2(CH2)6CH2—.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is 3- to 12-membered heteroalkylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • L is —(CH2)oO—(CH2CH2O)p—(CH2)q—;
  • o is 1, 2, or 3;
  • p is 0, 1, 2, 3, 4, or 5; and
  • q is 1, 2, or 3.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of
  • —CH2OCH2CH2—
  • —CH2CH2OCH2CH2—,
  • —CH2O(CH2CH2O)CH2CH2—
  • —CH2O(CH2CH2O)2CH2CH2—,
  • —CH2O(CH2CH2O)3CH2CH2—,
  • —CH2CH2O(CH2CH2O)6CH2CH2—,
  • —CH2CH2O(CH2CH2O)6CH2CH2—,
  • —CH2CH2CH2OCH2CH2OCH2CH2CH2—,
  • —CH2CH2CH2O(CH2CH2O)2CH2CH2CH2—, and
  • —CH2CH2CH2O(CH2)4OCH2CH2CH2—.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and A is absent.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is phenylenyl. In another embodiment, m is 0.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00022
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is 5-membered heteroarylenyl. In another embodiment, m is 0.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00023
  • Q3 is selected from the group consisting of —O—, —S—, and —N(R6)—; and
  • R6 is selected from the group consisting of hydrogen and C1-4 alkyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is 6-membered heteroarylenyl. In another embodiment, m is 0.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00024
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is heterocyclenyl. In another embodiment, m is 0.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00025
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is cycloalkylenyl. In another embodiment, m is 0.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00026
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • L is -A-(CH2)m—W—(CH2)n—; and
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is phenylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00027
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is 5-membered heteroarylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00028
  • Q3 is selected from the group consisting of —O—, —S—, and —N(R6)—; and
  • R6 is selected from the group consisting of hydrogen and C1-4 alkyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is 6-membered heteroarylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00029
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is heterocyclenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00030
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is cycloalkylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00031
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and A is a 5-membered heteroarylenyl. In another embodiment, A is a 5-membered heteroarylenyl selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00032
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and A is a 6-membered heteroarylenyl. In another embodiment, A is:
  • Figure US20210002289A1-20210107-C00033
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • L is —(CH2)r—W—(CH2)u—O—(CH2)v—;
  • r is 0, 1, or 2;
  • u is 1, 2, or 3; and
  • v is 1, 2, or 3.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein L is —(CH2)r—W—(CH2)u—O—(CH2)v— and W is selected from the group consisting of phenylenyl and heteroarylenyl. In another embodiment, W is 5-membered heteroarylenyl. In another embodiment, W is 6-membered heteroarylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein Y is selected from the group consisting of —C≡C—, —CH═CH—, —CH2—, —O—, and —N(R2c)—. In another embodiment, Y is —C≡C—. In another embodiment, Y is —CH2—. In another embodiment, Y is —O—.
  • In another embodiment, Y is —N(H)—. In another embodiment, Y is —CH═CH—.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • B is B-1a;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═; and
  • R16a is selected from the group consisting of hydrogen and halo.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • B is B-1a;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═; and
  • R16b is selected from the group consisting of hydrogen and halo.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein:
  • Bis B-1a;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═; and
  • R16c is selected from the group consisting of hydrogen and halo.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a and Z is —CH2—.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a and Z is —C(═O)—.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-1a and R5 is hydrogen.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is B-2.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B-3.
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein B is:
  • Figure US20210002289A1-20210107-C00034
  • In another embodiment, Compounds of the Disclosure are compounds having Formula I, and the salts or solvates thereof, wherein embodiment, B is:
  • Figure US20210002289A1-20210107-C00035
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein:
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00036
  • X is selected from the group consisting of —N(R2a)—,
  • Figure US20210002289A1-20210107-C00037
  • or
  • X is absent;
  • wherein the —N(H)— of
  • Figure US20210002289A1-20210107-C00038
  • is attached to L and the —O— of
  • Figure US20210002289A1-20210107-C00039
  • is attached to L;
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH2)m—W—(CH2)n—;
  • W is selected from the group consisting of optionally substituted phenylenyl, optionally substituted 5-membered heteroarylenyl, and optionally substituted 6-membered heteroarylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C≡C—, —CH═CH—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—; and
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro,
  • with the proviso that Y is absent when B is B-2.
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula I, and the salts or solvates thereof, wherein B is B-2a
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula II:
  • Figure US20210002289A1-20210107-C00040
  • and the pharmaceutically acceptable salts or solvates thereof, wherein X, L, Y, Z, and R5 are as defined in connection with Formula I. In another embodiment, R5 is hydrogen. In another embodiment, Z is —CH2—. In another embodiment, Z is —C(═O)—. In another embodiment, Y is selected from the group consisting of —C≡C—, —O—, —N(H)—, —C(═O)N(H)—, —N(H)C(═O)CH2O—, and —N(H)C(═O)CH2N(H)—. In another embodiment, Y is selected from the group consisting of —C≡C—, —CH═CH—, —O—, and —N(H)—. In another embodiment, Y is absent. In another embodiment, Y is —C≡C—.
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula III:
  • Figure US20210002289A1-20210107-C00041
  • and the pharmaceutically acceptable salts or solvates thereof, wherein X and L are as defined in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula IIIa:
  • Figure US20210002289A1-20210107-C00042
  • and the pharmaceutically acceptable salts or solvates thereof, wherein X and L are as defined in connection with Formula I.
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula IV:
  • Figure US20210002289A1-20210107-C00043
  • and the pharmaceutically acceptable salts or solvates thereof, wherein X, L, and Y are as defined in connection with Formula I. In another embodiment, Y is selected from the group consisting of —C≡C—, —CH═CH—, —O—, —N(H)—, —C(═O)N(H)—, —N(H)C(═O)CH2O—, and —N(H)C(═O)CH2N(H)—. In another embodiment, Y is selected from the group consisting of —C≡C—, —O—, and —N(H)—. In another embodiment, Y is absent. In another embodiment, Y is —C≡C—.
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula V:
  • Figure US20210002289A1-20210107-C00044
  • and the salts or solvates thereof, wherein:
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00045
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n— and —(CH2)m—W—(CH2)u—O—(CH2)v—;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C≡C—, —CH═CH—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl.
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula VI:
  • Figure US20210002289A1-20210107-C00046
  • and the salts or solvates thereof, wherein:
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00047
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n— and —(CH2)m—W—(CH2)u—O—(CH2)v—;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C≡C—, —CH═CH—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl.
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula VIa:
  • Figure US20210002289A1-20210107-C00048
  • and the salts or solvates thereof, wherein:
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00049
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n— and —(CH2)m—W—(CH2)u—O—(CH2)v—; or
  • L is absent;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C≡C—, —CH═CH—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl.
  • In another embodiment, Compounds of the Disclosure are compounds represented by Formula VIb:
  • Figure US20210002289A1-20210107-C00050
  • and the salts or solvates thereof, wherein:
  • X is selected from the group consisting of —C≡C—, —O—, and —N(R2a)—:
  • R2a is selected from the group consisting of hydrogen and C1-4 alkyl;
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00051
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n— and —(CH2)m—W—(CH2)u—O—(CH2)v—;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl.
  • In another embodiment, Compounds of the Disclosure are compounds represented by any one of Formulae I-IV, and the pharmaceutically acceptable salts or solvates
  • thereof, wherein X is selected from the group consisting of —N(H)—,
  • Figure US20210002289A1-20210107-C00052
  • In another embodiment, Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is C1-12 alkylenyl. In another embodiment, L is selected from the group consisting of —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2(CH2)2CH2—, —CH2(CH2)3CH2—, —CH2(CH2)4CH2—, —CH2(CH2)5CH2—, and —CH2(CH2)6CH2—.
  • In another embodiment, Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is 3- to 20-membered heteroalkylenyl. In another embodiment, L is selected from the group consisting of —(CH2)oO—(CH2CH2O)p—(CH2)q— and —(CH2)rO—(CH2)s—O(CH2)t—; wherein o is 2 or 3; p is 0, 1, 2, 3, 4, 5, 6, or 7; q is 2 or 3;
      • r is 2, 3, or 4; s is 3, 4, or 5; and t is 2 or 3. In another embodiment, L is selected from the group consisting of
  • —CH2CH2OCH2CH2—,
  • —CH2CH2O(CH2CH2O)2CH2CH2—,
  • —CH2CH2O(CH2CH2O)3CH2CH2—,
  • —CH2CH2O(CH2CH2O)4CH2CH2—,
  • —CH2CH2O(CH2CH2O)6CH2CH2—,
  • —CH2CH2O(CH2CH2O)6CH2CH2—,
  • —CH2CH2CH2OCH2CH2OCH2CH2CH2—,
  • —CH2CH2CH2O(CH2CH2O)2CH2CH2CH2—, and
  • —CH2CH2CH2O(CH2)4OCH2CH2CH2—.
  • In another embodiment, Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is —(CH2)m—W—(CH2)n—. In another embodiment, W is phenylenyl. In another embodiment, W is 5-membered heteroarylenyl. In another embodiment, W is 6-membered heteroarylenyl.
  • In another embodiment, Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or
  • Figure US20210002289A1-20210107-C00053
  • In another embodiment, Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00054
  • Q3 is selected from the group consisting of —O—, —S—, and —N(R6)—; and
  • R6 is selected from the group consisting of hydrogen and C1-4 alkyl.
  • In another embodiment, Compounds of the Disclosure are compounds represented by any one of Formulae I-VI, VIa, or VIb, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00055
  • In another embodiment, Compounds of the Disclosure are any one or more of the compounds of Table 1, and salts and solvates thereof.
  • TABLE 1
    Cpd.
    No. Structure Name
    1
    Figure US20210002289A1-20210107-C00056
         		2-(2,6-dioxopiperidin-3-yl)- 4-((3-(2-(2-(3- )piperidin-4- ylamino)propoxy)ethoxy) ethoxy)propyl)amino) isoindoline-1,3-dione
    2
    Figure US20210002289A1-20210107-C00057
         		4-((2-(2-(2-(2-(4- aminophenoxy)ethoxy) ethoxy)ethoxy) ethyl)amino)- 2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    3
    Figure US20210002289A1-20210107-C00058
         		4-((7-aminoheptyl)amino)- 2-(2,6-dioxopiperidin- 3-yl)isoindoline-1,3-dione
    4
    Figure US20210002289A1-20210107-C00059
         		5-amino-N-(2-(2,6-dioxo- piperidin-3-yl)-1- oxoisoindolin-4-yl) pentanamide
    5
    Figure US20210002289A1-20210107-C00060
         		N-(3-(2-(2-(3- aminopropoxy) ethoxy)ethoxy) propyl)-2-((2-(2,6- dioxopiperidin-3- yl)-1,3- dioxoisoindolin-4- yl)oxy)acetamide
    6
    Figure US20210002289A1-20210107-C00061
         		N-(3-(2-(2-(3- aminopropoxy) ethoxy)ethoxy) propyl)-2-((2-(2,6- dioxopiperidin-3-yl)- 1,3-dioxoisoindolin-4- yl)amino)acetamide
    7
    Figure US20210002289A1-20210107-C00062
         		4-((3-(2-(2-(3- aminopropoxy)ethoxy) ethoxy)propyl)amino)- 2- (2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione
    8
    Figure US20210002289A1-20210107-C00063
         		4-(2-(2-(2-(2-aminoethoxy) ethoxy)ethoxy) ethoxy)-2-(2,6- dioxopiperidin-3-yl) isoindoline-1,3-dione
    9
    Figure US20210002289A1-20210107-C00064
         		3-(4-(5-aminopentyl)- 1-oxoisoindolin-2- yl)piperidine-2,6-dione
    10
    Figure US20210002289A1-20210107-C00065
         		3-(4-(5-aminopentyl)- 1-oxoisoindolin-2- yl)piperidine-2,6-dione
    11
    Figure US20210002289A1-20210107-C00066
         		4-((3-aminopropyl)amino)- 2-(2,6-dioxopiperidin- 3-yl)isoindoline-1,3-dione
    12
    Figure US20210002289A1-20210107-C00067
         		4-((4-aminobutyl)amino)- 2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    13
    Figure US20210002289A1-20210107-C00068
         		4-((5-aminopentyl)amino)- 2-(2,6-dioxopiperidin- 3-yl)isoindoline-1,3-dione
    14
    Figure US20210002289A1-20210107-C00069
         		4-((6-aminohexyl)amino)- 2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    15
    Figure US20210002289A1-20210107-C00070
         		4-((2-(2-aminoethoxy) ethyl)amino)-2-(2,6- dioxopiperidin-3-yl) isoindoline-1,3-dione
    16
    Figure US20210002289A1-20210107-C00071
         		4-((2-(2-(2-aminoethoxy) ethoxy)ethyl)amino)-2- (2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    17
    Figure US20210002289A1-20210107-C00072
         		4-((2-(2-(2-(2- aminoethoxy)ethoxy) ethoxy)ethyl)amino)-2-(2,6- dioxopiperidin-3-yl) isoindoline-1,3-dione
    18
    Figure US20210002289A1-20210107-C00073
         		4-((3-(4-(3-aminopropoxy) butoxy)propyl)amino)- 2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione
    19
    Figure US20210002289A1-20210107-C00074
         		4-((23-amino-3,6,9,12,15,18,21- heptaoxatricosyl)amino)-2- (2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    20
    Figure US20210002289A1-20210107-C00075
         		3-(4-((2-(2-aminoethoxy)ethyl) amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    21
    Figure US20210002289A1-20210107-C00076
         		3-(4-((2-(2-(2-aminoethoxy) ethoxy)ethyl)amino)- 1-oxoisoindolin-2-yl) piperidine-2,6-dione
    22
    Figure US20210002289A1-20210107-C00077
         		3-(4-((2-(2-(2-(2- aminoethoxy)ethoxy)ethoxy) ethyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    23
    Figure US20210002289A1-20210107-C00078
         		3-(4-((14-amino-3,6,9,12- tetraoxatetradecyl)amino)- 1-oxoisoindolin-2- yl)piperidine-2,6-dione
    24
    Figure US20210002289A1-20210107-C00079
         		3-(4-((3-(2-(2-(3- aminopropoxy)ethoxy) ethoxy)propyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    25
    Figure US20210002289A1-20210107-C00080
         		4-((3-(2-(2-(3- aminopropoxy)ethoxy) ethoxy)propyl)amino)-2-(3- fluoro-2,6-dioxopiperidin- 3-yl)isoindoline-1,3- dione
    26
    Figure US20210002289A1-20210107-C00081
         		3-(4-(3-(2-aminoethoxy) propyl)-1-oxoisoindolin- 2-yl)piperidine-2,6-dione
    27
    Figure US20210002289A1-20210107-C00082
         		3-(4-(3-(2-(2-aminoethoxy) ethoxy)propyl)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    28
    Figure US20210002289A1-20210107-C00083
         		3-(4-(3-(2-(2-(2- aminoethoxy)ethoxy) ethoxy)propyl)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    29
    Figure US20210002289A1-20210107-C00084
         		4-((4-(2-(2-(2- aminoethoxy)ethoxy) ethoxy)butyl)amino)-2-(2,6- dioxopiperidin-3-yl) isoindoline-1,3-dione
    30
    Figure US20210002289A1-20210107-C00085
         		3-(4-((4-(2-(2-(2- aminoethoxy)ethoxy) ethoxy)butyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    31
    Figure US20210002289A1-20210107-C00086
         		3-(4-((3-(4-amino-1H- imidazol-1- yl)propyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    32
    Figure US20210002289A1-20210107-C00087
         		3-(4-(4-(4-amino-1H- imidazol-1-yl)butyl)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    33
    Figure US20210002289A1-20210107-C00088
         		3-(4-((2-(4-(aminomethyl)- 1H-imidazol-1- yl)ethyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    34
    Figure US20210002289A1-20210107-C00089
         		3-(4-(3-(4-(aminomethyl)- 1H-imidazol-1- yl)propyl)-1-oxoisoindolin- 2-yl)piperidine-2,6- dione
    35
    Figure US20210002289A1-20210107-C00090
         		3-(4-((3-(1-(2-aminoethyl)- 1H-imidazol-4- yl)propyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    36
    Figure US20210002289A1-20210107-C00091
         		3-(4-((3-(1-(3-aminopropyl)- 1H-imidazol-4- yl)propyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    37
    Figure US20210002289A1-20210107-C00092
         		3-(4-((3-(4-(3-aminopropyl)- 1H-imidazol-1- yl)propyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    38
    Figure US20210002289A1-20210107-C00093
         		3-(4-(4-(4-(3-aminopropyl)- 1H-imidazol-1- yl)butyl)-1-oxoisoindolin- 2-yl)piperidine-2,6- dione
    39
    Figure US20210002289A1-20210107-C00094
         		3-(4-((3-(5-(2-aminoethyl)- 1H-imidazol-2- yl)propyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    40
    Figure US20210002289A1-20210107-C00095
         		3-(4-(4-(5-(2-aminoethoxy)- 1H-imidazol-2- yl)butyl)-1-oxoisoindolin- 2-yl)piperidine-2,6- dione
    41
    Figure US20210002289A1-20210107-C00096
         		3-(4-(4-(4-aminomethyl)- 1H-imidazol-1- yl)butyl)-1-oxoisoindolin- 2-yl)piperidine-2,6- dione
    42
    Figure US20210002289A1-20210107-C00097
         		4-(4-(4-(aminomethyl)-1H- imidazol-1-yl)butyl)-2- (2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    43
    Figure US20210002289A1-20210107-C00098
         		3-(4-((3-(4-(2-aminoethyl)- 1H-imidazol-1- yl)propyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    44
    Figure US20210002289A1-20210107-C00099
         		3-(4-((3-(4-(aminomethyl)- 1H-imidazol-1- yl)propyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    45
    Figure US20210002289A1-20210107-C00100
         		3-(4-(4-(4-(2-aminoethyl)- 1H-imidazol-1- yl)butyl)-1-oxoisoindolin- 2-yl)piperidine-2,6- dione
    46
    Figure US20210002289A1-20210107-C00101
         		4-(4-(4-(2-aminoethyl)- 1H-imidazol-1-yl)butyl)-2- (2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    47
    Figure US20210002289A1-20210107-C00102
         		3-(4-(((1-(3-aminopropyl)- 1H-imidazol-4- yl)methyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    48
    Figure US20210002289A1-20210107-C00103
         		3-(4-((2-(4-(3-aminopropyl)- 1H-imidazol-2- yl)ethyl)amino)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    49
    Figure US20210002289A1-20210107-C00104
         		3-(4-(2-(1-(3-aminopropyl)- 1H-imidazol-4- yl)ethyl)-1-oxoisoindolin- 2-yl)piperidine-2,6-dione
    50
    Figure US20210002289A1-20210107-C00105
         		4-(2-(1-(3-aminopropyl)- 1H-imidazol-4-yl)ethyl)- 2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    51
    Figure US20210002289A1-20210107-C00106
         		3-(4-(3-((1-(3-aminopropyl)- 1H-imidazol-4- yl)methoxy)propyl)-1- oxoisoindolin-2- yl)piperidine-2,6-dione
    52
    Figure US20210002289A1-20210107-C00107
         		4-(3-((1-(3-aminopropyl)- 1H-imidazol-4- yl)methoxy)propyl)-2- (2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    53
    Figure US20210002289A1-20210107-C00108
         		3-(4-(3-(4-(3-aminopropyl)- 1H-imidazol-2- yl)propyl)-1-oxoisoindolin- 2-yl)piperidine-2,6- dione
    54
    Figure US20210002289A1-20210107-C00109
         		4-(3-(4-(3-aminopropyl)- 1H-imidazol-2- yl)propyl)-2-(2,6-dioxo- piperidin-3-yl)isoindoline- 1,3-dione
    55
    Figure US20210002289A1-20210107-C00110
         		4-(5-aminopentyl)-2- (2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    56
    Figure US20210002289A1-20210107-C00111
         		4-(3-(2-(2-(2-aminoethoxy) ethoxy)ethoxy)propyl)- 2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    57
    Figure US20210002289A1-20210107-C00112
         		4-(3-(2-aminoethoxy) propyl)-2-(2,6- dioxopiperidin-3-yl) isoindoline-1,3-dione
    58
    Figure US20210002289A1-20210107-C00113
         		3-(2-(2-aminoethoxy) ethoxy)-N-(2-(2,6- dioxopiperidin-3-yl)- 1-oxoisoindolin-4- yl)propanamide
    59
    Figure US20210002289A1-20210107-C00114
         		3-(2-(2-(2-aminoethoxy) ethoxy)ethoxy)-N-(2-(2,6- dioxopiperidin-3-yl)-1- oxoisoindolin-4- yl)propanamide
    60
    Figure US20210002289A1-20210107-C00115
         		4-((2-(2-(2-aminoethoxy) ethoxy)ethyl)amino)-2- (2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    61
    Figure US20210002289A1-20210107-C00116
         		3-(4-((4-aminobutyl) amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    62
    Figure US20210002289A1-20210107-C00117
         		3-(4-((3-(2-(2-(3- aminopropoxy)ethoxy) ethoxy)propyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    63
    Figure US20210002289A1-20210107-C00118
         		3-(4-((2-(2-(2-(3- aminopropoxy)ethoxy) ethoxy)ethyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    64
    Figure US20210002289A1-20210107-C00119
         		3-(4-((2-(2-(3-aminopropoxy) ethoxy)ethyl)amino)- 1-oxoisoindolin-2-yl) piperidine-2,6-dione
    65
    Figure US20210002289A1-20210107-C00120
         		3-(4-(1-amino-3,6,9,12-tetra- oxapentadecan-15-yl)- 1-oxoisoindolin-2-yl)piperidine- 2,6-dione
    66
    Figure US20210002289A1-20210107-C00121
         		3-(4-(3-(2-(2-(3- aminopropoxy)ethoxy) ethoxy)propyl)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    67
    Figure US20210002289A1-20210107-C00122
         		3-(4-(3-(2-(2-(3- aminopropoxy)ethoxy) ethoxy)prop-1-yn-1-yl)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    68
    Figure US20210002289A1-20210107-C00123
         		4-(3-(2-(2-aminoethoxy) ethoxy)propyl)-2-(2,6- dioxopiperidin-3-yl) isoindoline-1,3-dione
    69
    Figure US20210002289A1-20210107-C00124
         		4-(((1-(3-aminopropyl)- 1H-imidazol-4- yl)methyl)amino)-2- (2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
    70
    Figure US20210002289A1-20210107-C00125
         		(2S,4R)-1-((S)-2-(5- aminopentanamido)-3,3- dimethylbutanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5-yl)benzyl) pyrrolidine-2- carboxamide
    71
    Figure US20210002289A1-20210107-C00126
         		(2S,4R)-1-((S)-2-(3-(2-(2- aminoethoxy)ethoxy) propanamido)-3,3- dimethylbutanoyl)-4- hydroxy-N-(4-(4- methylthiazol-5-yl) benzyl)pyrrolidine-2- carboxamide
    72
    Figure US20210002289A1-20210107-C00127
         		N-(2-(2-(2-aminoethoxy) ethoxy)ethyl)-2-((2-(2,6- dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4- yl)oxy)acetamide
  • In another embodiment, Compounds of the Disclosure are any one or more of the compounds of Table 2, and salts and solvates thereof.
  • TABLE 2
    Cpd.
    No. Structure Name
     75
    Figure US20210002289A1-20210107-C00128
         		2-(2,6-dioxopiperidin-3-yl)-4-((2-(prop-2-yn-1- yloxy)ethyl)amino)isoindoline-1,3-dione
     76
    Figure US20210002289A1-20210107-C00129
         		2-(2,6-dioxopiperidin-3-yl)-4-(2-(2-(prop-2-yn-1- yloxy)ethoxy)ethoxy)isoindoline-1,3-dione
     77
    Figure US20210002289A1-20210107-C00130
         		2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(prop-2-yn-1- yloxy)ethoxy)ethyl)amino)isoindoline-1,3-dione
     78
    Figure US20210002289A1-20210107-C00131
         		2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(2-(prop-2-yn- 1-yloxy)ethoxy)ethoxy)ethyl)amino)isoindoline- 1,3-dione
     79
    Figure US20210002289A1-20210107-C00132
         		4-((3,6,9,12-tetraoxapentadec-14-yn-1-yl)amino)-2- (2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
     80
    Figure US20210002289A1-20210107-C00133
         		2-(2,6-dioxopiperidin-3-yl)-4-((2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)amino)isoindoline-1,3-dione
     81
    Figure US20210002289A1-20210107-C00134
         		2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-ethynyl-1H- pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione
     82
    Figure US20210002289A1-20210107-C00135
         		2-(2,6-dioxopiperidin-3-yl)-4-(((5-ethynylpyridin-2- yl)methyl)amino)isoindoline-1,3-dione
     83
    Figure US20210002289A1-20210107-C00136
         		2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(4-ethynyl-1H- pyrazol-1-yl)ethoxy)ethyl)amino)isoindoline-1,3- dione
     84
    Figure US20210002289A1-20210107-C00137
         		2-(2,6-dioxopiperidin-3-yl)-4-((3-(4-ethynyl-1H- pyrazol-1-yl)propyl)amino)isoindoline-1,3-dione
     85
    Figure US20210002289A1-20210107-C00138
         		3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)- 1-oxoisoindolin-2-yl)piperidine-2,6-dione
     86
    Figure US20210002289A1-20210107-C00139
         		2-(2,6-dioxopiperidin-3-yl)-4-(5-(5-ethynyl-1H- imidazol-2-yl)pent-1-yn-1-yl)isoindoline-1,3-dione
     87
    Figure US20210002289A1-20210107-C00140
         		3-(4-((4-(4-ethynyl-1H-imidazol-1-yl)butyl)amino)- 1-oxoisoindolin-2-yl)piperidine-2,6-dione
     88
    Figure US20210002289A1-20210107-C00141
         		2-(2,6-dioxopiperidin-3-yl)-4-(5-(4-ethynyl-1H- pyrazol-1-yl)pent-1-yn-1-yl)isoindoline-1,3-dione
     89
    Figure US20210002289A1-20210107-C00142
         		3-(4-(5-(5-ethynyl-1-methyl-1H-imidazol-2-yl)pent- 1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione
     90
    Figure US20210002289A1-20210107-C00143
         		2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-ethynyl-1H- pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione
     91
    Figure US20210002289A1-20210107-C00144
         		3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)- 1-oxoisoindolin-2-yl)piperidine-2,6-dione
     92
    Figure US20210002289A1-20210107-C00145
         		3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pent-1-yn-1-yl)- 1-oxoisoindolin-2-yl)piperidine-2,6-dione
     93
    Figure US20210002289A1-20210107-C00146
         		3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-1- oxoisoindolin-2-yl)piperidine-2,6-dione
     94
    Figure US20210002289A1-20210107-C00147
         		3-(4-(5-(4-ethynyl-1H-imidazol-1-yl)pent-1-yn-1- yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
     95
    Figure US20210002289A1-20210107-C00148
         		2-(2,6-dioxopiperidin-3-yl)-4-(5-(4-ethynyl-1H- imidazol-1-yl)pent-1-yn-1-yl)isoindoline-1,3-dione
     96
    Figure US20210002289A1-20210107-C00149
         		2-(2,6-dioxopiperidin-3-yl)-4-(5-(4-ethynyl-1H- imidazol-1-yl)pent-1-yn-1-yl)isoindoline-1,3-dione
     97
    Figure US20210002289A1-20210107-C00150
         		2-(2,6-dioxopiperidin-3-yl)-4-(4-(4-ethynyl-1H- pyrazol-1-yl)butoxy)isoindoline-1,3-dione
     98
    Figure US20210002289A1-20210107-C00151
         		3-(4-(5-(4-ethynyl-1H-1,2,3-triazol-1-yl)pent-1-yn- 1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
     99
    Figure US20210002289A1-20210107-C00152
         		3-(4-(5-(4-ethynyl-1H-1,2,3-triazol-1-yl)pentyl)-1- oxoisoindolin-2-yl)piperidine-2,6-dione
    100
    Figure US20210002289A1-20210107-C00153
         		3-(4-((4-(4-ethynyl-1H-1,2,3-triazol-1- yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine- 2,6-dione
    101
    Figure US20210002289A1-20210107-C00154
         		3-(4-((4-(6-ethynylpyridin-3-yl)butyl)amino)-1- oxoisoindolin-2-yl)piperidine-2,6-dione
    102
    Figure US20210002289A1-20210107-C00155
         		2-(2,6-dioxopiperidin-3-yl)-4-(4-(6-ethynylpyridin- 3-yl)butoxy)isoindoline-1,3-dione
    103
    Figure US20210002289A1-20210107-C00156
         		3-(4-(4-((6-ethynylpyridin-3-yl)oxy)butyl)-1- oxoisoindolin-2-yl)piperidine-2,6-dione
    104
    Figure US20210002289A1-20210107-C00157
         		3-(4-(5-(6-ethynylpyridin-3-yl)pent-1-yn-1-yl)-1- oxoisoindolin-2-yl)piperidine-2,6-dione
    105
    Figure US20210002289A1-20210107-C00158
         		3-(4-(4-((6-ethynylpyridin-3-yl)oxy)but-1-yn-1-yl)- 1-oxoisoindolin-2-yl)piperidine-2,6-dione
    106
    Figure US20210002289A1-20210107-C00159
         		3-(4-((4-(5-ethynylpyridin-2-yl)butyl)amino)-1- oxoisoindolin-2-yl)piperidine-2,6-dione
    107
    Figure US20210002289A1-20210107-C00160
         		3-(4-(5-(5-ethynylpyridin-2-yl)pent-1-yn-1-yl)-1- oxoisoindolin-2-yl)piperidine-2,6-dione
    108
    Figure US20210002289A1-20210107-C00161
         		3-(4-(5-(5-ethynyl-1H-imidazol-1-yl)pent-1-yn-1- yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    109
    Figure US20210002289A1-20210107-C00162
         		3-(4-(4-(3-(4-ethynyl-1H-pyrazol-1- yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    110
    Figure US20210002289A1-20210107-C00163
         		2-(2,6-dioxopiperidin-3-yl)-4-(4-(3-(4-ethynyl-1H- pyrazol-1-yl)propyl)piperazin-1-yl)isoindoline-1,3- dione
    111
    Figure US20210002289A1-20210107-C00164
         		3-(4-(4-(3-(4-ethynyl-1H-pyrazol-1- yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    112
    Figure US20210002289A1-20210107-C00165
         		2-(2,6-dioxopiperidin-3-yl)-4-(4-(3-(4-ethynyl-1H- pyrazol-1-yl)propyl)piperazin-1-yl)isoindoline-1,3- dione
    113
    Figure US20210002289A1-20210107-C00166
         		3-(4-((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3- yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6- dione
    114
    Figure US20210002289A1-20210107-C00167
         		3-(4-(((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3- yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine- 2,6-dione
    115
    Figure US20210002289A1-20210107-C00168
         		3-(4-(2-(1-((6-ethynylpyridin-3-yl)methyl)azetidin- 3-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione
    116
    Figure US20210002289A1-20210107-C00169
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-((6- ethynylpyridin-3-yl)methyl)azetidin-3- yl)methoxy)isoindoline-1,3-dione
    117
    Figure US20210002289A1-20210107-C00170
         		2-(2,6-dioxopiperidin-3-yl)-4-(((1-((6- ethynylpyridin-3-yl)methyl)azetidin-3- yl)methyl)amino)isoindoline-1,3-dione
    117
    Figure US20210002289A1-20210107-C00171
         		2-(2,6-dioxopiperidin-3-yl)-4-(2-(1-((6- ethynylpyridin-3-yl)methyl)azetidin-3- yl)ethyl)isoindoline-1,3-dione
    119
    Figure US20210002289A1-20210107-C00172
         		3-(4-((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3- yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6- dione
    120
    Figure US20210002289A1-20210107-C00173
         		3-(4-(((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3- yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine- 2,6-dione
    121
    Figure US20210002289A1-20210107-C00174
         		3-(4-(2-(1-((6-ethynylpyridin-3-yl)methyl)azetidin- 3-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6- dione
    122
    Figure US20210002289A1-20210107-C00175
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-((6- ethynylpyridin-3-yl)methyl)azetidin-3- yl)methoxy)isoindoline-1,3-dione
    123
    Figure US20210002289A1-20210107-C00176
         		2-(2,6-dioxopiperidin-3-yl)-4-(((1-((6- ethynylpyridin-3-yl)methyl)azetidin-3- yl)methyl)amino)isoindoline-1,3-dione
    124
    Figure US20210002289A1-20210107-C00177
         		2-(2,6-dioxopiperidin-3-yl)-4-(2-(1-((6- ethynylpyridin-3-yl)methyl)azetidin-3- yl)ethyl)isoindoline-1,3-dione
    125
    Figure US20210002289A1-20210107-C00178
         		3-(4-((1-((6-ethynylpyridin-3-yl)methyl)piperidin- 4-yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6- dione
    126
    Figure US20210002289A1-20210107-C00179
         		3-(4-(((1-((6-ethynylpyridin-3-yl)methyl)piperidin- 4-yl)methyl)amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    127
    Figure US20210002289A1-20210107-C00180
         		3-(4-(2-(1-((6-ethynylpyridin-3- yl)methyl)piperidin-4-yl)ethyl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    128
    Figure US20210002289A1-20210107-C00181
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-((6- ethynylpyridin-3-yl)methyl)piperidin-4- yl)methoxy)isoindoline-1,3-dione
    129
    Figure US20210002289A1-20210107-C00182
         		2-(2,6-dioxopiperidin-3-yl)-4-(((1-((6- ethynylpyridin-3-yl)methyl)piperidin-4- yl)methyl)amino)isoindoline-1,3-dione
    130
    Figure US20210002289A1-20210107-C00183
         		2-(2,6-dioxopiperidin-3-yl)-4-(2-(1-((6- ethynylpyridin-3-yl)methyl)piperidin-4- yl)ethyl)isoindoline-1,3-dione
    131
    Figure US20210002289A1-20210107-C00184
         		3-(4-((1-((6-ethynylpyridin-3-yl)methyl)piperidin- 4-yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6- dione
    132
    Figure US20210002289A1-20210107-C00185
         		3-(4-(((1-((6-ethynylpyridin-3-yl)methyl)piperidin- 4-yl)methyl)amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    133
    Figure US20210002289A1-20210107-C00186
         		3-(4-(2-(1-((6-ethynylpyridin-3- yl)methyl)piperidin-4-yl)ethyl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    134
    Figure US20210002289A1-20210107-C00187
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-((6- ethynylpyridin-3-yl)methyl)piperidin-4- yl)methoxy)isoindoline-1,3-dione
    135
    Figure US20210002289A1-20210107-C00188
         		2-(2,6-dioxopiperidin-3-yl)-4-(((1-((6- ethynylpyridin-3-yl)methyl)piperidin-4- yl)methyl)amino)isoindoline-1,3-dione
    136
    Figure US20210002289A1-20210107-C00189
         		2-(2,6-dioxopiperidin-3-yl)-4-(2-(1-((6- ethynylpyridin-3-yl)methyl)piperidin-4- yl)ethyl)isoindoline-1,3-dione
    137
    Figure US20210002289A1-20210107-C00190
         		3-(4-((4-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperazin-1-yl)methyl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    138
    Figure US20210002289A1-20210107-C00191
         		2-(2,6-dioxopiperidin-3-yl)-4-((4-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperazin-1- yl)methyl)isoindoline-1,3-dione
    139
    Figure US20210002289A1-20210107-C00192
         		3-(4-((4-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperazin-1-yl)methyl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    140
    Figure US20210002289A1-20210107-C00193
         		2-(2,6-dioxopiperidin-3-yl)-4-((4-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperazin-1- yl)methyl)isoindoline-1,3-dione
    141
    Figure US20210002289A1-20210107-C00194
         		3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    142
    Figure US20210002289A1-20210107-C00195
         		3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperidin-4-yl)amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    143
    Figure US20210002289A1-20210107-C00196
         		3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperidin-4-yl)methyl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    144
    Figure US20210002289A1-20210107-C00197
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)isoindoline- 1,3-dione
    145
    Figure US20210002289A1-20210107-C00198
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperidin-4- yl)amino)isoindoline-1,3-dione
    146
    Figure US20210002289A1-20210107-C00199
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperidin-4- yl)methyl)isoindoline-1,3-dione
    147
    Figure US20210002289A1-20210107-C00200
         		3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    148
    Figure US20210002289A1-20210107-C00201
         		3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperidin-4-yl)amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    149
    Figure US20210002289A1-20210107-C00202
         		3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperidin-4-yl)methyl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    150
    Figure US20210002289A1-20210107-C00203
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)isoindoline- 1,3-dione
    151
    Figure US20210002289A1-20210107-C00204
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperidin-4- yl)amino)isoindoline-1,3-dione
    152
    Figure US20210002289A1-20210107-C00205
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperidin-4- yl)methyl)isoindoline-1,3-dione
    153
    Figure US20210002289A1-20210107-C00206
         		3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-5- fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    154
    Figure US20210002289A1-20210107-C00207
         		3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-6- fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    155
    Figure US20210002289A1-20210107-C00208
         		3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-7- fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    156
    Figure US20210002289A1-20210107-C00209
         		3-(4-(4-(4-ethynyl-1H-pyrazol-1-yl)butoxy)-5- fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    157
    Figure US20210002289A1-20210107-C00210
         		3-(4-(4-(4-ethynyl-1H-pyrazol-1-yl)butoxy)-6- fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    158
    Figure US20210002289A1-20210107-C00211
         		3-(4-(4-(4-ethynyl-1H-pyrazol-1-yl)butoxy)-7- fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    159
    Figure US20210002289A1-20210107-C00212
         		3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)- 5-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    160
    Figure US20210002289A1-20210107-C00213
         		3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)- 6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    161
    Figure US20210002289A1-20210107-C00214
         		3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)- 7-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
    162
    Figure US20210002289A1-20210107-C00215
         		3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperidin-4-yl)amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    163
    Figure US20210002289A1-20210107-C00216
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperidin-4- yl)amino)isoindoline-1,3-dione
    164
    Figure US20210002289A1-20210107-C00217
         		3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1- yl)ethyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    165
    Figure US20210002289A1-20210107-C00218
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)isoindoline- 1,3-dione
    166
    Figure US20210002289A1-20210107-C00219
         		3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H- imidazol-4-yl)methoxy)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    167
    Figure US20210002289A1-20210107-C00220
         		3-(4-(((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H- imidazol-4-yl)methyl)amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    168
    Figure US20210002289A1-20210107-C00221
         		2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)-1H-imidazol-4- yl)methoxy)isoindoline-1,3-dione
    169
    Figure US20210002289A1-20210107-C00222
         		2-(2,6-dioxopiperidin-3-yl)-4-(((1-(2-(4-ethynyl- 1H-pyrazol-1-yl)ethyl)-1H-imidazol-4- yl)methyl)amino)isoindoline-1,3-dione
    170
    Figure US20210002289A1-20210107-C00223
         		3-(4-((4-((4-ethynyl-1H-pyrazol-1- yl)methyl)benzyl)oxy)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    171
    Figure US20210002289A1-20210107-C00224
         		3-(4-((4-((4-ethynyl-1H-pyrazol-1- yl)methyl)benzyl)amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    172
    Figure US20210002289A1-20210107-C00225
         		2-(2,6-dioxopiperidin-3-yl)-4-((4-((4-ethynyl-1H- pyrazol-1-yl)methyl)benzyl)oxy)isoindoline-1,3- dione
    173
    Figure US20210002289A1-20210107-C00226
         		2-(2,6-dioxopiperidin-3-yl)-4-((4-((4-ethynyl-1H- pyrazol-1-yl)methyl)benzyl)amino)isoindoline-1,3- dione
  • In another embodiment, Compounds of the Disclosure are any one or more of the compounds of Table 3, and salts and solvents thereof.
  • TABLE 3
    Cpd.
    No. Structure Name
    174
    Figure US20210002289A1-20210107-C00227
         		3-(4-(4-(4-ethynyl- 1H-pyrazol-1-yl) butoxy)-1-oxoisoindolin- 2-yl)piperidine-2,6-dione
    175
    Figure US20210002289A1-20210107-C00228
         		3-(5-((4-(4-ethynyl- 1H-pyrazol-1-yl) butyl)amino)-2-methyl- 4-oxoquinazolin-3(4H)-yl) piperidine-2,6-dione
    176
    Figure US20210002289A1-20210107-C00229
         		2-(2,6-dioxopiperidin- 3-yl)-4-((1-(3- (4-ethynyl-1H-pyrazol- 1-yl)propyl)piperidin- 4-yl)amino) isoindoline-1,3-dione
    177
    Figure US20210002289A1-20210107-C00230
         		2-(2,6-dioxopiperidin-3- yl)-4-((1-(2-(4- ethynyl-1H-pyrazol- 1-yl)ethyl)piperidin-4-yl) amino)isoindoline-1,3-dione
    178
    Figure US20210002289A1-20210107-C00231
         		2-(2,6-dioxopiperidin-3-yl)- 4-(4-(2-(4-ethynyl- 1H-pyrazol-1- yl)ethyl)piperazin-1-yl) isoindoline-1,3-dione
    179
    Figure US20210002289A1-20210107-C00232
         		3-(4-(((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)- 1H-imidazol- 4-yl)methyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    180
    Figure US20210002289A1-20210107-C00233
         		2-(2,6-dioxopiperidin-3-yl)- 4-(4-(3-(4-ethynyl- 1H-pyrazol-1-yl) propyl)piperazin-1-yl) isoindoline-1,3-dione
    181
    Figure US20210002289A1-20210107-C00234
         		3-(4-((4-((4-ethynyl-1H- pyrazol-1-yl)methyl) benzyl)amino)- 1-oxoisoindolin-2-yl) piperidine-2,6-dione
    182
    Figure US20210002289A1-20210107-C00235
         		3-(4-(((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)- 1H-imidazol- 5-yl)methyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    183
    Figure US20210002289A1-20210107-C00236
         		2-(2,6-dioxopiperidin-3-yl)- 4-(4-(4-(4-ethynyl-1H- pyrazol-1- yl)butyl)piperazin-1- yl)isoindoline-1,3-dione
    184
    Figure US20210002289A1-20210107-C00237
         		3-(4-(((1-(3-(4-ethynyl- 1H-pyrazol-1-yl)propyl)-1H- imidazol-4-yl)methyl) amino)-1- oxoisoindolin-2- yl)piperidine-2,6-dione
    185
    Figure US20210002289A1-20210107-C00238
         		3-(4-(((1-((5-ethynylpyridin- 2-yl)methyl)piperidin-4- yl)methyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    186
    Figure US20210002289A1-20210107-C00239
         		3-(4-(((1-((6-ethynylpyridin- 3-yl)methyl)azetidin-3- yl)methyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    187
    Figure US20210002289A1-20210107-C00240
         		2-(2,6-dioxopiperidin-3- yl)-4-((1-(2-(4-ethynyl- 1H-pyrazol- 1-yl)ethyl)piperidin-4-yl) oxy)isoindoline-1,3-dione
    188
    Figure US20210002289A1-20210107-C00241
         		3-(4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)- 1H-imidazol-4-yl) methoxy)-1-oxoisoindolin- 2-yl)piperidine-2,6-dione
    189
    Figure US20210002289A1-20210107-C00242
         		3-(4-((1-(3-(4-ethynyl-1H- pyrazol-1-yl)propyl) piperidin-4-yl) amino)-1-oxoisoindolin- 2-yl)piperidine-2,6-dione
    190
    Figure US20210002289A1-20210107-C00243
         		2-(2,6-dioxopiperidin-3-yl)- 4-((1-(3-(4-ethynyl- 1H-pyrazol-1-yl) propyl)piperidin-4-yl)oxy) isoindoline-1,3-dione
    191
    Figure US20210002289A1-20210107-C00244
         		3-(4-((1-(3-(4-ethynyl-1H- pyrazol-1-yl)propyl)- 1H-imidazol-4-yl) methoxy)-1-oxoisoindolin- 2-yl)piperidine-2,6-dione
    192
    Figure US20210002289A1-20210107-C00245
         		3-(4-((1-(4-(4-ethynyl-1H- pyrazol-1-yl)butyl) piperidin-4-yl) amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    193
    Figure US20210002289A1-20210107-C00246
         		2-(2,6-dioxopiperidin-3-yl)- 4-((1-(4-(4-ethynyl- 1H-pyrazol-1-yl) butyl)piperidin-4-yl) oxy)isoindoline-1,3-dione
    194
    Figure US20210002289A1-20210107-C00247
         		3-(4-(((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)- 1H-imidazol- 4-yl)methyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6- dione
    195
    Figure US20210002289A1-20210107-C00248
         		3-(4-(((1-(3-(4-ethynyl-1H- pyrazol-1-yl)propyl)-1H- imidazol-4-yl)methyl) amino)-1- oxoisoindolin-2- yl)piperidine-2,6-dione
    196
    Figure US20210002289A1-20210107-C00249
         		3-(4-(((1-(4-(4-ethynyl-1H- pyrazol-1-yl)butyl)- 1H-imidazol- 4-yl)methyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    197
    Figure US20210002289A1-20210107-C00250
         		3-(4-((4-((4-ethynyl- 1H-pyrazol-1-yl) methyl)cyclohexyl)amino)- 1-oxoisoindolin-2- yl)piperidine-2,6-dione
    198
    Figure US20210002289A1-20210107-C00251
         		3-(4-((3-((4-ethynyl- 1H-pyrazol-1-yl) methyl)cyclobutyl)amino)- 1-oxoisoindolin-2- yl)piperidine-2,6-dione
    199
    Figure US20210002289A1-20210107-C00252
         		3-(4-(((1-(2-(4-ethynyl- 1H-pyrazol-1-yl)ethyl) piperidin-4- yl)methyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    200
    Figure US20210002289A1-20210107-C00253
         		3-(4-(((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)azetidin- 3-yl)methyl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    201
    Figure US20210002289A1-20210107-C00254
         		3-(4-((1-(2-(4-ethynyl-1H- pyrazol-1-yl)ethyl)azetidin-3- yl)amino)-1-oxoisoindolin- 2-yl)piperidine-2,6-dione
    202
    Figure US20210002289A1-20210107-C00255
         		3-(4-((1-(3-(4-ethynyl-1H- pyrazol-1-yl)propyl) azetidin-3-yl) amino)-1-oxoisoindolin- 2-yl)piperidine-2,6-dione
    203
    Figure US20210002289A1-20210107-C00256
         		3-(4-(4-(3-(4-ethynyl-1H- pyrazol-1-yl)propyl) piperazin-1-yl)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
  • In another embodiment, Compounds of the Disclosure are any one or more of the compounds of Table 4, and salts and solvates thereof.
  • TABLE 4
    Cpd.
    No. Structure Name
    204
    Figure US20210002289A1-20210107-C00257
         		3-(4-(3-aminoprop-1-yn-1-yl)-1- oxoisoindolin-2-yl)piperidine-2,6- dione
    205
    Figure US20210002289A1-20210107-C00258
         		3-(4-(5-aminopent-1-yn-1-yl)-1- oxoisoindolin-2-yl)piperidine-2,6- dione
    206
    Figure US20210002289A1-20210107-C00259
         		3-(4-(3-aminopropyl)-1- oxoisoindolin-2-yl)piperidine-2,6- dione
    207
    Figure US20210002289A1-20210107-C00260
         		3-(4-(4-aminobut-1-yn-1-yl)-1- oxoisoindolin-2-yl)piperidine-2,6- dione
    208
    Figure US20210002289A1-20210107-C00261
         		3-(4-(4-aminobutyl)-1- oxoisoindolin-2-yl)piperidine-2,6- dione
    209
    Figure US20210002289A1-20210107-C00262
         		3-(1-oxo-4-(piperidin-4- ylamino)isoindolin-2-yl)piperidine- 2,6-dione
    210
    Figure US20210002289A1-20210107-C00263
         		3-(4-(azetidin-3-ylamino)-1- oxoisoindolin-2-yl)piperidine-2,6- dione
    211
    Figure US20210002289A1-20210107-C00264
         		3-(1-oxo-4-((piperidin-4- ylmethyl)amino)isoindolin-2- yl)piperidine-2,6-dione
    212
    Figure US20210002289A1-20210107-C00265
         		3-(4-((azetidin-3-ylmethyl)amino)- 1-oxoisoindolin-2-yl)piperidine- 2,6-dione
    213
    Figure US20210002289A1-20210107-C00266
         		3-(4-((1-(2-aminoethyl)piperidin-4- yl)amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    214
    Figure US20210002289A1-20210107-C00267
         		3-(4-((1-(2-aminoethyl)azetidin-3- yl)amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    215
    Figure US20210002289A1-20210107-C00268
         		3-(4-(((1-(2-aminoethyl)piperidin- 4-yl)methyl)amino)-1- oxoisoindolin-2-yl)piperidine-2,6- dione
    216
    Figure US20210002289A1-20210107-C00269
         		3-(4-(((1-(2-aminoethyl)azetidin-3- yl)methyl)amino)-1-oxoisoindolin- 2-yl)piperidine-2,6-dione
    217
    Figure US20210002289A1-20210107-C00270
         		3-(4-(2-(4-aminocyclohexyl)ethyl)- 1-oxoisoindolin-2-yl)piperidine- 2,6-dione
    218
    Figure US20210002289A1-20210107-C00271
         		3-(1-oxo-4-(piperidin-4- ylethynyl)isoindolin-2- yl)piperidine-2,6-dione
    219
    Figure US20210002289A1-20210107-C00272
         		3-(1-oxo-4-(2-(piperidin-4- yl)ethyl)isoindolin-2-yl)piperidine- 2,6-dione
    220
    Figure US20210002289A1-20210107-C00273
         		4-(4-(2-aminoethyl)piperazin-1-yl)- 2-(2,6-dioxopiperidin-3- yl)isoindoline-1,3-dione
  • In another embodiment, Compounds of the Disclosure are any one or more of the compounds of Table 5, and salts and solvates thereof.
  • TABLE 5
    Cpd.
    No. Structure Name
    221
    Figure US20210002289A1-20210107-C00274
         		(2S,4R)-1-((S)-2-(5- aminopentanamido)-3,3- dimethylbutanoyl)-4-hydroxy-N- ((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2- carboxamide
    222
    Figure US20210002289A1-20210107-C00275
         		(2S,4R)-1-((S)-2-(3-(2-(2- aminoethoxy)ethoxy) propanamido)-3,3- dimethylbutanoyl)-4- hydroxy-N-((S)-1-(4-(4- methylthiazol-5-yl)phenyl) ethyl)pyrrolidine-2- carboxamide
    223
    Figure US20210002289A1-20210107-C00276
         		(2S,4R)-1-((S)-1-amino-14- (tert-butyl)-12-oxo- 3,6,9-trioxa-13-azapentadecan- 15-oyl)-4-hydroxy- N-((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2- carboxamide
    224
    Figure US20210002289A1-20210107-C00277
         		3-(5-(5-aminopent-1-yn-1- yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    225
    Figure US20210002289A1-20210107-C00278
         		3-(6-(5-aminopent-1-yn-1- yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    226
    Figure US20210002289A1-20210107-C00279
         		3-(5-(5-aminopentyl)-1- oxoisoindolin-2- yl)piperidine-2,6-dione
    227
    Figure US20210002289A1-20210107-C00280
         		3-(6-(5-aminopentyl)-1- oxoisoindolin-2- yl)piperidine-2,6-dione
    228
    Figure US20210002289A1-20210107-C00281
         		3-(4-(((1r,4r)-4- aminocyclohexyl)ethynyl)- 1-oxoisoindolin-2- yl)piperidine-2,6-dione
    229
    Figure US20210002289A1-20210107-C00282
         		3-(4-(5-aminopent-1-yn- 1-yl)-7-fluoro-1- oxoisoindolin-2- yl)piperidine-2,6-dione
    230
    Figure US20210002289A1-20210107-C00283
         		3-(4-((Z)-2-((1r,4r)-4- aminocyclohexyl)vinyl)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    231
    Figure US20210002289A1-20210107-C00284
         		3-(4-(2-((1r,4s)-4- aminocyclohexyl)ethyl)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    232
    Figure US20210002289A1-20210107-C00285
         		3-(4-(6-(4-aminopiperidin- 1-yl)-6-oxohex-1-yn-1- yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    233
    Figure US20210002289A1-20210107-C00286
         		3-(4-(5-(4-aminopiperidin- 1-yl)-5-oxopent-1-yn-1- yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    234
    Figure US20210002289A1-20210107-C00287
         		N-((1r,4r)-4-aminocyclohexyl)- 6-(2-(2,6-dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)hex-5- ynamide
    235
    Figure US20210002289A1-20210107-C00288
         		N-((1r,4r)-4-aminocyclohexyl)- 5-(2-(2,6-dioxopiperidin-3- yl)-1-oxoisoindolin-4-yl)pent-4- ynamide
    236
    Figure US20210002289A1-20210107-C00289
         		3-(4-(3-(2-(2-aminoethoxy) ethoxy)prop-1-yn-1- yl)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    237
    Figure US20210002289A1-20210107-C00290
         		3-(4-(3-(2-(2-(2- aminoethoxy)ethoxy) ethoxy)prop-1-yn-1- yl)-1-oxoisoindolin-2- yl)piperidine-2,6- dione
    238
    Figure US20210002289A1-20210107-C00291
         		3-(4-(4-aminobutoxy)- 1-oxoisoindolin-2- yl)piperidine-2,6-dione
    239
    Figure US20210002289A1-20210107-C00292
         		3-(4-((1-(3-aminopropyl)- 1H-pyrazol-4-yl)ethynyl)- 1-oxoisoindolin-2- yl)piperidine-2,6-dione
    240
    Figure US20210002289A1-20210107-C00293
         		3-(4-(2-(1-(3-aminopropyl)- 1H-pyrazol-4-yl)ethyl)-1- oxoisoindolin-2-yl)piperidine- 2,6-dione
    241
    Figure US20210002289A1-20210107-C00294
         		3-(4-((1-(3-aminopropyl)- 1H-imidazol-5-yl)ethynyl)- 1-oxoisoindolin-2- yl)piperidine-2,6- dione
    242
    Figure US20210002289A1-20210107-C00295
         		3-(4-(2-(1-(3-aminopropyl)- 1H-imidazol-5-yl)ethyl)- 1-oxoisoindolin-2- yl)piperidine-2,6- dione
    243
    Figure US20210002289A1-20210107-C00296
         		3-(4-((1-(3-aminopropyl) piperidin-4-yl)amino)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    244
    Figure US20210002289A1-20210107-C00297
         		3-(4-(7-(4-aminopiperidin- 1-yl)hept-1-yn-1-yl)-1- oxoisoindolin-2-yl) piperidine-2,6-dione
    245
    Figure US20210002289A1-20210107-C00298
         		3-(4-((17-amino- 3,6,9,12,15- pentaoxaheptadecyl) amino)-1-oxoisoindolin-2- yl)piperidine-2,6-dione
    246
    Figure US20210002289A1-20210107-C00299
         		1-((2-(2,6-dioxopiperidin- 3-yl)-1,3-dioxoisoindolin- 4-yl)amino)-3,6,9,12,15,18,21,24- octaoxaheptacosan-27-oic acid
    247
    Figure US20210002289A1-20210107-C00300
         		14-((2-(2,6-dioxopiperidin- 3-yl)-1-oxoisoindolin- 4-yl)amino)-3,6,9,12- tetraoxatetradecanoic acid
    248
    Figure US20210002289A1-20210107-C00301
         		2-(2-(2-(2-aminoethoxy) ethoxy)ethoxy)-N-(2-(2,6- dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)acetamide
    249
    Figure US20210002289A1-20210107-C00302
         		1-((2-(2,6-dioxopiperidin- 3-yl)-1,3- dioxoisoindolin-4-yl)amino)- 3,6,9,12-tetraoxapentadecan- 15-oic acid
    250
    Figure US20210002289A1-20210107-C00303
         		3-(2-(2-(2-((2-(2,6- dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4- yl)amino)ethoxy)ethoxy) ethoxy)propanoic acid
    251
    Figure US20210002289A1-20210107-C00304
         		(2S,4R)-1-((S)-1-amino- 17-(tert-butyl)-15-oxo- 3,6,9,12-tetraoxa-16- azaoctadecan-18-oyl)-4- hydroxy-N-((S)-1-(4-(4- methylthiazol-2- yl)phenyl)ethyl)pyrrolidine- 2-carboxamide
    252
    Figure US20210002289A1-20210107-C00305
         		1-amino-N-(2-(2,6- dioxopiperidin-3-yl)-1- oxoisoindolin-4-yl)- 3,6,9,12-tetraoxapentadecan- 15-amide
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX:
  • Figure US20210002289A1-20210107-C00306
  • and the pharmaceutically acceptable salts or solvates thereof, wherein T is a monovalent radical of a target protein inhibitor, and X, L, Y, and B are as defined in connection with Formula I.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX:
  • Figure US20210002289A1-20210107-C00307
  • and the pharmaceutically acceptable salts or solvates thereof, wherein T is a monovalent radical of a target protein inhibitor, and X, L, Y, and B are as defined in connection with Formula I, the method comprising condensing a compound having Formula I, with compound having Formula X:

  • T-X3X
  • wherein:
  • T is a monovalent radical of a target protein inhibitor;
  • X3 is selected from the group consisting of —C(═O)OH and -LG; and
  • LG is a leaving group, e.g., —Cl, —Br, —I, —OTs, —OMs.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the pharmaceutically acceptable salts or solvates thereof, comprising:
  • (1) condensing a compound having Formula I:
  • Figure US20210002289A1-20210107-C00308
  • wherein:
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00309
  • X is selected from the group consisting of —C≡C—, —O—, —N(R2a)—,
  • Figure US20210002289A1-20210107-C00310
  • wherein the —N(R2b)— of
  • Figure US20210002289A1-20210107-C00311
  • is attached to L and the —O— of
  • Figure US20210002289A1-20210107-C00312
  • is attached to L
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n—, and —(CH2)r—W—(CH2)u—O—(CH2)v—;
  • A is absent; or
  • A is heteroarylenyl;
  • W is selected from the group consisting of phenylenyl, heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • r is 0, 1, 2 or 3;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C≡C—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2a, R2b, R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00313
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl, with compound having Formula X:

  • T-X3X
  • wherein:
  • T is a monovalent radical of a target protein inhibitor;
  • X3 is selected from the group consisting of —C(═O)OH and -LG; and
  • LG is a leaving group, e.g., —Cl, —Br, —I, —OTs, —OMs,
  • (2) isolating the compound having Formula IX.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the pharmaceutically acceptable salts or solvates thereof, wherein the compound having Formula I are not any one of the compounds of Table 6, or any stereoisomer thereof.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein X is —C≡C—.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein X is —N(H)—.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein X is
  • Figure US20210002289A1-20210107-C00314
  • and the carbon atom of
  • Figure US20210002289A1-20210107-C00315
  • is attached to L.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is C1-12 alkylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2(CH2)2CH2—, —CH2(CH2)3CH2—, —CH2(CH2)4CH2—, —CH2(CH2)5CH2—, and —CH2(CH2)6CH2—.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is 3- to 12-membered heteroalkylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is —(CH2)oO—(CH2CH2O)p—(CH2)q—;
  • o is 1, 2, or 3;
  • p is 0, 1, 2, 3, 4, or 5; and
  • q is 1, 2, or 3.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of
  • —CH2OCH2CH2—
  • —CH2CH2OCH2CH2—,
  • —CH2O(CH2CH2O)CH2CH2—
  • —CH2O(CH2CH2O)2CH2CH2—,
  • —CH2O(CH2CH2O)3CH2CH2—,
  • —CH2CH2O(CH2CH2O)6CH2CH2—,
  • —CH2CH2O(CH2CH2O)6CH2CH2—,
  • —CH2CH2CH2OCH2CH2OCH2CH2CH2—,
  • —CH2CH2CH2O(CH2CH2O)2CH2CH2CH2—, and
  • —CH2CH2CH2O(CH2)4OCH2CH2CH2—.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and A is absent.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is phenylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00316
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is 5-membered heteroarylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00317
  • Q3 is selected from the group consisting of —O—, —S—, and —N(R6)—; and
  • R6 is selected from the group consisting of hydrogen and C1-4 alkyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is 6-membered heteroarylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00318
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is heterocyclenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00319
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n—, A is absent, and W is cycloalkylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00320
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is -A-(CH2)m—W—(CH2)n—; and
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is phenylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula XX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00321
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is 5-membered heteroarylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00322
  • Q3 is selected from the group consisting of —O—, —S—, and —N(R6)—; and
  • R6 is selected from the group consisting of hydrogen and C1-4 alkyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is 6-membered heternarylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00323
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is heterocyclenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00324
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and W is cycloalkylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00325
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and A is a 5-membered heteroarylenyl. In another embodiment, A is a 5-membered heteroarylenyl selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00326
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is -A-(CH2)m—W—(CH2)n— and A is a 6-membered heteroarylenyl. In another embodiment, A is:
  • Figure US20210002289A1-20210107-C00327
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • L is —(CH2)r—W—(CH2)u—O—(CH2)v—;
  • r is 0, 1, or 2;
  • u is 1, 2, or 3; and
  • v is 1, 2, or 3.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein L is —(CH2)r—W—(CH2)u—O—(CH2)v— and W is selected from the group consisting of phenylenyl and heteroarylenyl. In another embodiment, W is 5-membered heteroarylenyl.
  • In another embodiment, W is 6-membered heteroarylenyl.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein Y is selected from the group consisting of —C≡C—, —CH2—, —O—, and —N(R2c)—. In another embodiment, Y is —C≡C—. In another embodiment, Y is —CH2—. In another embodiment, Y is —O—. In another embodiment, Y is —N(H)—.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-1a.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • Bis B-1a;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═; and
  • R16a is selected from the group consisting of hydrogen and halo.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • B is B-1a;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═; and
  • R16b is selected from the group consisting of hydrogen and halo.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein:
  • Bis B-1a;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═; and
  • R16c is selected from the group consisting of hydrogen and halo.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-1a and Z is —CH2—.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-1a and Z is —C(═O)—.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-1a and R5 is hydrogen.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B is B-2.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein B-3.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein T is a monovalent radical of an oncogenic protein inhibitor.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein T is a monovalent radical of a MDM2 protein inhibitor.
  • In another embodiment, the disclosure provides a method of preparing a compound having Formula IX, and the salts or solvates thereof, wherein T is a monovalent radical of a BET bromodomain protein inhibitor.
  • In another embodiment, the disclosure provides methods of making a compound having Formula VII:
  • Figure US20210002289A1-20210107-C00328
  • or a pharmaceutically acceptable salt or solvate thereof, wherein:
  • T is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00329
    Figure US20210002289A1-20210107-C00330
    Figure US20210002289A1-20210107-C00331
  • X is selected from the group consisting of —N(R2a)—,
  • Figure US20210002289A1-20210107-C00332
  • wherein the —N(H)— of
  • Figure US20210002289A1-20210107-C00333
  • is attached to L and the —O— of
  • Figure US20210002289A1-20210107-C00334
  • is attached to L;
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH2)m—W—(CH2)n—;
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C≡C—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2a, R2b, R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—; and
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro, the method comprising:
  • (1) reacting a compound selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00335
    Figure US20210002289A1-20210107-C00336
  • wherein R7 is a leaving group, e.g., R7 is selected from the group consisting of —Cl and —OH,
  • with a compound having Formula II:
  • Figure US20210002289A1-20210107-C00337
  • wherein:
  • X is selected from the group consisting of —N(R2a)—,
  • Figure US20210002289A1-20210107-C00338
  • wherein the —N(H)— of
  • Figure US20210002289A1-20210107-C00339
  • is attached to L and the —O— of
  • Figure US20210002289A1-20210107-C00340
  • is attached to L;
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH2)m—W—(CH2)n—;
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C≡C—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2a, R2b, R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2— and —C(═O)—; and
  • R5 is selected from the group consisting of hydrogen and fluoro, and
  • (2) isolating the compound having Formula VII, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the disclosure provides methods of making a compound having Formula VII, or a pharmaceutically acceptable salt or solvate thereof, the method comprising:
  • (1) reacting a compound having the structure:
  • Figure US20210002289A1-20210107-C00341
  • wherein:
  • R11a, R11b, R11c, and R11d are independently selected from the group consisting of hydrogen, chloro, and fluoro;
  • R12a and R12b are independently selected from the group consisting of hydrogen and C1-6 alkyl; or
  • R12a and R12b taken together with the carbon atom to which they are attached form a 4- to 8-membered optionally substituted cycloalkyl; and
  • Q is selected from the group consisting of substituted phenylenyl, optionally substituted heteroarylenyl, and optionally substituted cycloalkylenyl,
  • with a compound having Formula II, and
  • (2) isolating the compound having Formula VII, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the disclosure provides methods of making a compound having Formula VIII:
  • Figure US20210002289A1-20210107-C00342
  • or a pharmaceutically acceptable salt or solvate thereof, wherein:
  • T is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00343
    Figure US20210002289A1-20210107-C00344
    Figure US20210002289A1-20210107-C00345
  • X is selected from the group consisting of —N(R2a)—,
  • Figure US20210002289A1-20210107-C00346
  • wherein the —N(H)— of
  • Figure US20210002289A1-20210107-C00347
  • is attached to L and the —O— of
  • Figure US20210002289A1-20210107-C00348
  • is attached to L;
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH2)m—W—(CH2)n—;
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7; and
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • the method comprising:
  • (1) reacting a compound selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00349
    Figure US20210002289A1-20210107-C00350
    Figure US20210002289A1-20210107-C00351
  • wherein R7 is a leaving group, e.g., R7 is selected from the group consisting of —Cl and —OH,
  • with a compound having Formula III:
  • Figure US20210002289A1-20210107-C00352
  • wherein:
  • X is selected from the group consisting of —N(R2a)—,
  • Figure US20210002289A1-20210107-C00353
  • wherein the —N(H)— of
  • Figure US20210002289A1-20210107-C00354
  • is attached to L and the —O— of
  • Figure US20210002289A1-20210107-C00355
  • is attached to L;
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH2)m—W—(CH2)n—;
  • W is selected from the group consisting of optionally substituted phenyl, optionally substituted 5-membered heteroaryl, and optionally substituted 6-membered heteroaryl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7; and
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8, and
  • (2) isolating the compound having Formula VIII, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the disclosure provides methods of making a compound having Formula VIII, or a pharmaceutically acceptable salt or solvate thereof, the method comprising:
  • (1) reacting a compound having the structure:
  • Figure US20210002289A1-20210107-C00356
  • wherein:
  • R11a, R11b, R11c, and R11d are independently selected from the group consisting of hydrogen, chloro, and fluoro;
  • R12a and R12b are independently selected from the group consisting of hydrogen and C1-6 alkyl; or
  • R12a and R12b taken together with the carbon atom to which they are attached form a 4- to 8-membered optionally substituted cycloalkyl; and
  • Q is selected from the group consisting of substituted phenylenyl, optionally substituted heteroarylenyl, and optionally substituted cycloalkylenyl,
  • with a compound having Formula III, and
  • (2) isolating the compound having Formula VIII, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the disclosure provides methods of making a compound having Formula XI:
  • Figure US20210002289A1-20210107-C00357
  • or a pharmaceutically acceptable salt or hydrate thereof,
  • wherein:
  • R1 is selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl;
  • R2a′ and R2b′ are each independently selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R2a′ and R2b′ together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl;
  • R3a and R3b are each independently selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl; or
  • R3a and R3b together with the carbon atom to which they are attached form an optionally substituted 3- to 6-membered cycloalkyl;
  • R4 is selected from the group consisting of hydrogen, halogen, optionally substituted C1-4 alkyl, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, —NR6aR6b, —OR7d, —SR8a, —S(═O)R8b, —S(═O)2R8c, —C(═O)R9, (heteroaryl)alkyl, and alkoxyalkyl;
  • R6a and R6b are each independently selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and carboxamido; or
  • R6a and R6b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • R7d is selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, and carboxamido;
  • R8a is selected from the group consisting of optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R8b is selected from the group consisting of optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R8c is selected from the group consisting of optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and amino;
  • R9 selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkoxy, and amino;
  • Y1 is selected from the group consisting of —O—, —S—, and —NR10—;
  • R10 is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, (C3-6 cycloalkyl)C1-4 alkyl, aralkyl, (alkoxycarbonyl)alkyl, —C(═O)Ru, —SO2R12, —C(═O)—OR13, and —C(═O)—NR14aR14b;
  • R11 is selected from the group consisting of optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R12 is selected from the group consisting of optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R13 is selected from the group consisting of optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R14a and R14b are each independently selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl; or
  • R14a and R14b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
    Figure US20210002289A1-20210107-P00001
  • is a fused thienyl or fused phenyl group, wherein the fused phenyl group is additionally substituted with R15;
  • R15 is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, and alkoxy;
  • B is a monovalent radical of a ligand for an E3 ubiquitin ligase protein, e.g., B is:
  • Figure US20210002289A1-20210107-C00358
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n— and —(CH2)m—W—(CH2)u—O—(CH2)v—;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent;
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y1 is selected from the group consisting of —C≡C—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y1 is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl,
  • the method comprising:
  • (1) reacting, e.g., coupling, a compound having Formula XII:
  • Figure US20210002289A1-20210107-C00359
  • wherein:
  • X1 is selected from the group consisting of Br and I;
  • R1 is selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl;
  • R2a′ and R2b′ are each independently selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R2a′ and R2b′ together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl;
  • R3a and R3b are each independently selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl; or
  • R3a and R3b together with the carbon atom to which they are attached form an optionally substituted 3- to 6-membered cycloalkyl;
  • R4 is selected from the group consisting of hydrogen, halogen, optionally substituted C1-4 alkyl, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, —NR6aR6b, —OR7, —SR8a, —S(═O)R8b, —S(═O)2R8c, —C(═O)R9, (heteroaryl)alkyl, and alkoxyalkyl;
  • R6a and R6b are each independently selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, alkylsulfonyl, arylsulfonyl, and carboxamido; or
  • R6a and R6b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
  • R7 is selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkylcarbonyl, and carboxamido;
  • R8a is selected from the group consisting of optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R8b is selected from the group consisting of optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • R8c is selected from the group consisting of optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and amino;
  • R9 selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, alkoxy, and amino;
  • Y1 is selected from the group consisting of —O—, —S—, and —NR10—;
  • R10 is selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, (C3-6 cycloalkyl)C1-4 alkyl, aralkyl, (alkoxycarbonyl)alkyl, —C(═O)Ru, —SO2R12, —C(═O)—OR13, and —C(═O)—NR14aR14b;
  • R11 is selected from the group consisting of optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R12 is selected from the group consisting of optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R13 is selected from the group consisting of optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl;
  • R14a and R14b are each independently selected from the group consisting of hydrogen, optionally substituted C1-6 alkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl, and aralkyl; or
  • R14a and R14b taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 8-membered heterocyclo;
    Figure US20210002289A1-20210107-P00001
  • is a fused thienyl or fused phenyl group, wherein the fused phenyl group is additionally substituted with R15; and
  • R15 is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, and alkoxy,
  • with a compound having Formula V:
  • Figure US20210002289A1-20210107-C00360
  • wherein:
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00361
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n— and —(CH2)m—W—(CH2)u—O—(CH2)v—; A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent:
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C≡C—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl, and
  • (2) isolating the compound having Formula XI, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XIII:
  • Figure US20210002289A1-20210107-C00362
  • and the pharmaceutically acceptable salts or hydrates thereof, as described above for Formula XI, wherein R1, R2a, R2b, R3a, R3b, R4, L, Y, Y1, and B are as defined in connection with Formula XI.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XI or Formula XIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R3a and R3b are hydrogen.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XI or Formula XIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R1 is C1-4 alkyl. In another embodiment, R1 is methyl, or a pharmaceutically acceptable salt or hydrate thereof.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XI or Formula XIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R2a′ and R2b′ are each independently selected from the group consisting of hydrogen and C1-4 alkyl.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XIV:
  • Figure US20210002289A1-20210107-C00363
  • and the pharmaceutically acceptable salts or hydrates thereof, as described above for Formula XI, wherein R4, L, Y, Y1, and B are as defined in connection with Formula XI.
  • In another embodiment, the disclosure provides a method or making a compound represented by Formula XV:
  • Figure US20210002289A1-20210107-C00364
  • and the pharmaceutically acceptable salts or hydrates thereof, as described above for Formula XI, wherein R2a is C1-4 alkyl, and R4, L, Y, Y1, and B are as defined in connection with Formula XI.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XVI:
  • Figure US20210002289A1-20210107-C00365
  • and the pharmaceutically acceptable salts or hydrates thereof, as described above for Formula XI, wherein R2a is C1-4 alkyl, and R4, L, Y, Y1, and B are as defined in connection with Formula XI.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVI, and the pharmaceutically acceptable salts or hydrates thereof, wherein R4 is selected from the group consisting of halogen, C1-4 alkyl, optionally C2-4 alkenyl, optionally substituted C2-4 alkynyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, 3- to 14-membered heterocyclo, optionally substituted 5- to 14-membered heteroaryl. In another embodiment, R4 is aralkyl.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVI, and the pharmaceutically acceptable salts or hydrates thereof, Y1 is —O—. In another embodiment, Y1 is —N(H)—.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XVII:
  • Figure US20210002289A1-20210107-C00366
  • and the pharmaceutically acceptable salts and hydrates thereof, as described above for Formula XI, wherein R2a is selected from the group consisting of hydrogen and C1-3 alkyl; R17a and R17b are each independently selected from the group consisting of hydrogen, C1-4 alkyl, haloalkyl, C1-4 alkoxy, and halo; and L, Y, and B are as defined in connection with Formula XI.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is C1-12 alkylenyl. In another embodiment, L is selected from the group consisting of —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2(CH2)2CH2—, —CH2(CH2)3CH2—, —CH2(CH2)4CH2—, —CH2(CH2)5CH2—, and —CH2(CH2)6CH2—.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein, L is 3- to 12-membered heteroalkylenyl. In another embodiment, L is —(CH2)oO—(CH2CH2O)p—(CH2)q—; o is 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 1, 2, or 3.
  • In another embodiment, the disclosure provides methods for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of: —CH2OCH2CH2—, —CH2CH2OCH2CH2—, —CH2O(CH2CH2O)CH2CH2—, —CH2O(CH2CH2O)2CH2CH2—, —CH2O(CH2CH2O)3CH2CH2—, —CH2CH2O(CH2CH2O)6CH2CH2—, —CH2CH2O(CH2CH2O)6CH2CH2—, —CH2CH2CH2OCH2CH2OCH2CH2CH2—, —CH2CH2CH2O(CH2CH2O)2CH2CH2CH2—, and —CH2CH2CH2O(CH2)4OCH2CH2CH2—.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is —(CH2)m—W—(CH2)n—. In another embodiment, W is phenylenyl. In another embodiment, W is 5-membered heteroarylenyl. In another embodiment, W is 6-membered heteroarylenyl. In another embodiment, wherein m is 0. In another embodiment, wherein n is 1, 2, 3, 4, or 5.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is —(CH2)m—W—(CH2)u-0-(CH2)v—. In another embodiment, W is phenylenyl. In another embodiment, W is 5-membered heteroarylenyl. In another embodiment, W is 6-membered heteroarylenyl.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00367
  • In another embodiment, wherein m is 0. In another embodiment, wherein n is 1, 2, 3, 4, or 5.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00368
  • Q3 is selected from the group consisting of —O—, —S—, and —N(R6)—; and R6 is selected from the group consisting of hydrogen and C1-4 alkyl. In another embodiment, wherein m is 0. In another embodiment, wherein n is 1, 2, 3, 4, or 5. In another embodiment, L is L-3. In another embodiment, L is L-4. In another embodiment, L is L-5. In another embodiment, L is L-6. In another embodiment, L is L-7. In another embodiment, L is L-8. In another embodiment, L is L-9.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XVII, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00369
  • In another embodiment, wherein m is 0. In another embodiment, wherein n is 1, 2, 3, 4, or 5. In another embodiment, L is L-10. In another embodiment, L is L-11. In another embodiment, L is L-12. In another embodiment, L is L-13.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XVIII:
  • Figure US20210002289A1-20210107-C00370
  • and the pharmaceutically acceptable salts or solvates thereof, as described above for Formula XI, wherein n is 2, 3, 4, or 5, and R2a′, R17a, Y, and B are as defined in connection with Formula XVII.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XIX:
  • Figure US20210002289A1-20210107-C00371
  • and the pharmaceutically acceptable salts or solvates thereof, as described above for Formula XI, wherein n is 2, 3, 4, or 5, and R2a′, R17a, Y, and B are as defined in connection with Formula XVII.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XX:
  • Figure US20210002289A1-20210107-C00372
  • and the pharmaceutically acceptable salts or solvates thereof, as described above for Formula XI, wherein n is 2, 3, 4, or 5, and R2a′, R17a, Y, and B are as defined in connection with Formula XVII.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formulae XVIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein R2a is hydrogen. In another embodiment, R2a is methyl.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formulae XVIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein Y is selected from the group consisting of —C≡C—, —CH2—, —O—, and —N(H)—. In another embodiment, Y is —C≡C—. In another embodiment, Y is —CH2—. In another embodiment, Y is —O—. In another embodiment, Y is —N(H)—.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XX, wherein B is B-1a. In another embodiment, A1 is —C(R16a)═ and R16a is selected from the group consisting of hydrogen and halo. In another embodiment, A2 is —C(R16b)═ and R16b is selected from the group consisting of hydrogen and halo. In another embodiment, A3 is —C(R16c)═ and R16c is selected from the group consisting of hydrogen and halo. In another embodiment, A1 is —N═, A2 is —C(R16b)═, and A3 is —C(R16c)═. In another embodiment, A1 is —C(R16a)═, A2 is —N═, and A3 is —C(R16c)═. In another embodiment, A1 is —C(R16a)═, A2 is —C(R16b)═ and A3 is —N═. In another embodiment, Z is —CH2—. In another embodiment, Z is —C(═O)—. In another embodiment, R5 is hydrogen. In another embodiment, B-1a is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00373
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-2.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XI or XIII-XX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-3.
  • In another embodiment, the disclosure provides a method of making a compound having Formula XXI:
  • Figure US20210002289A1-20210107-C00374
  • or a pharmaceutically acceptable salt or hydrate thereof,
  • wherein:
  • R1 is selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl;
  • R2a′ and R2b′ are each independently selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R2a′ and R2b′ together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl;
  • R3 is selected from the group consisting of optionally substituted C6-14 aryl and optionally substituted 5- to 14-membered heteroaryl
  • R4 is selected from the group consisting of hydrogen, halogen, optionally substituted C1-4 alkyl, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • Figure US20210002289A1-20210107-P00001
    is a fused thienyl or fused phenyl group, wherein the fused phenyl group is additionally substituted with R15;
  • R15 is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, and alkoxy;
  • B is a monovalent radical of a ligand for an E3 ubiquitin ligase protein, e.g., B is:
  • Figure US20210002289A1-20210107-C00375
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n— and —(CH2)m—W—(CH2)u—O—(CH2)v—;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent;
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C≡C—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl,
  • the method comprising:
  • (1) reacting a compound having Formula XXII:
  • Figure US20210002289A1-20210107-C00376
  • wherein:
  • X1 is selected from the group consisting of —Br and —I;
  • R1 is selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl;
  • R2a′ and R2b′ are each independently selected from the group consisting of hydrogen, optionally substituted C1-4 alkyl, and (alkoxycarbonyl)alkyl, or
  • R2a′ and R2b′ together with the carbon atom to which they are attached form a 3- to 6-membered cycloalkyl;
  • R3 is selected from the group consisting of optionally substituted C6-14 aryl and optionally substituted 5- to 14-membered heteroaryl;
  • R4 is selected from the group consisting of hydrogen, halogen, optionally substituted C1-4 alkyl, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, aralkyl, optionally substituted C6-14 aryl, optionally substituted C3-12 cycloalkyl, optionally substituted 3- to 14-membered heterocyclo, and optionally substituted 5- to 14-membered heteroaryl;
  • Figure US20210002289A1-20210107-P00001
    is a fused thienyl or fused phenyl group, wherein the fused phenyl group is additionally substituted with R15; and
  • R15 is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, and alkoxy,
  • with a compound having Formula V:
  • Figure US20210002289A1-20210107-C00377
  • wherein:
  • Figure US20210002289A1-20210107-C00378
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n— and —(CH2)m—W—(CH2)u—O—(CH2)v—;
  • A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl; or
  • A is absent;
  • W is selected from the group consisting of phenylenyl, 5-membered heteroarylenyl, 6-membered heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • u is 0, 1, 2, or 3;
  • v is 1, 2, 3, or 4;
  • Y is selected from the group consisting of —C≡C—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—;
  • R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
  • A1 is selected from the group consisting of —C(R16a)═ and —N═;
  • A2 is selected from the group consisting of —C(R16b)═ and —N═;
  • A3 is selected from the group consisting of —C(R16c)═ and —N═;
  • R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
  • R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
  • R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl, and
  • (2) isolating the compound having Formula XXI, or a pharmaceutically acceptable salt or solvate thereof.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXIII
  • Figure US20210002289A1-20210107-C00379
  • and the pharmaceutically acceptable salts or hydrates thereof, as described above for Formula XXI, wherein R1, R2a′, R2b′, R3, R4, L, Y, and B are as defined in connection with Formula XXI.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXI or Formula XXIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R3 is optionally substituted phenyl.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXI or Formula XXIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R1 is C1-4 alkyl. In another embodiment, R1 is methyl.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXI or Formula XXIII, and the pharmaceutically acceptable salts or hydrates thereof, wherein R2a′ and R2b′ are each independently selected from the group consisting of hydrogen and C1-4 alkyl.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXIV:
  • Figure US20210002289A1-20210107-C00380
  • and the pharmaceutically acceptable salts or hydrates thereof, as described above for Formula XXI, wherein R3, R4, L, Y, and B are as defined in connection with Formula XXI.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXV:
  • Figure US20210002289A1-20210107-C00381
  • and the pharmaceutically acceptable salts or hydrates thereof, as described above for Formula XXI, wherein R2a is C1-4 alkyl, and R3, R4, L, Y, and B are as defined in connection with Formula XXI.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXVI:
  • Figure US20210002289A1-20210107-C00382
  • and the pharmaceutically acceptable salts or hydrates thereof, as described above for Formula XXI, wherein R2a′ is C1-4 alkyl, and R3, R4, L, Y, and B are as defined in connection with Formula XXI.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI, or XXIII-XXVI, and the pharmaceutically acceptable salts or hydrates thereof, wherein R4 is C1-4 alkyl. In another embodiment, R4 is methyl. In another embodiment, R4 is hydrogen.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXVII:
  • Figure US20210002289A1-20210107-C00383
  • and the pharmaceutically acceptable salts and hydrates thereof, as described above for Formula XXI, wherein R2a′ is selected from the group consisting of hydrogen and C1-3 alkyl; R17a and R17b are each independently selected from the group consisting of hydrogen, C1-4 alkyl, haloalkyl, C1-4 alkoxy, and halo; and L, Y, and B are as defined in connection with Formula XXI. In another embodiment, R17a and R17b are each independently selected from the group consisting of hydrogen and halo.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is C1-12 alkylenyl. In another embodiment, L is selected from the group consisting of —CH2—, —CH2CH2—, —CH2CH2CH2—, —CH2(CH2)2CH2—, —CH2(CH2)3CH2—, —CH2(CH2)4CH2—, —CH2(CH2)5CH2—, and —CH2(CH2)6CH2—.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein, L is 3- to 12-membered heteroalkylenyl. In another embodiment, L is —(CH2)oO—(CH2CH2O)p—(CH2)q—; o is 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; and q is 1, 2, or 3.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of: —CH2OCH2CH2—, —CH2CH2OCH2CH2—, —CH2O(CH2CH2O)CH2CH2—, CH2O(CH2CH2O)2CH2CH2—, —CH2O(CH2CH2O)3CH2CH2—, —CH2CH2O(CH2CH2O)6CH2CH2—, —CH2CH2O(CH2CH2O)6CH2CH2—, —CH2CH2CH2OCH2CH2OCH2CH2CH2—, —CH2CH2CH2O(CH2CH2O)2CH2CH2CH2—, and —CH2CH2CH2O(CH2)4OCH2CH2CH2—.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is —(CH2)m—W—(CH2)n—. In another embodiment, W is phenylenyl. In another embodiment, W is 5-membered heteroarylenyl. In another embodiment, W is 6-membered heteroarylenyl. In another embodiment, wherein m is 0. In another embodiment, wherein n is 1, 2, 3, 4, or 5.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is —(CH2)m—W—(CH2)u—O—(CH2)v—. In another embodiment, W is phenylenyl. In another embodiment, W is 5-membered heteroarylenyl. In another embodiment, W is 6-membered heteroarylenyl.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00384
  • In another embodiment, m is 0. In another embodiment, n is 1, 2, 3, 4, or 5.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00385
  • Q3 is selected from the group consisting of —O—, —S—, and —N(R6)—; and R6 is selected from the group consisting of hydrogen and C1-4 alkyl. In another embodiment, m is 0. In another embodiment, n is 1, 2, 3, 4, or 5. In another embodiment, n is 2, 3, or 4. In another embodiment, L is L-3. In another embodiment, L is L-4. In another embodiment, L is L-5. In another embodiment, L is L-6. In another embodiment, L is L-7. In another embodiment, L is L-8. In another embodiment, L is L-9.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00386
  • In another embodiment, m is 0. In another embodiment, n is 1, 2, 3, 4, or 5. In another embodiment, n is 2, 3, or 4. In another embodiment, L is L-10. In another embodiment, L is L-11. In another embodiment, L is L-12. In another embodiment, L is L-13.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXVII, and the pharmaceutically acceptable salts or solvates thereof, wherein L is —(CH2)m—W—(CH2)u—O—(CH2)v—; W is selected from the group consisting of 5-membered heteroarylenyl and optionally substituted 6-membered heteroarylenyl; m is 0, 1, 2, 3, 4, 5, 6, or 7; u is 0; and v is 1, 2, 3, or 4. In another embodiment, m is 0.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXVIII:
  • Figure US20210002289A1-20210107-C00387
  • and the pharmaceutically acceptable salts or solvates thereof, as described above for Formula XXI, wherein n is 2, 3, 4, or 5, and R2a′, R17a, R17b, Y, B, and n are as defined in connection with Formula XXVII.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXIX:
  • Figure US20210002289A1-20210107-C00388
  • and the pharmaceutically acceptable salts or solvates thereof, as described above for Formula XXI, wherein n is 2, 3, 4, or 5, and R2a′, R17a, R17b, Y, B, and n are as defined in connection with Formula XXVII.
  • In another embodiment, the disclosure provides a method for making a compound represented by Formula XXX:
  • Figure US20210002289A1-20210107-C00389
  • and the pharmaceutically acceptable salts or solvates thereof, as described above for Formula XXI, wherein n is 2, 3, 4, or 5, and R2a′, R17a, R17b, Y, B, and n are as defined in connection with Formula XXVII.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXVIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein R2a is hydrogen. In another embodiment, R2a is methyl.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXVIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein Y is selected from the group consisting of —C≡C—, —CH2—, —O—, and —N(H)—. In another embodiment, Y is —C≡C—. In another embodiment, Y is —CH2—. In another embodiment, Y is —O—. In another embodiment, Y is —N(H)—.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-1a. In another embodiment, A1 is —C(R16a)═ and R16a is selected from the group consisting of hydrogen and halo. In another embodiment, A2 is —C(R16b)═ and R16b is selected from the group consisting of hydrogen and halo. In another embodiment, A3 is —C(R16c)═ and R16c is selected from the group consisting of hydrogen and halo. In another embodiment, A1 is —N═, A2 is —C(R16b)═, and A3 is —C(R16c)═. In another embodiment, A1 is —C(R16a)═, A2 is —N═, and A3 is —C(R16c)═. In another embodiment, A1 is —C(R16a)═, A2 is —C(R16b)═ and A3 is —N═. In another embodiment, Z is —CH2—. In another embodiment, Z is —C(═O)—. In another embodiment, R5 is hydrogen. In another embodiment, B-1a is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00390
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-2.
  • In another embodiment, the disclosure provides a method for making a compound represented by any one of Formulae XXI or XXIII-XXX, and the pharmaceutically acceptable salts or solvates thereof, wherein B is B-3.
  • In another embodiment, the disclosure provides methods of making a compound having Formula XXXI:
  • Figure US20210002289A1-20210107-C00391
  • and the pharmaceutically acceptable salts and solvates thereof, wherein:
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00392
  • R1a is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and —N(H)R3c;
  • Q1 is ═CH— and Q2 is —N═; or
  • Q1 is ═N— and Q2 is —CH═; or
  • Q1 is ═N— and Q2 is —N═;
  • R3c is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
  • X2 is —C(═O)N(H)—, wherein the nitrogen atom of —C(═O)N(H)— is attached to L,
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH2)m—W—(CH2)n—;
  • W is selected from the group consisting of optionally substituted phenylenyl, optionally substituted 5-membered heteroarylenyl, and optionally substituted 6-membered heteroarylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C≡C—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—; and
  • R5 is selected from the group consisting of hydrogen and fluoro,
  • with the proviso that Y is absent when B is B-2,
  • the method comprising:
  • (1) reacting, e.g., condensing, a compound having Formula XXXII:
  • Figure US20210002289A1-20210107-C00393
  • wherein:
  • R1a is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and —N(H)R3;
  • Q1 is ═CH— and Q2 is —N═; or
  • Q1 is ═N— and Q2 is —CH═; or
  • Q1 is ═N— and Q2 is —N═;
  • R3c is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
  • R7a is a leaving group, e.g., R7a is selected from the group consisting of chloro and —OR7b; and
  • R7b is hydrogen,
  • with a compound having Formula VI:
  • Figure US20210002289A1-20210107-C00394
  • wherein:
  • B is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00395
  • L is selected from the group consisting of alkylenyl, heteroalkylenyl, and —(CH2)m—W—(CH2)n—;
  • W is selected from the group consisting of optionally substituted phenylenyl, optionally substituted 5-membered heteroarylenyl, and optionally substituted 6-membered heteroarylenyl;
  • m is 0, 1, 2, 3, 4, 5, 6, or 7;
  • n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
  • Y is selected from the group consisting of —C≡C—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
  • Y is absent;
  • wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
  • R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
  • Z is selected from the group consisting of —CH2 and —C(═O)—; and
  • R5 is selected from the group consisting of hydrogen and fluoro,
  • with the proviso that Y is absent when B is B-2,
  • in a suitable organic solvent, e.g., DMF, THF, etc, and
  • (2) isolating the compound having Formula XXXI, and the pharmaceutically acceptable salts and solvates thereof.
  • Salts, hydrates, and solvates of the Compounds of the Disclosure can also be used in the methods disclosed herein. The present disclosure further includes all possible stereoisomers and geometric isomers of Compounds of the Disclosure to include both racemic compounds and optically active isomers. When a Compound of the Disclosure is desired as a single enantiomer, it can be obtained either by resolution of the final product or by stereospecific synthesis from either isomerically pure starting material or use of a chiral auxiliary reagent, for example, see Z. Ma et al., Tetrahedron: Asymmetry, 8(6), pages 883-888 (1997). Resolution of the final product, an intermediate, or a starting material can be achieved by any suitable method known in the art. Additionally, in situations where tautomers of the Compounds of the Disclosure are possible, the present disclosure is intended to include all tautomeric forms of the compounds.
  • The present disclosure encompasses the preparation and use of salts of Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure, including pharmaceutically acceptable salts. As used herein, the pharmaceutical “pharmaceutically acceptable salt” refers to salts or zwitterionic forms of Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure. Salts of Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure can be prepared during the final isolation and purification of the compounds or separately by reacting the compound with an acid having a suitable cation. The pharmaceutically acceptable salts of Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure can be acid addition salts formed with pharmaceutically acceptable acids. Examples of acids which can be employed to form pharmaceutically acceptable salts include inorganic acids such as nitric, boric, hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric.
  • Nonlimiting examples of salts of compounds of the disclosure include, but are not limited to, the hydrochloride, hydrobromide, hydroiodide, sulfate, bi sulfate, 2-hydroxyethansulfonate, phosphate, hydrogen phosphate, acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerolphsphate, hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate, maleate, ascorbate, isethionate, salicylate, methanesulfonate, me sitylene sulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylproprionate, picrate, pivalate, propionate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, paratoluenesulfonate, undecanoate, lactate, citrate, tartrate, gluconate, methane sulfonate, ethanedisulfonate, benzene sulfonate, and p-toluenesulfonate salts. In addition, available amino groups present in the compounds of the disclosure can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides. In light of the foregoing, any reference Compounds of the Disclosure appearing herein is intended to include compounds of Compounds of the Disclosure as well as pharmaceutically acceptable salts, hydrates, or solvates thereof.
  • The present disclosure encompasses the preparation and use of solvates of Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure. Solvates typically do not significantly alter the physiological activity or toxicity of the compounds, and as such may function as pharmacological equivalents. The term “solvate” as used herein is a combination, physical association and/or solvation of a compound of the present disclosure with a solvent molecule such as, e.g. a disolvate, mono solvate or hemisolvate, where the ratio of solvent molecule to compound of the present disclosure is about 2:1, about 1:1 or about 1:2, respectively. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate can be isolated, such as when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. Thus, “solvate” encompasses both solution-phase and isolatable solvates. Compounds of the Disclosure and the heterobifunctional target protein degraders prepared from Compounds of the Disclosure can be present as solvated forms with a pharmaceutically acceptable solvent, such as water, methanol, and ethanol, and it is intended that the disclosure includes both solvated and unsolvated forms of Compounds of the Disclosure. One type of solvate is a hydrate. A “hydrate” relates to a particular subgroup of solvates where the solvent molecule is water. Solvates typically can function as pharmacological equivalents. Preparation of solvates is known in the art. See, for example, M. Caira et al, J. Pharmaceut. Sci., 93(3):601-611 (2004), which describes the preparation of solvates of fluconazole with ethyl acetate and with water. Similar preparation of solvates, hemisolvates, hydrates, and the like are described by E. C. van Tender et al., AAPS Pharm. Sci. Tech., 5(1) Article 12 (2004), and A. L. Bingham et al., Chem Commun. 603-604 (2001). A typical, non-limiting, process of preparing a solvate would involve dissolving a Compound of the Disclosure in a desired solvent (organic, water, or a mixture thereof) at temperatures above 20° C. to about 25° C., then cooling the solution at a rate sufficient to form crystals, and isolating the crystals by known methods, e.g., filtration. Analytical techniques such as infrared spectroscopy can be used to confirm the presence of the solvent in a crystal of the solvate.
  • The present disclosure provides heterobifunctional target protein degraders for the treatment of a variety of diseases and conditions wherein degradation of the target proteins has a beneficial effect. Heterobifunctional target protein degraders typically have a binding affinity (IC50) to the target protein of interest of less than 100 μM, e.g., less than 50 μM, less than 25 μM, and less than 5 μM, less than about 1 μM, less than about 0.5 μM, or less than about 0.1 μM. In one embodiment, the present disclosure relates to a method of treating an individual suffering from a disease or condition wherein degradation of a target protein provides a benefit comprising administering a therapeutically effective amount of a heterobifunctional target protein degrader to an individual in need thereof.
  • A “monovalent radical of a target protein inhibitor” is derived from the removal of a hydrogen or other suitable atom, e.g., Br, I, or group, e.g., —OH, from a parent protein inhibitor, e.g., an oncogenic protein inhibitor such as BET bromodomain inhibitor or a MDM2 inhibitor. The removal of a hydrogen atom or other suitable atom or group facilitates the linkage of the target protein inhibitor to an E3 ubiquitin ligase protein ligand to give a heterobifunctional compound having Formula IX, as defined above. In one embodiment, a hydrogen atom is removed from any suitable —NH2 group of the target protein inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —OH group of the target protein inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —N(H)— group of the target protein inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —CH3, —CH2—, —CH═, or —C≡CH group of the target protein inhibitor. In another embodiment, the hydrogen atom is removed from any suitable —OH group of the target protein inhibitor. In another embodiment, a Br or I atom is removed from any suitable aryl or heteroaryl group of the target protein inhibitor.
  • The term “target protein inhibitor” or “parent target protein inhibitor” and the like refers to a compound that disrupts, interferes with, or inhibits protein activity.
  • The term “oncogenic protein inhibitor” or “parent oncogenic protein inhibitor” and the like refers to a compound that disrupts, interferes with, or inhibits oncogenic protein activity.
  • “Oncogenic proteins” are proteins encoded by oncogenes (dysregulated or activated genes).
  • An “oncogene” is any gene that is a causative factor in the initiation of cancerous growth, e.g., a gene that has a potential to cause cancer. For example, transcription factors, kinases, and growth factors are oncogenic proteins because they are genetically involved in signaling systems leading to cell growth, survival, differentiation, and programmed cell death (apoptosis). Other oncogenic proteins include MDM2 and BET bromodomain proteins.
  • A “monovalent radical of a ligand for an E3 ubiquitin ligase protein” is derived from the removal of a hydrogen or other suitable atom, e.g., Br, I, or group, e.g., —OH, from a parent E3 ubiquitin ligase protein ligand. The removal of a hydrogen atom or other suitable atom or group facilitates the linkage of the parent E3 ubiquitin ligase protein ligand to a target protein inhibitor to give a heterobifunctional compound having Formula IX, as defined above. In one embodiment, a hydrogen atom is removed from any suitable —NH2 group of the parent E3 ubiquitin ligase protein ligand. In another embodiment, a hydrogen atom is removed from any suitable —OH group of the parent E3 ubiquitin ligase protein ligand. In another embodiment, a hydrogen atom is removed from any suitable —N(H)— group of the parent E3 ubiquitin ligase protein ligand. In another embodiment, a hydrogen atom is removed from any suitable —CH3, —CH2—, —CH═ group of the parent E3 ubiquitin ligase protein ligand. In another embodiment, the hydrogen atom is removed from any suitable —OH group of the the parent E3 ubiquitin ligase protein ligand. In another embodiment, a Br or I atom is removed from any suitable aryl or heteroaryl group of the parent E3 ubiquitin ligase protein ligand. Exemplary non-limiting monovalent radicals of E3 ubiquitin ligase protein ligands include:
  • Figure US20210002289A1-20210107-C00396
    Figure US20210002289A1-20210107-C00397
    Figure US20210002289A1-20210107-C00398
    Figure US20210002289A1-20210107-C00399
  • A “ligand for an E3 ubiquitin ligase protein” or “parent ligand for an E3 ubiquitin ligase protein” or “E3 ubiquitin ligase protein ligand” refers to a compound that binds, e.g., inhibits, an E3 ubiquitin ligase protein, including the von Hippel-Lindau protein (VHL). Ligands for E3 ubiquitin ligase proteins are known to those of ordinary skill in the art. Exemplary non-limiting ligands for an E3 ubiquitin ligase protein include phthalimide-based drugs such as thalidomide.
  • A “monovalent radical of a MDM2 inhibitor” is derived from the removal of a hydrogen or other suitable atom, e.g., Br, I, or group, e.g., —OH, from a parent MDM2 inhibitor. The removal of a hydrogen atom or other suitable atom or group facilitates the linkage of the MDM2 inhibitor to an E3 ubiquitin ligase protein ligand to give a heterobifunctional compound having Formula IX, as defined above. In one embodiment, a hydrogen atom is removed from any suitable —NH2 group of the parent MDM2 inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —OH group of the parent MDM2 inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —N(H)— group of the parent MDM2 inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —CH3, —CH2—, —CH═, or —C≡CH group of the parent MDM2 inhibitor. In another embodiment, the hydrogen atom is removed from any suitable —OH group of the parent MDM2 inhibitor. In another embodiment, the —OH group is removed from any suitable —C(═O)OH group of the parent MDM2 inhibitor. In another embodiment, a Br or I atom is removed from any suitable aryl or heteroaryl group of the parent MDM2 inhibitor.
  • A “MDM2 inhibitor” or “parent MDM2 inhibitor” refers to a compound that disrupts the p53-MDM2 interaction and/or interferes with MDM2 activity. MDM2 inhibitors are known to those of ordinary skill in the art. See, e.g., Shangary. et al., Annual Review Of Pharmacology and Toxicology 49: 223-241 (2009); and Weber, Expert Opinion On Therapeutic Patents 20: 179-191 (2010).
  • In one embodiment, the MDM2 inhibitor is a spiro-oxindole compound. As used herein, the term “spiro-oxindole MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Pat. Nos. 7,759,383; 7,737,174; 8,518,984; 8,680,132; or 8,629,141.
  • In another embodiment, the MDM2 inhibitor is a cis-imidazoline compound As used herein, the term “cis-imidazoline MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Pat. Nos. 6,617,346; 6,734,302; 7,132,421; 7,425,638; or 7,579,368; or U.S. Patent Application Publication Nos. 2005/0288287 or U.S. 2009/0143364. A cis-imidazoline MDM2 inhibitor is commonly referred to as a “nutlin.” In a particular embodiment, the cis-imidazoline is Nutlin-1, Nutlin-2, or Nutlin-3 (Chart 3; see Vassilev, L. T. et al., Science 303:844-848 (2004)).
  • Figure US20210002289A1-20210107-C00400
  • In another particular embodiment, the MDM2 inhibitor is any one of the inhibitors disclosed and/or claimed in U.S. Pat. No. 6,734,302. For example, the MDM2 inhibitor is a compound of Formula III-A:
  • Figure US20210002289A1-20210107-C00401
  • or pharmaceutically acceptable salts or esters thereof, wherein:
  • R is —C═R1;
  • wherein R1 is selected from C1-C4 alkyl, —C═CHCOOH, —NHCH2CH2R2, —N(CH2CH2OH)CH2CH2OH, —N(CH3)CH2CH2NHCH3, —N(CH3)CH2CH2N(CH3)CH3, saturated 4-, 5- and 6-membered rings, and saturated and unsaturated 5- and 6-membered rings containing at least one hetero atom wherein the hetero atom is selected from S, N and O and being optionally substituted with a group selected from lower alkyl, —C═O—R5, —OH, lower alkyl substituted with hydroxy, lower alkyl substituted with —NH2, N-lower alkyl, —SO2CH3, ═O, —CH2C═OCH3, and 5- and 6-membered saturated rings containing at least one hetero atom selected from S, N and O;
  • wherein R5 is selected from H, lower alkyl, —NH2, —N-lower alkyl, lower alkyl substituted with hydroxy, and lower alkyl substituted with NH2;
  • wherein R2 is selected from —N(CH3)CH3, —NHCH2CH2NH2, —NH2, morpholinyl and piperazinyl;
  • X1, X2 and X3 are independently selected from —OH, C1-C2 alkyl, C1-C5 alkoxy, —Cl, —Br, —F, —CH2OCH3, and —CH2OCH2CH3;
  • or one of X1, X2 or X3 is H and the other two are independently selected from hydroxy, lower alkyl, lower alkoxy, —Cl, —Br, —F, —CF3, —CH2OCH3, —CH2OCH2CH3, —OCH2CH2R3, —OCH2CF3, and —OR4;
  • or one of X1, X2 or X3 is H and the other two taken together with the two carbon atoms and the bonds between them from the benzene ring to which they are substituted form a 5- or 6-membered saturated ring that contains at least one hetero atom selected from S, N, and O, wherein R3 is selected from —F, —OCH3, —N(CH3)CH3, unsaturated 5- and 6-membered rings containing at least one hetero atom wherein the hetero atom is selected from S, N and O;
  • wherein R4 is a 3- to 5-membered saturated ring; and
  • Y1 and Y2 are each independently selected from —Cl, —Br, —NO2, —C≡N, and —C≡CH.
  • In another embodiment, the MDM2 inhibitor is a substituted piperidine compound. As used herein, the term “substituted piperidine MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Pat. Nos. 7,060,713 or 7,553,833.
  • In another embodiment, the MDM2 inhibitor is a spiroindolinone compound. As used herein, the term “spiroindolinone MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Pat. Nos. 6,916,833; 7,495,007; or 7,638,548.
  • In another embodiment, the MDM2 inhibitor is an oxindole compound. As used herein, the term “oxindole MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Pat. No. 7,576,082.
  • In another embodiment, the MDM2 inhibitor is a diphenyl-dihydro-imidazopyridinone compound. As used herein, the term “diphenyl-dihydro-imidazopyridinone MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Pat. No. 7,625,895.
  • In another embodiment, the MDM2 inhibitor is an imidazothiazole compound. As used herein, the term “imidazothiazole MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. 2009/0312310.
  • In another embodiment, the MDM2 inhibitor is a deazaflavin compound. As used herein, the term “deazaflavin MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Patent Application Publication Nos. 2006/0211718 or 2010/0048593.
  • In another embodiment, the MDM2 inhibitor is a benzodiazapine compound. As used herein, the term “benzodiazapine MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. 2005/0227932.
  • In another embodiment, the MDM2 inhibitor is a isoindolin-1-one compound. As used herein, the term “isoindolin-1-one MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. 2008/0261917.
  • In another embodiment, the MDM2 inhibitor is a boronic acid. As used herein, the term “boronic acid MDM2 inhibitor” refers, for example, to a compound disclosed and/or claimed in U.S. Patent Application Publication Nos. 2009/0227542 or 2008/0171723.
  • In another embodiment, the MDM2 inhibitor is a peptide or polypeptide. As used herein, the term “peptidic MDM2 inhibitor” refers for example, to a compound disclosed and/or claimed in U.S. Pat. No. 7,083,983; U.S. 2006/0211757 A1; U.S. 2005/0137137; U.S. 2002/0132977; U.S. 2009/0030181; or WO 2008/106507.
  • In another embodiment, the MDM2 inhibitor is a compound disclosed and/or claimed in any of Shangary, S, et al., Proc. Natl. Acad. Sci. USA 105:3933-3938 (2008); Vassilev, L. T., Trends Mol. Med. 13:23-31 (2007); Vassilev, L. T. et al., Science 303:844-848 (2004); Ding, K. et al., J. Med. Chem. 49:3432-3435 2006; Shangary, S. et al., Clin. Cancer Res. 14:5318-5324 (2008); Chene, P., Molecular Cancer Research 2:20-28 (2004); Pazgier et al., Proc. Natl. Acad. Sci. USA 106:4665-4670 (2009); U.S. 2008/0280769; U.S. 008/0039472; U.S. 2009/0149493; or U.S. 2004/0171035.
  • In another embodiment, the MDM2 inhibitor is a compound disclosed and/or claimed in any of WO 2009/151069 A1; WO 2009/037343 A1 (U.S. application Ser. No. 12/678,680); WO 2008/125487 A1 (U.S. Pat. No. 7,625,895); WO 2008/119741 A2 (U.S. application Ser. No. 12/593,721); and WO 2009/156735 A2.
  • In another particular embodiment, the MDM2 inhibitor is any one of the inhibitors disclosed and/or claimed in WO 2009/156735 A2. For example, the MDM2 inhibitor is a compound of Formulae IV-F or V-F:
  • Figure US20210002289A1-20210107-C00402
  • wherein in both Formulae IV-F and V-F:
  • X is selected from O, N or S;
  • R1 is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl;
  • R2 is selected from hydrogen, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted branched hydroxyalkyl, substituted or unsubstituted cycloalkyl having 6 ring carbon atoms or greater, substituted or unsubstituted cycloalkenyl, hydroxyalkylaralkyl, hydroxyalkylhetero aralkyl, and a carboxylic acid-containing group;
  • R3 is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaralkyl; and
  • R4-R7 represents groups R4, R5, R6 and R7 which are independently selected from hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroaralkyl, substituted or unsubstituted alkylamine, substituted or unsubstituted alkoxy, trifluoromethyl, amino, nitro, carboxyl, carbonylmethylsulfone, trifluoromethylsulfone, cyano and substituted or unsubstituted sulfonamide;
  • wherein R2 is substituted or unsubstituted branched hydroxyalkyl, X is O or S; and
  • wherein R2 is hydrogen, at least one of R4-R7 is not hydrogen and R3 is not a benzimidazole derivative or a benzimidazoline derivative; and wherein, in the Formula V, the 6-membered ring may have 0, 1, or 2 C═C double bonds.
  • In a particular embodiment, the MDM2 inhibitor is any one of the inhibitors disclosed and/or claimed in WO 2009/1511069 A1. For example, the MDM2 inhibitor is a compound of Formula VI-G:
  • Figure US20210002289A1-20210107-C00403
  • Possible examples of substituent groups include where:
  • Ar1 and Ar2 are each independently selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl;
  • R1 is selected from the group consisting of hydrogen, optionally substituted alkyl, and —COR1a;
  • R1a is selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted aryl;
  • R2 and R3 are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; or
  • R2 and R3 taken together form a 3- to 6-membered optionally substituted cycloalkyl or heterocyclo;
  • R4 and R5 are each independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted aryl;
  • W is selected from the group consisting of:
  • Figure US20210002289A1-20210107-C00404
  • wherein:
  • R6 and R7 are each independently selected from the group consisting of hydrogen, hydroxy and optionally substituted alkyl; or
  • R6 and R7 taken together form a 3- to 6-membered optionally substituted cycloalkyl or an oxo, i.e., C═O;
  • R8 is selected from the group consisting of hydrogen or optionally substituted alkyl;
  • R9 and R10 are each independently selected from the group consisting of hydrogen or optionally substituted alkyl; or
  • R9 and R10 taken together form a 3- to 6-membered optionally substituted cycloalkyl or heterocyclo; and
  • X is a carbon atom.
  • In a particular embodiment, MDM2 inhibitor is a compound of Formula VI-G wherein possible examples of substituent groups include where:
  • Ar1 and Ar2 are each independently selected from the group consisting of optionally substituted phenyl and optionally substituted pyridyl;
  • R1 is selected from the group consisting of hydrogen, optionally substituted C1-C6 alkyl, and —COR1a;
  • R1a is selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl;
  • R2 and R3 are each independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl; or
  • R2 and R3 taken together form a 3- to 6-membered optionally substituted cycloalkyl;
  • R4 and R5 are each independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl;
  • W is:
  • Figure US20210002289A1-20210107-C00405
  • wherein:
  • R6 and R7 are each independently selected from the group consisting of hydrogen and optionally substituted C1-C6 alkyl; or
  • R6 and R7 taken together form a 3- to 6-membered optionally substituted cycloalkyl or an oxo.
  • A “monovalent radical of a BET bromodomain protein inhibitor” is derived from the removal of a hydrogen or other suitable atom, e.g., Br, I, or group, e.g., —OH, from a parent BET bromodomain inhibitor. The removal of a hydrogen atom or other suitable atom or group facilitates the linkage of the BET bromodomain inhibitor to an E3 ubiquitin ligase protein ligand to give a heterobifunctional compound having Formula IX, as defined above. In one embodiment, a hydrogen atom is removed from any suitable —NH2 group of the parent BET bromodomain inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —OH group of the parent BET bromodomain inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —N(H)— group of the parent BET bromodomain inhibitor. In another embodiment, a hydrogen atom is removed from any suitable —CH3, —CH2—, —CH═, or —C≡CH group of the parent BET bromodomain inhibitor. In another embodiment, the hydrogen atom is removed from any suitable —OH group of the parent BET bromodomain inhibitor. In another embodiment, the —OH group is removed from any suitable —C(═O)OH group of the parent BET bromodomain inhibitor. In another embodiment, a Br or I atom is removed from any suitable aryl or heteroaryl group of the parent BET bromodomain inhibitor.
  • A “BET bromodomain inhibitor” or “parent BET bromodomain inhibitor” refers to a compound that interferes with, e.g., inhibits, BET bromodomain activity. BET bromodomain inhibitors are known to those of ordinary skill in the art. For example, BET bromodomain protein inhibitors are disclosed in the following U.S. patents: U.S. Pat. Nos. 8,044,042, 8,476,260, 8,114,995, 8,557,984, and 8,580,957; the following U.S. patent application publications: US 20120059002, US 20120208800, US 2012202799, US 2012252781, US 20130252331, US 20140011862, US 20130184264, US 2013079335, US 20140011862, US 20140005169, US 20130331382, US 20130281450, US 20130281399, US 20120157428, US 20100286127, US 20140256706, and US 2015/0246923; and the following international applications: WO 1998011111, WO 2006129623, WO 2008092231, WO 2009084693, WO 2009158404, WO 2010123975, WO 2011054843, WO 2011054844, WO 2011054845, WO 2011054846, WO 2011054848, WO 2011143651, WO 2011143660, WO 2011143669, WO 2011161031, WO 2012075383, WO 2012116170, WO 2012151512, WO 2012174487, WO 2013024104, WO 2013027168, WO 2013030150, WO 2013033268, WO 2013097601, and WO 2014164596. BET bromodomain inhibitors are also disclosed in Delmore et al., Cell 146:904-917 (2011) and Seal et al., Bioorg. Med. Chem. Lett. 22:2968-2972 (2012).
  • The term “leaving group” or “LG” refers to an atom or group of atoms that becomes detached from an atom or group of atoms in what is considered to be the residual or main part of the molecule in a specified reaction. Non-limiting exemplary leaving groups include —Cl, —I, —Br, —OTf, —OMs, and -OTs.
  • The terms “condensing” or “reacting” and the like refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product. Reacting can take place in the presence or absence of solvent.
  • The term “about,” as used herein, includes the recited number ±10%. Thus, “about 10” means 9 to 11.
  • In the present disclosure, the term “halo” as used by itself or as part of another group refers to —Cl, —F, —Br, or —I.
  • In the present disclosure, the term “nitro” as used by itself or as part of another group refers to —NO2.
  • In the present disclosure, the term “cyano” as used by itself or as part of another group refers to —CN.
  • In the present disclosure, the term “hydroxy” as used by itself or as part of another group refers to —OH.
  • In the present disclosure, the term “alkyl” as used by itself or as part of another group refers to unsubstituted straight- or branched-chain aliphatic hydrocarbons containing from one to twelve carbon atoms, i.e., C1-20 alkyl, or the number of carbon atoms designated, e.g., a C1 alkyl such as methyl, a C2 alkyl such as ethyl, a C3 alkyl such as propyl or isopropyl, a C1-3 alkyl such as methyl, ethyl, propyl, or isopropyl, and so on. In one embodiment, the alkyl is a C1-10 alkyl. In another embodiment, the alkyl is a C1-6 alkyl. In another embodiment, the alkyl is a C1-4 alkyl. In another embodiment, the alkyl is a straight chain C1-10 alkyl. In another embodiment, the alkyl is a branched chain C3-10 alkyl. In another embodiment, the alkyl is a straight chain C1-6 alkyl. In another embodiment, the alkyl is a branched chain C3-6 alkyl. In another embodiment, the alkyl is a straight chain C1-4 alkyl. In another embodiment, the alkyl is a branched chain C3-4 alkyl. In another embodiment, the alkyl is a straight or branched chain C3-4 alkyl. Non-limiting exemplary C1-10 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, iso-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, and decyl. Non-limiting exemplary C1-4 alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, and iso-butyl.
  • In the present disclosure, the term “heteroalkyl” as used by itself or part of another group refers to unsubstituted straight- or branched-chain aliphatic hydrocarbons containing from three to thirty chain atoms, i.e., 3- to 30-membered heteroalkyl, or the number of chain atoms designated, wherein at least one —CH2— is replaced with at least one —O—, —N(H)—, or —S—. The —O—, N(H)—, or —S— can independently be placed at any interior position of the aliphatic hydrocarbon chain so long as each —O—, N(H)—, or —S— group is separated by at least two —CH2— groups. In one embodiment, one —CH2— group is replaced with one —O— group. In another embodiment, two —CH2— groups are replaced with two —O— groups. In another embodiment, three —CH2— groups are replaced with three —O— groups. In another embodiment, four —CH2— groups are replaced with four —O— groups. Non-limiting exemplary heteroalkyl groups include:
  • —CH2OCH3;
  • —CH2OCH2CH2CH3;
  • —CH2CH2CH2OCH3;
  • —CH2OCH2CH2OCH3; and
  • —CH2OCH2CH2OCH2CH2OCH3.
  • In the present disclosure, the term “alkylenyl” as used herein by itself or part of another group refers to a divalent form of an alkyl group. In one embodiment, the alkylenyl is a divalent form of a C1-12 alkyl. In one embodiment, the alkylenyl is a divalent form of a C1-10 alkyl. In one embodiment, the alkylenyl is a divalent form of a C1-8 alkyl. In one embodiment, the alkylenyl is a divalent form of a C1-6 alkyl. In another embodiment, the alkylenyl is a divalent form of a C1-4 alkyl. Non-limiting exemplary alkylenyl groups include:
  • —CH2—,
  • —CH2CH2—,
  • —CH2CH2CH2—,
  • —CH2(CH2)2CH2—,
  • —CH(CH2)3CH2—,
  • —CH2(CH2)4CH2—,
  • —CH2(CH2)5CH2—,
  • —CH2CH(CH3)CH2—, and
  • —CH2C(CH3)2CH2—.
  • In the present disclosure, the term “heteroalkylenyl” as used herein by itself or part of another group refers to a divalent form of a heteroalkyl group. In one embodiment, the heteroalkylenyl is a divalent form of a 3- to 12-membered heteroalkyl. In another embodiment, the heteroalkylenyl is a divalent form of a 3- to 10-membered heteroalkyl. In another embodiment, the heteroalkylenyl is a divalent form of a 3- to 8-membered heteroalkyl. In another embodiment, the heteroalkylenyl is a divalent form of a 3- to 6-membered heteroalkyl. In another embodiment, the heteroalkylenyl is a divalent form of a 3- to 4-membered heteroalkyl. In another embodiment, the heteroalkylenyl is a radical of the formula: —(CH2)oO—(CH2CH2O)p—(CH2)q—, wherein o is 2 or 3; p is 0, 1, 2, 3, 4, 5, 6, or 7; and q is 2 or 3. In another embodiment, the heteroalkylenyl is a radical of the formula: —(CH2)rO—(CH2)s—O(CH2)t—, wherein r is 2, 3, or 4; s is 3, 4, or 5; and t is 2 or 3. Non-limiting exemplary heteroalkylenyl groups include:
  • —CH2OCH2—;
  • —CH2CH2OCH2CH2—;
  • —CH2OCH2CH2CH2—;
  • —CH2CH2OCH2CH2CH2—;
  • —CH2CH2OCH2CH2OCH2CH2—; and
  • —CH2CH2OCH2CH2OCH2CH2O—.
  • In the present disclosure, the term “optionally substituted alkyl” as used by itself or as part of another group means that the alkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from nitro, haloalkoxy, aryloxy, aralkyloxy, alkylthio, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, cycloalkyl, and the like. In one embodiment, the optionally substituted alkyl is substituted with two substituents. In another embodiment, the optionally substituted alkyl is substituted with one substituent. Non-limiting exemplary optionally substituted alkyl groups include —CH2CH2NO2, —CH2SO2CH3 CH2CH2CO2H, —CH2CH2SO2CH3, —CH2CH2COPh, and —CH2C6H11.
  • In the present disclosure, the term “cycloalkyl” as used by itself or as part of another group refers to saturated and partially unsaturated (containing one or two double bonds) cyclic aliphatic hydrocarbons containing one to three rings having from three to twelve carbon atoms (i.e., C3-12 cycloalkyl) or the number of carbons designated. In one embodiment, the cycloalkyl group has two rings. In one embodiment, the cycloalkyl group has one ring. In another embodiment, the cycloalkyl group is chosen from a C3-5 cycloalkyl group. In another embodiment, the cycloalkyl group is chosen from a C3-6 cycloalkyl group. Non-limiting exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, and cyclopentenyl, cyclohexenyl.
  • In the present disclosure, the term “optionally substituted cycloalkyl” as used by itself or as part of another group means that the cycloalkyl as defined above is either unsubstituted or substituted with one, two, or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkyl sulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (carboxamido)alkyl, mercaptoalkyl, and (heterocyclo)alkyl. In one embodiment, the optionally substituted cycloalkyl is substituted with two substituents. In another embodiment, the optionally substituted cycloalkyl is substituted with one substituent.
  • In the present disclosure, the term “cycloalkylenyl” as used herein by itself or part of another group refers to a divalent form of an optionally substituted cycloalkyl group. Non-limiting examples of a 5 cycloalkylenyl include:
  • Figure US20210002289A1-20210107-C00406
  • In the present disclosure, the term “alkenyl” as used by itself or as part of another group refers to an alkyl group as defined above containing one, two or three carbon-to-carbon double bonds. In one embodiment, the alkenyl group is chosen from a C2-6 alkenyl group. In another embodiment, the alkenyl group is chosen from a C2-4 alkenyl group. Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.
  • In the present disclosure, the term “optionally substituted alkenyl” as used herein by itself or as part of another group means the alkenyl as defined above is either unsubstituted or substituted with one, two or three substituents independently chosen from halo, ultra, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclo.
  • In the present disclosure, the term “alkynyl” as used by itself or as part of another group refers to an alkyl group as defined above containing one to three carbon-to-carbon triple bonds. In one embodiment, the alkynyl has one carbon-to-carbon triple bond. In one embodiment, the alkynyl group is chosen from a C2-6 alkynyl group. In another embodiment, the alkynyl group is chosen from a C2-4 alkynyl group. Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups.
  • In the present disclosure, the term “optionally substituted alkynyl” as used herein by itself or as part of another group means the alkynyl as defined above is either unsubstituted or substituted with one, two or three substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclo.
  • In the present disclosure, the term “haloalkyl” as used by itself or as part of another group refers to an alkyl group substituted by one or more fluorine, chlorine, bromine and/or iodine atoms. In one embodiment, the alkyl group is substituted by one, two, or three fluorine and/or chlorine atoms. In another embodiment, the haloalkyl group is chosen from a C1-4 haloalkyl group. Non-limiting exemplary haloalkyl groups include fluoromethyl, 2-fluoroethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups.
  • In the present disclosure, the term “hydroxyalkyl” as used by itself or as part of another group refers to an alkyl group substituted with one or more, e.g., one, two, or three, hydroxy groups. In one embodiment, the hydroxyalkyl group is a monohydroxyalkyl group, i.e., substituted with one hydroxy group. In another embodiment, the hydroxyalkyl group is a dihydroxyalkyl group, i.e., substituted with two hydroxy groups, e.g.,
  • Figure US20210002289A1-20210107-C00407
  • In another embodiment, the hydroxyalkyl group is chosen from a C1-4 hydroxyalkyl group. Non-limiting exemplary hydroxyalkyl groups include hydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, such as 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl, 2-hydroxy-1-methylpropyl, and 1,3-dihydroxyprop-2-yl.
  • In the present disclosure, the term “alkoxy” as used by itself or as part of another group refers to an optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl attached to a terminal oxygen atom. In one embodiment, the alkoxy group is chosen from a C1-4 alkoxy group. In another embodiment, the alkoxy group is chosen from a C1-4 alkyl attached to a terminal oxygen atom, e.g., methoxy, ethoxy, and tert-butoxy.
  • In the present disclosure, the term “alkylthio” as used by itself or as part of another group refers to a sulfur atom substituted by an optionally substituted alkyl group. In one embodiment, the alkylthio group is chosen from a C1-4 alkylthio group. Non-limiting exemplary alkylthio groups include —SCH3, and —SCH2CH3.
  • In the present disclosure, the term “alkoxyalkyl” as used by itself or as part of another group refers to an alkyl group substituted with an alkoxy group. Non-limiting exemplary alkoxyalkyl groups include methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl, iso-propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, tert-butoxymethyl, isobutoxymethyl, sec-butoxymethyl, and pentyloxymethyl.
  • In the present disclosure, the term “haloalkoxy” as used by itself or as part of another group refers to a haloalkyl attached to a terminal oxygen atom. Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy.
  • In the present disclosure, the term “aryl” as used by itself or as part of another group refers to a monocyclic or bicyclic aromatic ring system having from six to fourteen carbon atoms (i.e., C6-C14 aryl). Non-limiting exemplary aryl groups include phenyl (abbreviated as “Ph”), naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. In one embodiment, the aryl group is chosen from phenyl or naphthyl.
  • In the present disclosure, the term “optionally substituted aryl” as used herein by itself or as part of another group means that the aryl as defined above is either unsubstituted or substituted with one to five substituents independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamide, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (carboxamido)alkyl, mercaptoalkyl, or (heterocyclo)alkyl.
  • In one embodiment, the optionally substituted aryl is an optionally substituted phenyl. In one embodiment, the optionally substituted phenyl has four substituents. In another embodiment, the optionally substituted phenyl has three substituents. In another embodiment, the optionally substituted phenyl has two substituents. In another embodiment, the optionally substituted phenyl has one substituent. Non-limiting exemplary substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl 3,5-di-methylphenyl, 3,5-dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, and 3-chloro-4-fluorophenyl. The term optionally substituted aryl is meant to include groups having fused optionally substituted cycloalkyl and fused optionally substituted heterocyclo rings. Non-limiting examples include:
  • Figure US20210002289A1-20210107-C00408
  • In the present disclosure, the term “phenylenyl” as used herein by itself or part of another group refers to a divalent form of an optionally substituted phenyl group. Non-limiting examples include:
  • Figure US20210002289A1-20210107-C00409
  • In the present disclosure, the term “aryloxy” as used by itself or as part of another group refers to an optionally substituted aryl attached to a terminal oxygen atom. A non-limiting exemplary aryloxy group is PhO—.
  • In the present disclosure, the term “aralkyloxy” as used by itself or as part of another group refers to an aralkyl group attached to a terminal oxygen atom. A non-limiting exemplary aralkyloxy group is PhCH2O—.
  • In the present disclosure, the term “heteroaryl” or “heteroaromatic” refers to monocyclic and bicyclic aromatic ring systems having 5 to 14 ring atoms (i.e., C5-C14 heteroaryl), wherein at least one carbon atom of one of the rings is replaced with a heteroatom independently selected from the group consisting of oxygen, nitrogen and sulfur. In one embodiment, the heteroaryl contains 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of oxygen, nitrogen and sulfur. In one embodiment, the heteroaryl has three heteroatoms. In another embodiment, the heteroaryl has two heteroatoms. In another embodiment, the heteroaryl has one heteroatom. Non-limiting exemplary heteroaryl groups include thienyl, benzo[b]thienyl, naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl, isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2H-pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl, quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, and phenoxazinyl. In one embodiment, the heteroaryl is chosen from thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl), pyrrolyl (e.g., 1H-pyrrol-2-yl and 1H-pyrrol-3-yl), imidazolyl (e.g., 2H-imidazol-2-yl and 2H-imidazol-4-yl), pyrazolyl (e.g., 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, and 1H-pyrazol-5-yl), pyridyl (e.g., pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl), isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl), and indazolyl (e.g., 1H-indazol-3-yl). The term “heteroaryl” is also meant to include possible N-oxides. A non-limiting exemplary N-oxide is pyridyl N-oxide.
  • In one embodiment, the heteroaryl is a 5- or 6-membered heteroaryl. In one embodiment, the heteroaryl is a 5-membered heteroaryl, i.e., the heteroaryl is a monocyclic aromatic ring system having 5 ring atoms wherein at least one carbon atom of the ring is replaced with a heteroatom independently selected from nitrogen, oxygen, and sulfur. Non-limiting exemplary 5-membered heteroaryl groups include thienyl, furyl, pyrrolyl, oxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, and isoxazolyl.
  • In another embodiment, the heteroaryl is a 6-membered heteroaryl, e.g., the heteroaryl is a monocyclic aromatic ring system having 6 ring atoms wherein at least one carbon atom of the ring is replaced with a nitrogen atom. Non-limiting exemplary 6-membered heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl.
  • In the present disclosure, the term “optionally substituted heteroaryl” as used by itself or as part of another group means that the heteroaryl as defined above is either unsubstituted or substituted with one to four substituents, e.g., one or two substituents, independently chosen from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkyl thio, carboxamide, sulfonamide, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (carboxamido)alkyl, mercaptoalkyl, or (heterocyclo)alkyl. In one embodiment, the optionally substituted heteroaryl has one substituent. Any available carbon or nitrogen atom can be substituted. Non-limiting exemplary optionally substituted 5-membered heteroaryl groups include, but are not limited to:
  • Figure US20210002289A1-20210107-C00410
    Figure US20210002289A1-20210107-C00411
    Figure US20210002289A1-20210107-C00412
  • The term optionally substituted heteroaryl is also meant to include groups having fused optionally substituted cycloalkyl and fused optionally substituted heterocyclo rings. Non-limiting examples include:
  • Figure US20210002289A1-20210107-C00413
  • In the present disclosure, the term “heteroarylenyl” as used herein by itself or part of another group refers to a divalent form of an optionally substituted heteroaryl group. In one embodiment, the heteroarylenyl is a 5-membered heteroarylenyl. Non-limiting examples of a 5-membered heteroarylenyl include:
  • Figure US20210002289A1-20210107-C00414
  • In one embodiment, the heteroarylenyl is a 6-membered heternarylenyl. Non-limiting examples of a 6-membered heteroarylenyl include:
  • Figure US20210002289A1-20210107-C00415
  • In the present disclosure, the term “heterocycle” or “heterocyclo” as used by itself or as part of another group refers to saturated and partially unsaturated (e.g., containing one or two double bonds) cyclic groups containing one, two, or three rings having from three to fourteen ring members (i.e., a 3- to 14-membered heterocyclo) wherein at least one carbon atom of one of the rings is replaced with a heteroatom. Each heteroatom is independently selected from the group consisting of oxygen, sulfur, including sulfoxide and sulfone, and/or nitrogen atoms, which can be oxidized or quaternized. The term “heterocyclo” is meant to include groups wherein a ring —CH2— is replaced with a —C(═O)—, for example, cyclic ureido groups such as 2-imidazolidinone and cyclic amide groups such as β-lactam, γ-lactam, δ-lactam, ε-lactam, and piperazin-2-one. The term “heterocyclo” is also meant to include groups having fused optionally substituted aryl groups, e.g., indolinyl, chroman-4-yl. In one embodiment, the heterocyclo group is chosen from a 5- or 6-membered cyclic group containing one ring and one or two oxygen and/or nitrogen atoms. The heterocyclo can be optionally linked to the rest of the molecule through any available carbon or nitrogen atom. Non-limiting exemplary heterocyclo groups include dioxanyl, tetrahydropyranyl, 2-oxopyrrolidin-3-yl, piperazin-2-one, piperazine-2,6-dione, 2-imidazolidinone, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, and indolinyl.
  • In the present disclosure, the term “optionally substituted heterocyclo” as used herein by itself or part of another group means the heterocyclo as defined above is either unsubstituted or substituted with one to four substituents independently selected from halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido, alkylcarbonyl, alkoxycarbonyl, CF3C(═O)—, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl, (carboxamido)alkyl, mercaptoalkyl, or (heterocyclo)alkyl. Substitution may occur on any available carbon or nitrogen atom, or both. Non-limiting exemplary optionally substituted heterocyclo groups include:
  • Figure US20210002289A1-20210107-C00416
  • In the present disclosure, the term “amino” as used by itself or as part of another group refers to —NR10aR10b, wherein R10a and R10b are each independently hydrogen, alkyl, hydroxyalkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclo, or optionally substituted heteroaryl, or R10a and R10b are taken together to form a 3- to 8-membered optionally substituted heterocyclo. Non-limiting exemplary amino groups include —NH2 and —N(H)(CH3).
  • In the present disclosure, the term “(amino)alkyl” as used by itself or as part of another group refers to an alkyl group substituted with an amino group. Non-limiting exemplary amino alkyl groups include —CH2CH2NH2, and —CH2CH2N(H)CH3, —CH2CH2N(CH3)2, and —CH2N(H)cyclopropyl.
  • In the present disclosure, the term “carboxamido” as used by itself or as part of another group refers to a radical of formula —C(═O)NR9aR9b, wherein R9a and R9b are each independently hydrogen, optionally substituted alkyl, hydroxyalkyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclo, or optionally substituted heteroaryl, or R9a and R9b taken together with the nitrogen to which they are attached form a 3- to 8-membered optionally substituted heterocyclo group. In one embodiment, R9a and R9b are each independently hydrogen or optionally substituted alkyl. In one embodiment, R9a and R9b are taken together to taken together with the nitrogen to which they are attached form a 3- to 8-membered optionally substituted heterocyclo group. Non-limiting exemplary carboxamido groups include, but are not limited to, —CONH2, —CON(H)CH3, —CON(CH3)2, —CON(H)Ph,
  • Figure US20210002289A1-20210107-C00417
  • In the present disclosure, the term “sulfonamido” as used by itself or as part of another group refers to a radical of the formula —SO2NR8aR8b, wherein R8a and R8b are each independently hydrogen, optionally substituted alkyl, or optionally substituted aryl, or R8a and R8b taken together with the nitrogen to which they are attached from a 3- to 8-membered heterocyclo group. Non-limiting exemplary sulfonamido groups include —SO2NH2, —SO2N(H)CH3, and —SO2N(H)Ph.
  • In the present disclosure, the term “alkylcarbonyl” as used by itself or as part of another group refers to a carbonyl group, i.e., —C(═O)—, substituted by an alkyl group. A non-limiting exemplary alkylcarbonyl group is —COCH3.
  • In the present disclosure, the term “arylcarbonyl” as used by itself or as part of another group refers to a carbonyl group, i.e., —C(═O)—, substituted by an optionally substituted aryl group. A non-limiting exemplary arylcarbonyl group is —COPh.
  • In the present disclosure, the term “alkoxycarbonyl” as used by itself or as part of another group refers to a carbonyl group, i.e., —C(═O)—, substituted by an alkoxy group.
  • Non-limiting exemplary alkoxycarbonyl groups include —C(═O)OMe, —C(═O)OEt, and —C(═O)OtBu.
  • In the present disclosure, the term “alkylsulfonyl” as used by itself or as part of another group refers to a sulfonyl group, i.e., —SO2—, substituted by any of the above-mentioned optionally substituted alkyl groups. A non-limiting exemplary alkylsulfonyl group is —SO2CH3.
  • In the present disclosure, the term “arylsulfonyl” as used by itself or as part of another group refers to a sulfonyl group, i.e., —SO2—, substituted by any of the above-mentioned optionally substituted aryl groups. A non-limiting exemplary arylsulfonyl group is —SO2Ph.
  • In the present disclosure, the term “mercaptoalkyl” as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted by a —SH group.
  • In the present disclosure, the term “carboxy” as used by itself or as part of another group refers to a radical of the formula —COOH.
  • In the present disclosure, the term “carboxyalkyl” as used by itself or as part of another group refers to any of the above-mentioned alkyl groups substituted with a —COOH. A non-limiting exemplary carboxyalkyl group is —CH2CO2H.
  • In the present disclosure, the terms “aralkyl” or “arylalkyl” as used by themselves or as part of another group refers to an alkyl group substituted with one, two, or three optionally substituted aryl groups. In one embodiment, the optionally substituted aralkyl group is a C1-4 alkyl substituted with one optionally substituted aryl group. In one embodiment, the optionally substituted aralkyl group is a C1 or C2 alkyl substituted with one optionally substituted aryl group. In one embodiment, the optionally substituted aralkyl group is a C1 or C2 alkyl substituted with one optionally substituted phenyl group. Non-limiting exemplary optionally substituted aralkyl groups include benzyl, phenethyl, —CHPh2, —CH2(4-F-Ph), —CH2(4-Me-Ph), —CH2(4-CF3—Ph), and —CH(4-F-Ph)2.
  • In the present disclosure, the terms “(heterocyclo)alkyl” as used by itself or part of another group refers to an alkyl group substituted with an optionally substituted heterocyclo group. In one embodiment, the (heterocyclo)alkyl is a C1-4 alkyl substituted with one optionally substituted heterocyclo group. Non-limiting exemplary (heterocyclo)alkyl groups include:
  • Figure US20210002289A1-20210107-C00418
  • The present disclosure encompasses any of the Compounds of the Disclosure being isotopically-labelled, i.e., radiolabeled, by having one or more atoms replaced by an atom having a different atomic mass or mass number. Examples of isotopes that can be incorporated into Compounds of the Disclosure include isotopes of hydrogen, carbon, nitrogen, sulfur, oxygen, fluorine, and chlorine, such as 2H (or deuterium (D)), 3H, 11C, 13C, 14C, 15N, 18O, 17O, 35S, 18F, and 36Cl, e.g., 2H, 3H, and 13C. In one embodiment, a portion of the atoms at a position within a Compound of the Disclosure are replaced, i.e., the Compound of the Disclosure is enriched at a position with an atom having a different atomic mass or mass number. In one embodiment, at least about 1% of the atoms are replaced with an atom having a different atomic mass or mass number. In another embodiment, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 100% of the atoms are replaced with an atom having a different atomic mass or mass number. For example, when B of Formula I, is B-1a, B-1b, B-1c, or B-1d, and R5 is hydrogen, the hydrogen at R5 may be replaced entirely or partially with deuterium, e.g., at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the hydrogen atoms at R5 are deuterium atoms. Isotopically-labeled Compounds of the Disclosure can be prepared by methods known in the art.
    • General Synthesis of Compounds
  • Compounds of the Disclosure are prepared using methods known to those skilled in the art in view of this disclosure, or by the illustrative methods shown in the General Schemes below. Suitable protecting can be employed in the synthesis, if needed. See Wuts, P. G. M.; Greene, T. W., “Greene's Protective Groups in Organic Synthesis”, 4th Ed., J. Wiley & Sons, N Y, 2007.
  • Heterobifunctional protein degraders of the disclosure are prepared using methods known to those skilled in the art in view of this disclosure, or by the illustrative methods shown in General Scheme 1, below.
  • Figure US20210002289A1-20210107-C00419
  • In General Scheme 1, a compound having Formula XXXII, wherein R7a is —OH, is reacted with a compound having Formula VI in an organic solvent to give a compound having Formula XXXI, wherein X is —C(═O)N(H)—. Compounds having Formula XXXII may be prepared as described in US 2014/0256706 and US 2015/0246923. Compounds having Formula VI may be prepared using methods known in the art and/or as illustrated in the Examples below. Suitable amine-to-amide coupling reagents and conditions e.g., HATU/base, HBTU/base, or EDCl/HOBt/base, are well known in the art. See Montalbetti and Falque, Tetrahedron 61:10827-10852 (2005).
    • EXAMPLES Example 1
  • Synthesis of (3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(4-((4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)carbamoyl)phenyl)-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamide
    • Step 1: Synthesis of S1
  • Figure US20210002289A1-20210107-C00420
  • To a round-bottom flask, 3-hydroxyphthalic anhydride (1 g, 6.09 mmol) and 3-aminoperidine-2,6-dione hydrochloride (1.0 g, 6.09 mmol) were mixed in 50 mL of toluene. Triethyl amine (0.93 mL, 6.7 mmol) was added. The resulting reaction mixture was heated to reflux for 12 h with Dean-Stark Trap equipment. After cooling to ambient temperature, evaporation of most of the solvent to give a crude product, which was purified by flash column chromatography with DCM:EA to get the desired product as a slightly yellow solid S1 (1.5 g, 90% yield). 1H NMR (400 MHz, DMSO-d6) δ (ppm) 11.16 (s, 1H), 11.08 (s, 1H), 7.65 (t, J=7.6 Hz, 1H), 7.32 (d, J=7.2 Hz, 1H), 7.25 (d, J=8.4 Hz, 1H), 5.07 (dd, J=12.8 Hz, J=5.2 Hz, 1H), 2.93-2.84 (m, 1H), 2.61-2.46 (m, 1H), 2.05-2.01 (m, 1H).
    • Step 1: Synthesis of S2
  • Figure US20210002289A1-20210107-C00421
  • To a round-bottom flask, S1 (1.5 g, 5.5 mmol) was dissolved in 10 mL of DML. To the stirred solution, KI (91 mg, 0.55 mmol) and KHCO3 (826 mg, 8.25 mmol) were added. Then tert-butyl bromoacetate (0.98 mL, 6.6 mmol) was dropwised. The resulting mixture was stirred at room temperature for 12 h. After normal workup with EtOAc and saturated brine, the combined organic layer was dried over Na2SO4. After filtration and evaporation, the residue was purified by flash column chromatography with DCM:EA to get the desired product S2 as a white solid (1.7 g, 80% yield). 1H NMR (400 MHz, DMSO-d6) δ (ppm) 11.13 (s, 1H), 7.80 (t, J=8.0 Hz, 1H), 7.48 (d, J=7.2 Hz, 1H), 7.38 (d, J=8.4 Hz, 1H), 5.13 (dd, J=12.8 Hz, J=5.2 Hz, 1H), 4.97 (s, 2H), 2.97-2.85 (m, 1H), 2.65-2.52 (m, 2H), 2.14-2.03 (m, 1H), 1.43 (s, 9H); 13C NMR (100 MHz, DMSO-d6) δ (ppm) 173.2, 170.3, 167.5, 167.2, 165.6, 155.5, 137.2, 133.7, 120.4, 116.9, 116.3, 66.0, 60.2, 49.3, 31.4, 28.1, 22.5.
    • Step 3: Synthesis of S3
  • Figure US20210002289A1-20210107-C00422
  • To a round-bottom flask, S2 (1.7 g, 4.4 mmol) was dissolved in 8.0 mL of TFA. The reaction mixture was stirred at room temperature for 2 h. After evaporation of the solvent, the residue was used in the following steps without further purification. ESI-MS calculated for C15H13N2O7 [M+H]+=333.07, obtained: 333.17. 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.16 (s, 1H), 11.11 (s, 1H), 7.80 (t, J=8.0 Hz, 1H), 7.48 (d, J=7.2 Hz, 1H), 7.40 (d, J=8.8 Hz, 1H), 5.11 (dd, J=12.8 Hz, J=5.2 Hz, 1H), 4.99 (s, 2H), 2.95-2.86 (m, 1H), 2.63-2.48 (m, 2H), 2.08-2.03 (m, 1H).
    • Step 4: Synthesis of S4
  • Figure US20210002289A1-20210107-C00423
  • To a round-bottom flask, S3 (99.7 mg, 0.3 mmol) was dissolved in 2 mL of anhydrous DMF. N-Boc-1,4-butanediamine (68 mg, 0.36 mmol), HATU (137 mg, 0.36 mmol) and DIPEA (157 μL, 0.9 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 2 h, and then purified by HPLC to get the desired compound S4 as a slightly yellow solid (128 mg, 85% yield).
    • Step 5: Synthesis of S5
  • Figure US20210002289A1-20210107-C00424
  • To a round-bottom flask, S4 (15.1 mg, 0.03 mmol) was dissolved in 3 mL of DCM and TFA (2:1). After stirring for 1 h, the solvent was evaporated to give the crude product S5, which was used in the next step without further purification. ESI-MS calculated for C19H23N4O6 [M+H]+=403.16, obtained: 403.17.
    • Step 6: Synthesis of (3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(4-((4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)carbamoyl)phenyl)-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamide
  • Figure US20210002289A1-20210107-C00425
  • HATU (13.3 mg, 0.035 mmol) and N,N-diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a solution of Cpd. A (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, S5 (0.35 mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, re-dissolved in H2O, frozen and lyophilized to give Compound A (TLA salt) as a white powder.
  • LC-MS(ESI) m/z (M+H)+: 966.28, 5.13 min; calcd: 966.28; >98% purity. 1H NMR (400 MHz, MeOD) δ 7.80-7.68 (m, 4H), 7.62-7.56 (m, 2H), 7.54 (dd, J=8.3, 2.5 Hz, 1H), 7.48 (dd, J=7.2, 1.4 Hz, 1H), 7.43-7.32 (m, 2H), 7.18 (t, J=8.1 Hz, 1H), 7.11 (dd, J=8.2, 1.9 Hz, 1H), 6.79 (d, J=1.9 Hz, 1H), 5.31 (d, J=10.8 Hz, 1H), 5.08 (dd, J=12.6, 5.2 Hz, 1H), 4.97 (d, J=10.8 Hz, 1H), 4.75 (s, 2H), 3.36 (dd, J=4.6, 3.0 Hz, 4H), 2.92-2.64 (m, 4H), 2.25-2.13 (m, 1H), 2.13-2.04 (m, 1H), 2.04-1.84 (m, 3H), 1.78 (d, J=11.5 Hz, 2H), 1.72-1.48 (m, 5H), 1.31-1.16 (m, 2H).
    • Example 2 Synthesis of N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide Step 1: Synthesis of S7
  • Figure US20210002289A1-20210107-C00426
  • To a round-bottom flask, S3 (99.7 mg, 0.3 mmol) was dissolved in 2 mL of anhydrous DMF. tert-butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate (68 mg, 0.36 mmol), HATU (137 mg, 0.36 mmol) and DIPEA (157 μL, 0.9 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 2 h, and then purified by HPLC to get the desired compound S7 as a slightly yellow solid (128 mg, 85% yield).
    • Step 2: Synthesis of N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide
  • Figure US20210002289A1-20210107-C00427
  • To a round-bottom flask, S7 (15 mg) was dissolved in 3 mL of DCM and TEA (2:1). After stirring for 1 h, the solvent was evaporated to give the crude product N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide. [M+H]+=535.24, obtained: 535.14.
    • Example 3 Synthesis of N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide Step 1: Synthesis of S16
  • Figure US20210002289A1-20210107-C00428
  • To a round-bottom flask, 3-nitrophthalic anhydride (5.79 g, 30 mmol) and p-toluenesulfonic acid monohydrate (571 mg, 3 mmol) were mixed in 20 mL of benzyl alcohol. The mixture was heat to 100° C. to stir overnight. After cooling to room temperature, benzyl bromide (7.1 mL, 45 mmol), KI (498 mg, 3 mmol), KHCO3 (9.0 g, 90 mmol) and DMF (25 mL) were added. The mixture was heated to 100° C. for 6 h. After the reaction was cooled to room temperature, the solvent was evaporated as much as possible and was poured into larger amount of water. The solution was extracted with ethyl acetate. The combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration and evaporation, the crude residue was purified by flash column chromatography with hexane/ethyl acetate to give S16 as a slightly yellow solid (9.4 g, 80% yield).
    • Step 2: Synthesis of S17
  • Figure US20210002289A1-20210107-C00429
  • To a round-bottom flask, compound S16 (9.4 g, 24 mmol) was dissolved in 100 mL of ethyl acetate. Then Tin (II) chloride dehydrate (11.3 g, 50 mmol) was added portionwisely to the reaction mixture. The resulting reaction mixture was heated to 50° C. to stir overnight. Aqueous NaOH and NaHCO3 solution were added to the reaction mixture to quench the reaction. The reaction mixture was filtered through celite and washed with ethyl acetate. The filtrate was extracted with ethyl acetate and brine. The combined organic layer was dried over anhydrous Na2SO4. After filtration and evaporation, the crude residue was purified by flash column chromatography with hexane/ethyl acetate to give compound S17 as a slightly yellow solid (7.8 g, 90% yield).
    • Step 3: Synthesis of S18
  • Figure US20210002289A1-20210107-C00430
  • To a round-bottom flask, compound S17 (2.0 g, 5.54 mmol) and KI (100 mg, 0.56 mmol) were added to 10 mL of anhydrous DMF. Tert-butyl bromoacetate (2.4 mL, 16.6 mmol) and DIPEA (4.8 mL, 27.7 mmol) were added to the reaction mixture. The reaction mixture was heated to 90° C. to stir overnight. After cooling to room temperature, most of the solvent was evaporated and the residue was purified by column chromatography with hexane/ethyl acetate to give compound S18 as a slightly yellow solid (1.05 g, 40% yield).
    • Step 4: Synthesis of S19
  • Figure US20210002289A1-20210107-C00431
  • To a round-bottom flask, compound S18 (1.0 g, 2.1 mmol) was dissolved in 20 mL of methanol. 100 mg of Pd/C (10 wt %) was added. The reaction mixture was stirred at room temperature under 1 atm H2 atmosphere. Once the starting material disappeared by TLC, the mixture was filtrated through celite and washed with methanol. After evaporation of the solvent, 3-aminopiperidine-2,6-dione hydrochloride (380 mg, 2.31 mmol) and 20 mL of pyridine were added. The reaction mixture was heated to 110° C. to stir overnight. After cooling to room temperature, the solvent was evaporated as much as possible and the residue was poured into water. After extraction with ethyl acetate for three times, the combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration and evaporation, the crude residue was purified by flash column chromatography with DCM/ethyl acetate to give compound S19 as a yellow solid (325 mg, 40% yield).
    • Step 5: Synthesis of S20
  • Figure US20210002289A1-20210107-C00432
  • To a round-bottom flask, S19 (1.7 g) was dissolved in 8.0 mL of TFA. The reaction mixture was stirred at room temperature for 2 h. After evaporation of the solvent, the residue was used in the following steps without further purification. 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.91 (s, 1H), 11.10 (s, 1H), 7.59 (t, J=8.0 Hz, 1H), 7.08 (d, J=6.80 Hz, 1H), 6.99 (d, J=8.4 Hz, 1H), 6.86 (t, J=5.6 Hz, 1H), 5.08 (dd, J=13.2 Hz, J=5.6 Hz, 1H), 4.12 (d, J=5.2 Hz, 2H), 2.94-2.85 (m, 1H), 2.63-2.49 (m, 2H), 2.09-2.07 (m, 1H); 13C NMR (100 MHz, DMSO-d6) δ (ppm) 173.3, 171.9, 170.5, 169.3, 167.8, 146.3, 136.6, 132.5, 118.2, 111.5, 110.1, 60.2, 49.1, 31.5, 22.6.
    • Step 6: Synthesis of S21
  • Figure US20210002289A1-20210107-C00433
  • Following the procedure for S4 synthesis, compound S21 was synthesized with S20 (99.7 mg, 0.3 mmol), amine (115 mg, 0.36 mmol), HATU (137 mg, 0.36 mmol) and DIPEA (157 μL, 0.9 mmol). ESI-MS calculated for C30H43N5NaO10[M+Na]+=656.29, obtained: 656.26.
    • Step 7: Synthesis of N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide
  • Figure US20210002289A1-20210107-C00434
  • To a round-bottom flask, S21 (15.1 mg) was dissolved in 3 mL of DCM and TFA (2:1). After stirring for 1 h, the solvent was evaporated to give crude product N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide, which was used in the next step without further purification.
    • Example 4 Synthesis of 4-((3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Step 1: Synthesis of S13
  • Figure US20210002289A1-20210107-C00435
  • To a round-bottom flask, 3-fluorophthalic anhydride (6.64 g, 40 mmol), 3-aminopiperidine-2,6-dione hydrochloride (6.58 g, 40 mmol) and sodium acetate (3.94 g, 48 mmol) were mixed in 120 mL of acetic acid. The resulting reaction mixture was heated to reflux at 140° C. for 12 h. After cooling to room temperature, most of acetic acid was evaporated and the residue was purified by flash column chromatography with DCM/MeOH to get S13 as a slightly yellow solid (9.7 g, 88% yield). ESI-MS calculated for C13H10FN2O4 [M+H]+=277.06, obtained: 277.02. 1H NMR (400 MHz, DMSO-d6) δ (ppm) 11.15 (s, 1H), 7.98-7.93 (m, 1H), 7.80-7.72 (m, 2H), 5.17 (dd, J=13.2 Hz, J=5.2 Hz, 1H), 2.95-2.86 (m, 1H), 2.64-2.47 (m, 2H), 2.10-2.06 (m, 1H);
    • Step 2: Synthesis of S14
  • Figure US20210002289A1-20210107-C00436
  • To a round-bottom flask, S13 (276 mg, 1.0 mmol) was dissolved in 3.0 mL of anhydrous DMF. Amine (320 mg, 1.0 mmol) and DIPEA (259 mg, 2.0 mmol) were added. The reaction mixture was stirred at 90° C. for 12 h. The mixture was cooled to room temperature, poured into water and extracted with ethyl acetate for two times. The combined organic layer was washed with brine, dried over anhydrous Na2SO4. After filtration and evaporation, the crude residue was purified by HPLC with H2O/MeCN to give compound S14 as colorless oil (172 mg, 30% yield). ESI-MS calculated for C28H41N4O9 [M+H]+=577.2; Observed: 577.3.
    • Step 3: Synthesis of 4-((3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00437
  • To a round-bottom flask, S14 (15 mg) was dissolved in 3 mL of DCM and TEA (2:1). After stirring for 1 h, the solvent was evaporated to give crude product 4-((3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione.
    • Example 5 Synthesis of 4-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00438
  • To a round-bottom flask, 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethanol (2.9 g, 15 mmol) was diluted in 10 mL of ethanol. Di-tert-butyl dicarbonate (3.6 g, 16.5 mmol) was dissolved in 10 mL of ethanol and the solution was dropwised within a period of 10 min. The resulting reaction mixture was stirred at room temperature for 2 h. After evaporation of the solvent, the residue was purified by column chromatography with DCM/MeOH to obtain S9 as colorless oil (3.69 g, 80% yield). 1H NMR (400 MHz, CDCl3) δ (ppm) 5.49 (s, 1H), 3.46-3.25 (m, 14H), 3.02 (s, 2H), 1.18 (s, 9H); ESI-MS calculated for C13H27NNaO6 [M+Na]+=316.17, obtained: 316.18.
    • Step 2: Synthesis of S10
  • Figure US20210002289A1-20210107-C00439
  • To a round-bottom flask, S9 (3.69 g, 12 mmol) was diluted in 100 mL of DCM. After cooling to 0° C. 4-toluenesulfonyl chloride (2.75 g, 14.4 mmol) and triethyl amine (2.51 mL, 18 mmol) were added sequentially. The resulting reaction mixture was stirred at 0° C. for 30 min and then room temperature for 2 h. After workup with DCM and saturated NaHCO3 solution, the combined organic layer was dried over anhydrous Na2SO4. After filtration and evaporation, the residue was purified by column chromatography with hexane:ethyl acetate to give S10 as colorless oil (4.98 g, 90% yield). 1H NMR (400 MHz, CDCl3) δ (ppm) 7.76 (d, J=8.4 Hz, 2H), 7.31 (d, J=8.4 Hz, 2H), 4.12 (m, 2H), 3.67-3.47 (m, 12H), 3.25-3.23 (m, 2H), 2.40 (s, 3H), 1.39 (s, 9H); ESI-MS calculated for C20H33NNaO8S [M+Na]+=470.18, obtained: 470.20.
    • Step 3: Synthesis of S11
  • Figure US20210002289A1-20210107-C00440
  • To a round-bottom flask, S1 (274 mg, 1.0 mmol) and S10 (492 mg, 1.1 mmol) were mixed in 5.0 mL of anhydrous DMF. KI (17 mg, 0.1 mmol) and KHCO3 (150 mg, 1.5 mmol) were added sequentially. The reaction mixture was stirred at room temperature for 12 h. After evaporation of most of the solvent, the residue was purified by column chromatography with DCM/MeOH to get S11 as colorless oil (453 mg, 82% yield). ESI-MS calculated for C25H36N3O10Na [M+Na]+=572.22, obtained: 572.13.
    • Step 4: Synthesis of 4-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00441
  • To a round-bottom flask, S11 (15 mg) was dissolved in 3 mL of DCM and TFA (2:1). After stirring for 1 h, the solvent was evaporated to give crude product 4-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. ESI-MS calculated for C21H28N3O8 [M+Na]+=450.19, obtained: 450.20.
    • Example 6 Synthesis of 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Step 1: Synthesis of S23
  • Figure US20210002289A1-20210107-C00442
  • To a round-bottom flask, methyl 3-bromo-2-(bromomethyl)benzoate (50 mg) and Et3N (60 mg) were added to a solution of 3-aminopiperidine-2,6-dione (30 mg) in CH3CN (5 mL). The mixture was stirred for 10 hours at 60° C. and purified by flash column chromatography to yield S23 in 30 mg. ESI-MS calculated for C13H12BrN2O3 [M+H]+=323.0; Observed: 323.2.
    • Step 2: Synthesis of S24
  • Figure US20210002289A1-20210107-C00443
  • To a round-bottom flask, S23 (50 mg) and tert-butyl pent-4-yn-1-ylcarbamate (50 mg) were added to a solution of CuI (6.3 mg) and Pd(PPh3)2Cl2 (11 mg) in THF (5 mL) and Et3N (2 mL). The mixture was stirred for 10 hours at 70° C. under Ar and purified directly by flash column chromatography to yield S24 in 20 mg. ESI-MS calculated for C23H28N3O5 [M+H]+=426.2; Observed: 426.4.
    • Step 3: Synthesis of 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00444
  • S24 (30 mg) was dissolved in MeOH (10 mL). 5 mg 10% Pd/C was added, the reaction mixture was degassed 2 times, each time replacing the vacuum with hydrogen, then stirred at room temperature under H2 overnight. The mixture was filtered and concentrated on a rotary evaporator to give the crude which was dissolved in 3 mL of DCM and TEA (2:1). After stirring for 1 h, the solvent was evaporated to give crude product 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. ESI-MS calculated for C18H24N3O3 [M+H]+=330.1; Observed: 330.4.
    • Example 7 Synthesis of 4-((4-aminobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00445
  • To a round-bottom flask, S13 (276 mg, 1.0 mmol) was dissolved in 3.0 mL of anhydrous DMF. tert-butyl (4-aminobutyl)carbamate (320 mg) and DIPEA (259 mg, 2.0 mmol) were added. The reaction mixture was stirred at 90° C. for 12 h. The mixture was cooled to room temperature, poured into water and extracted with ethyl acetate for two times. The combined organic layer was washed with brine, dried over anhydrous Na2SO4. After filtration and evaporation, the crude residue was dissolved in 3 mL of DCM and TEA (2:1). After stirring for 1 h, the solvent was evaporated to give the crude which was purified by HPLC with H2O/MeCN to give compound 4-((4-aminobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione as colorless oil (100 mg). ESI-MS calculated for C17H21N4O4 [M+H]+=345.1; Observed: 345.4.
    • Example 8 Synthesis of 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00446
  • To a round-bottom flask, S13 (276 mg, 1.0 mmol) was dissolved in 3.0 mL of anhydrous DMF. tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (320 mg) and DIPEA (259 mg, 2.0 mmol) were added. The reaction mixture was stirred at 90° C. for 12 h. The mixture was cooled to room temperature, poured into water and extracted with ethyl acetate for two times. The combined organic layer was washed with brine, dried over anhydrous Na2SO4. After filtration and evaporation, the crude residue was dissolved in 3 mL of DCM and TEA (2:1). After stirring for 1 h, the solvent was evaporated to give the crude which was purified by HPLC with H2O/MeCN to give 4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione as colorless oil (130 mg). ESI-MS calculated for C19H25N4O6 [M+H]+=405.1; Observed: 405.4.
    • Example 9 Synthesis of 3-(4-(3-(2-aminoethoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Step 1: Synthesis of S28
  • Figure US20210002289A1-20210107-C00447
  • To a round-bottom flask, S23 (50 mg) and tert-butyl (2-(prop-2-yn-1-yloxy)ethyl)carbamate (60 mg) were added to a solution of CuI (6.3 mg) and Pd(PPh3)2Cl2 (11 mg) in THF (5 mL) and Et3N (2 mL). The mixture was stirred for 10 hours at 70° C. under Ar and purified directly by flash column chromatography to yield 22 mg of S28. ESI-MS calculated for C23H28N3O6[M+H]+=442.1; Observed: 442.3.
    • Step 2: Synthesis of 3-(4-(3-(2-aminoethoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00448
  • S28 (30 mg) was dissolved in MeOH (10 mL). 5 mg 10% Pd/C was added, the reaction mixture was degassed 2 times, each time replacing the vacuum with hydrogen, then stirred at room temperature under H2 overnight. The mixture was filtered and concentrated on a rotary evaporator to give the crude which was dissolved in 3 mL of DCM and TFA (2:1). After stirring for 1 h, the solvent was evaporated to give 3-(4-(3-(2-aminoethoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione. ESI-MS calculated for C18H24N3O4 [M+H]+=346.1; Observed: 346.3.
    • Example 10 Synthesis of 4-(5-aminopentyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Step 1: Synthesis of S30
  • Figure US20210002289A1-20210107-C00449
  • To a round-bottom flask, 3-bromophthalic anhydride (6.64 g), 3-aminopiperidine-2,6-dione hydrochloride (6.58 g, 40 mmol) and sodium acetate (3.94 g, 48 mmol) were mixed in 120 mL of acetic acid. The resulting reaction mixture was heated to reflux at 140° C. for 12 h. After cooling to room temperature, most of acetic acid was evaporated and the residue was purified by flash column chromatography with DCM/MeOH to get S130 as a solid (7 g). ESI-MS calculated for C13H10BrN2O4 [M+H]+=336.9, obtained: 336.9.
    • Step 2: Synthesis of S31
  • Figure US20210002289A1-20210107-C00450
  • To a round-bottom flask, S30 (50 mg) and tert-butyl pent-4-yn-1-ylcarbamate (50 mg) were added to a solution of CuI (6.3 mg) and Pd(PPh3)2Cl2 (11 mg) in THE (5 mL) and Et3N (2 mL). The mixture was stirred for 10 hours at 70° C. under Ar and purified directly by flash column chromatography to yield 14 mg of S31. ESI-MS calculated for C23H26N3O6 [M+H]+=440.1; Observed: 440.3.
    • Step 3: Synthesis of 4-(5-aminopentyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00451
  • S31 (30 mg) was dissolved in MeOH (10 mL). 5 mg 10% Pd/C was added, the reaction mixture was degassed 2 times, each time replacing the vacuum with hydrogen, then stirred at room temperature under H2 overnight. The mixture was filtered and concentrated on a rotary evaporator to give the crude which was dissolved in 3 mL of DCM and TEA (2:1). After stirring for 1 h, the solvent was evaporated to give 4-(5-aminopentyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. ESI-MS calculated for C18H22N3O4 [M+H]+=344.1; Observed: 344.4.
    • Example 11 Synthesis of 4-(3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Step 1: Synthesis of S33
  • Figure US20210002289A1-20210107-C00452
  • To a round-bottom flask, S30 (50 mg) and tert-butyl (2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)ethyl)carbamate (60 mg) were added to a solution of CuI (6.3 mg) and Pd(PPh3)2Cl2 (11 mg) in THF (5 mL) and Et3N (2 mL). The mixture was stirred for 10 hours at 70° C. under Ar and purified directly by flash column chromatography to yield S33 in 18 mg. ESI-MS calculated for C27H34N3O9 [M+H]+=544.2; Observed: 544.4.
    • Step 2: Synthesis of 4-(3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00453
  • S33 (30 mg) was dissolved in MeOH (10 mL) and 5 mg 10% Pd/C was added. The reaction mixture was degassed 2 times, each time replacing the vacuum with hydrogen, then stirred at room temperature under H2 overnight. The mixture was filtered and concentrated on a rotary evaporator to give the crude which was dissolved in 3 mL of DCM and TFA (2:1). After stirring for 1 h, the solvent was evaporated to give crude product 4-(3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. ESI-MS calculated for C22H30N3O7 [M+H]+=448.2; Observed: 448.3.
    • Example 12 Synthesis of 4-(3-(2-aminoethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione Step 1: Synthesis of S35
  • Figure US20210002289A1-20210107-C00454
  • To a round-bottom flask, S30 (50 mg) and tert-butyl (2-(prop-2-yn-1-yloxy)ethyl)carbamate (60 mg) were added to a solution of CuI (6.3 mg) and Pd(PPh3)2Cl2 (11 mg) in THF (5 mL) and Et3N (2 mL). The mixture was stirred for 10 hours at 70° C. under Ar and purified directly by flash column chromatography to yield 19 mg of S35. ESI-MS calculated for C23H26N3O7 [M+H]+=456.1; Observed: 456.3.
    • Step 2: Synthesis of 4-(3-(2-aminoethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00455
  • S35 (30 mg) was dissolved in MeOH (10 mL). 5 mg 10% Pd/C was added, the reaction mixture was degassed 2 times, each time replacing the vacuum with hydrogen, then stirred at room temperature under H2 overnight. The mixture was filtered and concentrated on a rotary evaporator to give the crude which was dissolved in 3 mL of DCM and TFA (2:1). After stirring for 1 h, the solvent was evaporated to give crude product 4-(3-(2-aminoethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. ESI-MS calculated for C18H22N3O5 [M+H]+=360.1; Observed: 360.2.
    • Example 13 Synthesis of 3-(2-(2-aminoethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propanamide
  • Figure US20210002289A1-20210107-C00456
  • To a round-bottom flask, N,N-diisopropylethylamine (50 mg) were added to a solution of 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione (20 mg), HATU (30 mg), and 2,2-dimethyl-4-oxo-3,8,11-trioxa-5-azatetradecan-14-oic acid (50 mg) in DMF (1 mL) at room temperature. The mixture was stirred for 30 min and the solvent was evaporated as much as possible and the residue was poured into water. After extraction with ethyl acetate for three times, the combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration and evaporation, the crude residue was dissolved in 3 mL of DCM and TFA (2:1). After stirring for 1 h, the solvent was evaporated to give the crude product which was purified by flash column chromatography to yield 3-(2-(2-aminoethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propanamide. ESI-MS calculated for C20H27N4O6[M+H]+=419.1; Observed: 419.2.
    • Example 14 Synthesis of 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propanamide
  • Figure US20210002289A1-20210107-C00457
  • To a round-bottom flask, N,N-diisopropylethylamine (50 mg) were added to a solution of 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione (20 mg), HATU (30 mg), and 2,2-dimethyl-4-oxo-3,8,11,14-tetraoxa-5-azaheptadecan-17-oic acid (50 mg) in DMF (1 mL) at room temperature. The mixture was stirred for 30 min and the solvent was evaporated as much as possible and the residue was poured into water. After extraction with ethyl acetate for three times, the combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration and evaporation, the crude residue was dissolved in 3 mL of DCM and TFA (2:1). After stirring for 1 h, the solvent was evaporated to give the crude product which was purified by flash column chromatography to yield 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propanamide. ESI-MS calculated for C22H31N4O7[M+H]+=463.2; Observed: 463.4.
    • Example 15 Synthesis of 3-(4-((4-aminobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00458
    • Step 1: Synthesis of tert-butyl (4-oxobutyl)carbamate
  • To solution of tert-butyl 4-hydroxybutyl)carbamate (380 mg, 2 mmol) in 15 ml of DCM was added Dess-Martin periodinane reagent (1.7 g, 4 mmol). After stirring at room temperature for 1 h the reaction mixture was filtered by celite. The filtrate was then washed with brine, dried over Na2SO4, filtered, and the solvent evaporated in vacuo. The residue was purified by chromatography over silica gel, to yield tert-butyl (4-oxobutyl)carbamate as colorless oil.
    • Step 2: Synthesis of 3-(4-((4-aminobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • To tert-butyl (4-oxobutyl)carbamate (190 mg, 1 mmol) in 1,2-dichloroethane (15 mL) was added Lenalidomide (285 mg, 1.1 mmol), and the resulting solution was stirred at room temperature for 30 min. The solution was treated with Na(OAc)3BH (0.42 g, 2 mmol), and the resulting suspension was stirred overnight. The solvent was diluted with DCM and washed with sat. NaHCO3, brine, dried (Na2SO4), filtered, and concentrated. Then residue was diluted in 10 mL DCM then 2 mL trifluoroacetic acid was added to the reaction and stirred for 30 min. The solvent was removed by vacuo and the residue was purified by reverse phase chromatography over C18 column to yield 3-(4-((4-aminobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione as colorless oil.
    • Example 16 Synthesis of 5-amino-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentanamide
  • Figure US20210002289A1-20210107-C00459
  • HATU (380 mg, 1 mmol) and N,N-diisopropylethylamine (0.44 mL, 2.5 mmol) were added to a solution of Boc-5-aminopentanoic acid (110 mg, 0.5 mmol) in 3 mL DMF and stirred. After 10 minutes, Lenalidomide (200 mg, 0.75 mmol) was added to the reaction. After 30 minutes, the solvent was removed and the crude was dissolved in 10 mL DCM and 2 mL trifluoroacetic acid. The reaction was stirred for 30 min and then the solvent was removed by vacuo. The residue was purified by reverse phase chromatography over C18 column to yield 5-amino-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentanamide as colorless oil.
    • Example 17 Synthesis of 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00460
    • Step 1: Synthesis of tert-butyl (5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)carbamate
  • To a solution of tert-butyl pent-4-yn-1-ylcarbamate (236 mg, 1.29 mmol) and 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (400 mg, 1.29 mmol) in triethylamine (3 mL) and DMF (3 mL), CuI (50 mg, 0.25 mmol) and the Pd(Ph3P)2Cl2 (90 mg, 0.13 mmol) were added. The mixture was stirred at 80° C. under N2-atmosphere overnight. The reaction mixture was poured into a saturated aqueous solution of NH4Cl and after separation of the organic layer the aqueous layer was extracted with Ethyl Acetate. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography to afford tert-butyl (5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)carbamate as white solid.
    • Step 2: Synthesis of 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • To a solution of tert-butyl (5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)carbamate (210 mg, 0.5 mmol) in EtOH (5 mL) was added Pd/C (20 mg). The reaction was stirred under H2-atmosphere for 2 hr. Then the mixture was filtered by celite and the solvent was removed by vacuo. The residue was dissolved in 10 mL DCM and 2 mL trifluoroacetic acid. The reaction was stirred for 30 min and then the solvent was removed by vacuo. The residue was purified by reverse phase chromatography over C18 column to 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione as colorless oil.
    • Example 18 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((2-(prop-2-yn-1-yloxy)ethyl)amino)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00461
  • Step 1: To a solution of 2-(prop-2-yn-1-yloxy)ethan-1-amine (99 mg, 1 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (276 mg, 1 mmol) in DMF (1 mL) was added DIPEA (0.35 mL, 2 mmol). The reaction mixture was heated at 90° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was subject to HPLC purification to afford 2-(2,6-dioxopiperidin-3-yl)-4-((2-(prop-2-yn-1-yloxy)ethyl)amino)isoindoline-1,3-dione (25 mg, 7% yield). 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.53 (t, J=7.8 Hz, 1H), 7.14 (d, J=7.1 Hz, 1H), 6.96 (d, J=8.6 Hz, 1H), 4.94 (dd, J=11.2, 5.3 Hz, 1H), 4.24 (s, 2H), 3.80 (t, J=4.9 Hz, 2H), 3.53 (t, J=5.0 Hz, 2H), 2.88 (dd, J=25.7, 11.5 Hz, 1H), 2.77 (ddd, J=16.3, 13.2, 3.6 Hz, 2H), 2.49 (s, 1H), 2.23-2.05 (m, 1H). ESI-MS: (M+H) 356.07.
    • Example 19 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy) isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00462
  • Step 1: Chloropoly(ethyoxy)ethanol (2.49 g, 20 mmol) was added dropwise to a suspension of NaH (60% in mineral oil, 1.6 g, 40 mmol) in THE (50 mL) at −20° C. under N2. After cooled to −78° C., propargyl bromide solution (3.6 mL, 20 mmol) was added dropwise and the mixture was refluxed for 2 h. The THF solvent was evaporated and the residue was taken up in DCM, washed with water. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (dichloramethane) to afford 3-(2-(2-chloroethoxy)ethoxy)prop-1-yne in 70% yield.
  • Step 2: To a solution of 3-(2-(2-chloroethoxy)ethoxy)prop-1-yne (81 mg, 0.5 mmol), 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (70 mg, 0.25 mmol) in DMF (2 mL) was added KHCO3 (50 mg) and KI (10 mg). The reaction mixture was stirred at 70° C. for 12 hour prior to being taken up in ethyl acetate and water. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (DCM:EtOAc 2:1) to afford 2-(2,6-dioxopiperidin-3-yl)-4-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy) isoindoline-1,3-dione (80 mg, 80%). 1H NMR (400 MHz, CDCl3) δ 7.69 (dd, J=8.4, 7.4, Hz, 1H), 7.48 (d, J=7.3 Hz, 1H), 7.32-7.27 (m, 1H), 5.00-4.96 (m, 1H), 4.43-4.32 (m, 2H), 4.22 (s, 2H), 3.99-3.90 (m, 2H), 3.85-3.80 (m, 2H), 3.74-3.70 (m, 2H), 2.99-2.71 (m, 3H), 2.52 (s, 1H), 2.14-2.10 (m, 1H). ESI-MS: 401.10.
    • Example 20 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino) isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00463
  • Step 1: To a solution of 4-iodo-1H-pyrazole (2.4 g, 12 mmol) and triethylamine (1.85 mL, 13 mmol) in DCM (20 mL) at 0° C. was added MsCl (1 mL, 12.6 mmol). The reaction mixture was allowed to warm to r.t. and stirred for another 1 hour. The reaction mixture was quenched with saturated NH4Cl solution, extracted with DCM. The organic layer was separated, washed with brine, dried, and evaporated. The residue was dissolved in CH3CN (70 mL) and tert-butyl (4-hydroxybutyl)carbamate (1.89 g, 10 mmol) and Cs2CO3 (3.9 g, 12 mmol) was added. The reaction mixture was heated to reflux for 12 h. After the reaction was cooled, the mixture was filtered and the filtrate was evaporated. The residue was taken up in EtOAc and water. The organic layer was separated, washed with brine, dried, and evaporated. The residue was purified by chromatography (EtOAc/Hexanes:1:2) to afford crude tert-butyl (4-(4-iodo-1H-pyrazol-1-yl)butyl)carbamate (2.3 g, 53%), which was treated with DCM (5 mL) and TEA (5 mL). The reaction mixture was stirred for 12 hours. All the volatiles were removed under vacuum and the residue was subject to HPLC purification to afford the 4-(4-iodo-1H-pyrazol-1-yl)butan-1-amine.
  • Step 2: To a solution of TEA salt of 4-(4-iodo-1H-pyrazol-1-yl)butan-1-amine (378 mg, 1 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (276 mg, 1 mmol) in DMF (1 mL) was added DIPEA (0.52 mL, 3 mmol). The reaction mixture was heated at 90° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was subject to HPLC purification to afford 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-iodo-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione (122 mg, 23% yield).
  • Step 3: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-iodo-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione (100 mg, 0.2 mmol), and ethynyltrimethylsilane (39.2 mg, 0.4 mmol), THF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 40° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (EtOAc) to afford crude product, which was dissolved in THF and a solution of TBAF in THF (1M, 0.2 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was subjected to HPLC purification to afford 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino) isoindoline-1,3-dione (50 mg, 60% yield). ESI-MS: 420.13.
    • Example 21 Synthesis of 3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00464
  • Step 1: To a solution of 4-iodo-1H-pyrazole (3.88 g, 20 mmol) in CH3CN (140 mL) was added 4-chlorobutan-1-ol (3.3 g, 1.3 eq), Cs2CO3 (16.4 g, 60 mmol), and NaI (600 mg). The reaction mixture was heated at 50° C. for 12 hour. The reaction mixture was filtered and the filtrate was evaporated. The residue was purified by chromatography (EtOAc/Hexanes: 1:1 to EtOAc) to afford 4-(4-iodo-1H-pyrazol-1-yl)butan-1-ol (4 g, 75%).
  • Step 2: To a solution of 4-(4-iodo-1H-pyrazol-1-yl)butan-1-ol (4 g, 15 mmol) in DMSO (24 mL) and Et3N (16 mL) was added SO3-pyridine complex (7.1 g, 45 mmol). The reaction mixture was stirred for 3 h prior to being quenched with water. The reaction mixture was extracted with EtOAc. The organic layer was separated, washed with brine, dried, and evaporated. The residue was purified by chromatography (EtOAc/Hexanes: 1:2 to EtOAc) to afford 4-(4-iodo-1H-pyrazol-1-yl)butanal (2.8 g, 73%). 1H NMR (400 MHz, CDCl3) δ 9.76 (s, 1H), 7.52 (s, 1H), 7.44 (s, 1H), 4.20 (t, J=6.7 Hz, 2H), 2.48 (t, J=6.9 Hz, 2H), 2.18-2.10 (m, 2H).
  • Step 3: To a solution of 4-(4-iodo-1H-pyrazol-1-yl)butanal (526 mg, 2 mmol) and lenalidomide (520 mg, 2 mmol) in DCE (20 mL) was added acetic acid (0.06 mL). The reaction was stirred for 20 minutes prior to the addition of NaHB(OAc)3 (848 mg). The reaction mixture was stirred for 12 h prior to being quenched with water. The reaction mixture was extracted with DCM. The organic layer was separated, washed with brine, dried, and evaporated. The residue was purified by HPLC to afford 3-(4-((4-(4-iodo-1H-pyrazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (420 mg, 38%). 1H NMR (400 MHz, MeOD) δ 7.73-7.70 (m, 1H), 7.50-7.45 (m, 1H), 7.32-7.25 (m, 1H), 7.10-7.05 (m, 1H), 6.80-6.75 (m, 1H), 5.16-5.06 (m, 1H), 4.28-4.20 (m, 2H), 4.22-4.12 (m, 2H), 3.24-3.20 (m, 2H), 2.84-2.80 (m, 2H), 2.48-2.40 (m, 1H), 2.20-2.15 (m, 1H), 1.99-1.89 (m, 2H), 1.63-1.58 (m, 2H). ESI-MS: 508.95.
  • Step 4: To a Schlenk tube was added CuI (9.5 mg), Pd(Ph3P)2Cl2 (35 mg), 3-(4-((4-(4-iodo-1H-pyrazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (267 mg, 0.5 mmol), and ethynyltrimethylsilane (98 mg, 1 mmol), THE (4 mL) and Et3N (1 mL). The reaction mixture was heated at 40° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (EtOAc) to afford crude product (215 mg, 90%), which was dissolved in THE and a solution of TBAF in THE (1M, 0.45 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was purified by chromatography (EtOAc) to afford crude product, which was further purified by HPLC to afford 3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 55% yield). ESI-MS: 406.24.
    • Example 22 Synthesis of 3-(4-((4-(4-ethynyl-1H-imidazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00465
  • Step 1: To a suspension of 4-iodo-1H-imidazole (3.88 g, 20 mmol) in THF (140 mL) was added NaH (960 mg, 24 mmol, 1.2 eq) portionwise at 0° C. under N2. The mixture was stirred for 20 minutes at 0° C. prior to the addition of (4-bromobutoxy)(tert-butyl)diphenylsilane (3.5 g, 9 mmol). The reaction mixture was allowed to warm to r.t. and stirred for 1 h. The reaction mixture was heated at reflux for 4 hours. The reaction mixture was quenched with water and extracted with EtOAc. The residue was purified by chromatography (EtOAc/Hexanes: 1:1 to EtOAc) to afford 1-(4-((tert-butyldiphenylsilyl)oxy)butyl)-4-iodo-1H-imidazole (1 g, 22%). 1H NMR (400 MHz, CDCl3) δ 7.70-7.62 (m, 4H), 7.51-7.38 (m, 6H), 7.33 (s, 1H), 6.97 (s, 1H), 3.92 (t, J=6.9 Hz, 2H), 3.70 (t, J=5.5 Hz, 2H), 1.94-1.83 (m, 2H), 1.57-1.50 (m, 2H), 1.07 (s, 9H).
  • Step 2: To a solution of 1-(4-((tert-butyldiphenylsilyl)oxy)butyl)-4-iodo-1H-imidazole (1 g, 2 mmol) in THF (8 mL) was added a solution of TBAF in THF (1M, 2 mL) was added. After 1 hour, the reaction mixture was evaporated and the residue was purified by chromatography (EtOAc) to afford 4-(4-iodo-1H-imidazol-1-yl)butan-1-ol (80 mg), which was dissolved in DMSO (2 mL) and Et3N (1 mL). SO3-pyridine complex (96 mg, 0.6 mmol) was then added. The reaction mixture was stirred for 1 h prior to being quenched with water. The reaction mixture was extracted with EtOAc. The organic layer was separated, washed with brine, dried, and evaporated. The residue was purified by chromatography (EtOAc/Hexanes: 1:2 to EtOAc) to afford 4-(4-iodo-1H-imidazol-1-yl)butanal. 1H NMR (400 MHz, CDCl3) δ 9.80 (s, 1H), 7.37 (s, 1H), 7.02 (s, 1H), 4.01 (t, J=7.0 Hz, 2H), 2.50 (t, J=6.9 Hz, 2H), 2.25-2.01 (m, 2H).
  • Step 3: To a solution of 4-(4-iodo-1H-imidazol-1-yl)butanal (240 mg, 0.9 mmol) and lenalidomide (235 mg, 0.9 mmol) in DCE (10 mL) was added acetic acid (0.06 mL). The reaction was stirred for 20 minutes prior to the addition of NaHB(OAc)3 (381 mg). The reaction mixture was stirred for 12 h prior to being quenched with water. The reaction mixture was extracted with DCM. The organic layer was separated, washed with brine, dried, and evaporated. The residue was purified by HPLC to afford 3-(4-((4-(4-iodo-1H-imidazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (320 mg, 70%). 1HNMR (400 MHz, MeOD) δ 8.85 (s, 1H), 7.74 (s, 1H), 7.35 (t, J=7.6 Hz, 1H), 7.12 (d, J=7.6 Hz, 1H), 6.84 (d, J=8.0 Hz, 1H), 5.18 (dd, J=13.2, 5.1 Hz, 1H), 4.28-4.20 (m, 4H), 3.39-3.30 (m, 2H), 2.99-2.87 (m, 1H), 2.81-2.71 (m, 1H), 2.57-2.40 (m, 1H), 2.21-2.15 (m, 1H), 2.09-1.93 (m, 3H), 1.75-1.62 (m, 2H). ESI-MS: 508.03.
  • Step 4: To a Schlenk tube was added CuI (5.7 mg), Pd(Ph3P)2Cl2 (21 mg), 3-(4-((4-(4-iodo-1H-imidazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (150 mg, 0.3 mmol), and ethynyltriisopropylsilane (109 mg, 0.6 mmol), THF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 60° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (DCM:MeOH 9:1) to afford crude product (100 mg, 0.18 mmol), which was dissolved in THE and a solution of TBAF in THE (1M, 0.2 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was purified by HPLC to afford 3-(4-((4-(4-ethynyl-1H-imidazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (55 mg). ESI-MS: 406.12.
    • Example 23 Synthesis of 3-(4-(5-(5-ethynyl-1-methyl-1H-imidazol-2-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00466
  • Step 1: Hex-5-ynal (2 g, 15 mmol) was carefully dissolved in a solution of ammonia in methanol (7M, 21.4 mL) at 0° C. To this mixture was added glyoxal (10.87 g, 40% wt solution in water) dropwise. The reaction mixture was allowed to warm to r.t. and stirred for 12 h. The reaction mixture was concentrated, extracted with EtOAc. The organic layer was filtered to remove the insoluble. The residue was purified by chromatography (DCM/MeOH: 9:1) to afford 2-(pent-4-yn-1-yl)-1H-imidazole (1 g, 50%). 1H NMR (400 MHz, CDCl3) δ 9.10 (s, 1H), 6.99 (s, 2H), 2.91-2.85 (m, 2H), 2.28-2.20 (m, 2H), 2.04-2.00 (m, J=10.8 Hz, 4H).
  • Step 2: To a solution of 2-(pent-4-yn-1-yl)-1H-imidazole (1.4 g, 10 mmol) in THE (100 mL) was added NaH (600 mg, 15 mmol) portionwise at 0° C. under N2. The mixture was stirred for 20 minutes at 0° C. prior to the addition of MeI (0.62 mL, 10 mmol). The reaction mixture was allowed to warm to r.t. and stirred for 12 h. The reaction mixture was quenched with water and extracted with EtOAc. The residue was purified by chromatography (EtOAc/Hexanes: 1:1 to EtOAc) to afford 1-methyl-2-(pent-4-yn-1-yl)-1H-imidazole (1.4 g, 95%). 1H NMR (400 MHz, CDCl3) δ 6.92 (s, 1H), 6.78 (s, 1H), 3.59 (s, 3H), 2.88-2.71 (m, 2H), 2.31-2.11 (m, 2H), 2.14-1.91 (m, 3H).
  • Step 3: To a Schlenk tube was added CuI (5 mg), Pd(Ph3P)2Cl2 (17 mg), 1-methyl-2-(pent-4-yn-1-yl)-1H-imidazole (71 mg, 0.5 mmol), and 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (80 mg, 0.25 mmol), DMF (1 mL) and Et3N (0.5 mL). The reaction mixture was heated at 60-70° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by HPLC to afford 3-(4-(5-(1-methyl-1H-imidazol-2-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (70 mg, 32% yield). ESI-MS: 724.13.
  • Step 4: To a solution of 3-(4-(5-(1-methyl-1H-imidazol-2-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (96 mg, 0.25 mmol) in acetic acid (2 mL) was added NIS (56 mg). The reaction was stirred for 1 h prior to being concentrated. The residue was purified by HPLC to afford 3-(4-(5-(5-iodo-1-methyl-1H-imidazol-2-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (36 mg, 27%). ESI-MS: 517.12.
  • Step 5: To a Schlenk tube was added CuI (1 mg), Pd(Ph3P)2Cl2 (3.5 mg), 3-(4-(5-(5-iodo-1-methyl-1H-imidazol-2-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (36 mg, 0.069 mmol), and ethynyltrimethylsilane (20 mg), THF (2 mL) and Et3N (0.5 mL). The reaction mixture was heated at 50° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (DCM:MeOH 9:1) to afford crude product, which was dissolved in THF and a solution of TBAF in THF (1M, 0.1 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was purified by HPLC to afford 3-(4-(5-(5-ethynyl-1-methyl-1H-imidazol-2-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (20 mg,70%). ESI-MS: 406.12.
    • Example 24 Synthesis of 3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00467
  • Step 1: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.31 mmol), and 1-(pent-4-yn-1-yl)-1H-pyrazole (50 mg, 0.37 mmol), DMF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 80° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (MeOH/DCM) to afford the desired product (82 mg, 70% yield). ESI-MS: 377.15.
  • Step 2: 3-(4-(5-(1H-pyrazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (94 mg, 0.25 mmol) in acetic acid (2 mL) was added NIS (56 mg). The reaction was stirred for 6 h prior to being concentrated. The residue was purified by HPLC to afford 3-(4-(5-(4-iodo-1H-pyrazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (113 mg, 90%). ESI-MS: 503.19.
  • Step 3: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-(5-(4-iodo-1H-pyrazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.2 mmol), and ethynyltrimethylsilane (39.2 mg, 0.4 mmol), THF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 40° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (EtOAc) to afford crude product, which was dissolved in THF and a solution of TBAF in THF (1M, 0.2 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was subjected to HPLC purification to afford 3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (40 mg, 50% yield). ESI-MS: 401.11.
    • Example 25 Synthesis of 3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00468
  • Step 1: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.31 mmol), and 1-(pent-4-yn-1-yl)-1H-pyrazole (50 mg, 0.37 mmol), DMF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 80° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (MeOH/DCM) to afford the desired product (82 mg, 70% yield). ESI-MS: 377.15.
  • Step 2: To a solution of the product from step 1 (100 mg, 0.266 mmol) in MeOH (2 mL) was added 10% Pd/C. The reaction was stirred under H2 balloon for 4 h prior to being filtered. The organic solvent was removed to afford 3-(4-(5-(1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (97 mg, 95%).
  • Step 3: 3-(4-(5-(1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.26 mmol) in acetic acid (2 mL) was added NIS (56 mg). The reaction was stirred for 6 h prior to being concentrated. The residue was purified by HPLC to afford 3-(4-(5-(4-iodo-1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (118 mg, 90%). ESI-MS: 507.19.
  • Step 4: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-(5-(4-iodo-1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (101 mg, 0.2 mmol), and ethynyltrimethylsilane (39.2 mg, 0.4 mmol), THF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 40° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (EtOAc) to afford crude product, which was dissolved in THF and a solution of TBAF in THF (1M, 0.2 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was subjected to HPLC purification to afford 3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (44 mg, 55% yield). ESI-MS: 405.19.
    • Example 26 Synthesis of 3-(4-(5-(4-ethynyl-1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00469
  • Step 1: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.31 mmol), and 1-(pent-4-yn-1-yl)-1H-imidazole (50 mg, 0.37 mmol), DMF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 80° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (MeOH/DCM) to afford 3-(4-(5-(1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (42 mg, 36% yield). ESI-MS: 377.22.
  • Step 2: 3-(4-(5-(1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.26 mmol) in acetic acid (2 mL) was added NIS (56 mg). The reaction was stirred for 1 h prior to being concentrated. The residue was purified by HPLC to afford 3-(4-(5-(4-iodo-1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (39 mg, 30%). ESI-MS: 503.11.
  • Step 3: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-(5-(4-iodo-1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (101 mg, 0.2 mmol), and ethynyltrimethylsilane (39.2 mg, 0.4 mmol), THE (4 mL) and Et3N (1 mL). The reaction mixture was heated at 40° C. for 12 horns. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (EtOAc) to afford crude product, which was dissolved in THE and a solution of TBAF in THE (1M, 0.2 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was subjected to HPLC purification to afford 3-(4-(5-(4-ethynyl-1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (50 mg, 63% yield). ESI-MS: 401.17.
    • Example 27 Synthesis of 3-(4-(5-(4-ethynyl-1H-1,2,3-triazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00470
  • To a round-bottomed flask, methyl 3-bromo-2-methylbenzoate (18.3 g, 80 mmol, 1.0 eq), N-bromosuccinimide (17.1 g, 96 mmol, 1.2 eq) and benzoyl peroxide (1.9 g, 8.0 mmol, 0.1 eq) were mixed in 150 mL of benzene. The reaction mixture was stirred at 80° C. for 12 h. After cooling to room temperature, the reaction mixture was evaporated to remove most of the solvent. The resulting residue was purified by flash column chromatography with hexane/ethyl acetate to give the desired product S1 as colorless oil (23.4 g, 95% yield).
  • To a round-bottomed flask, compound S1 (23.4 g, 76 mmol, 1.0 eq) and 3-aminopiperidine-2,6-dione hydrochloride (13.8 g, 83.6 mmol, 1.1 eq) were mixed in 150 mL of acetonitrile. The resulting reaction mixture was stirred at 85° C. for 12 h. After cooling to room temperature, the reaction mixture was poured into 200 ml. of cooled water. The resulting mixture was filtrated and the solid was washed with water and ethyl acetate sequentially. After drying, a slightly purple solid was obtained, which was used directly in the following reactions without further purification (19.6 g, 80% yield). UPLC-MS calculated for C13H12BrN2O3[M+1]+: 323.00, found 322.96.
  • Figure US20210002289A1-20210107-C00471
  • To a round-bottomed flask, compound S2 (2.59 g, 8.0 mmol, 1.0 eq), 4-pentyn-1-ol (1.01 g, 12.0 mmol, 1.5 eq), Pd(PPh3)2Cl2 (421 mg, 0.6 mmol, 0.075 eq) and CuI (228 mg, 1.2 mmol, 0.15 eq) were mixed in 24 mL of DMF. The reaction mixture was sealed and filled with nitrogen. 10 mL of triethylamine was added and the reaction mixture was heated to 80° C. to stir for 8 h. After cooling to room temperature, the reaction mixture was evaporated to remove most of the solvent to give the dark residue, which was purified by flash column chromatography with DCM/MeOH to afford the final compound S3 as a white solid (2.08 g, 80% yield). UPLC-MS calculated for C18H19N2O4 [M+1]+: 327.13, found 327.15.
  • To a round-bottomed flask, compound S3 (1.04 g, 3.2 mmol, 1.0 eq) was suspended in 100 mL of dichioromethane. Mesyl chloride (495 μL, 6.4 mmol, 2.0 eq) was added dropwise to the upper solution at 0° C. Then triethylamine (1.33 mL. 9.6 mmol, 3.0 eq) was added. The suspended solution turned clear within 1 min. The reaction mixture was stirred at room temperature for 1 h. Then the solvent was evaporated to give crude product S4, which was used in the next step reaction without further purification. UPLC-MS calculated for C19H21N2O6S [M+1]+: 405.11, found 405.14.
  • Crude S4 was dissolved in 15 mL of DMF. Then sodium azide (416 mg, 6.4 mmol, 2.0 eq) was added and the solution was stirred at 60° C. for 1 h. After cooling to room temperature, the reaction mixture was diluted with water and purified by HPLC with MeCN/H2O (0.1% TFA) as the eluent to afford the desired compound S5 as a white solid (690 mg, 61% yield). UPLC-MS calculated for C18H18N5O3[M+1]+: 352.14, found 352.15.
  • Figure US20210002289A1-20210107-C00472
  • To a solution of 1,4-bis(trimethylsiliyl)-buta-1,3-diyne (1.0 g, 5.14 mmol) in 15 mL of dry ethyl ether, MeLi LiBr (1.5 M in ether, 6.68 mmol, 4.45 mL) was added and the reaction mixture was stirred at room temperature for 12 h. The reaction was quenched with saturated NH4Cl (aq) at 0° C. and the product was extracted with ethyl ether. The combined organic layer was dried over anhydrous Na2SO4. After filtration, the solution was carefully evaporated in vacuum to give the crude S6 as slightly dark oil, which was diluted in 5 mL of i-BuOH and stored below 0° C.
  • To a solution of azide S5 (690 mg, 1.97 mmol, 1.0 eq), S6 (0.5 M in t-BuOH, 4.7 mL, 2.36 mmol, 1.2 eq) in 30 mL of acetonitrile was added CuI (74 mg, 0.39 mmol, 0.2 eq) and DIPEA (1.7 mL, 9.83 mmol, 5.0 eq). The reaction mixture was stirred at room temperature for 12 h. After evaporation to remove the solvent, the crude residue was purified by reverse flash column with MeCN/H2O (0.1% TFA) to give the product S7 as a white solid (338 mg, 36% yield). UPLC-MS calculated for C25H28N5O3Si [M+1]+: 474.20, found 474.23.
  • To suspended solution of S7 (338 mg, 0.71 mmol, 1.0 eq) in 10 mL of acetonitrile was added TBAF (1.0 M in THF, 1.42 mL, 1.42 mmol, 2.0 eq). The solution turned clear within 1 min. After 1 h, the reaction mixture was diluted with water and purified by HPLC with MeCN/H2O (0.1% TFA) to afford the desired product S8 as a white solid (270 mg, 95% yield). UPLC-MS calculated for C22H20N5O3 [M+1]+: 402.16, found 402.21.
    • Example 28 Synthesis of 3-(4-(5-(4-ethynyl-1H-1,2,3-triazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00473
  • To a suspended solution of S3 (684 mg) in 100 mL of MeOH under nitrogen atmosphere was added 70 mg of Pd/C (10 wt %). Hydrogen was filled/evacuated into the flask three times. The solution was stirred at room temperature under 1 atm hydrogen atmosphere for 12 h. After consumption of the starting material, the solvent was evaporated and the residue was purified by flash column chromatography with DCM/MeOH to afford the desired product S11 as a white solid (693 mg, 90% yield). UPLC-MS calculated for C18H23N2O4[M+1]+: 331.17, found 331.13.
  • To a suspended solution of S11 (693 mg, 2.1 mmol, 1.0 eq) in 30 mL of DCM was added mesyl chloride (325 μL, 4.2 mmol, 2.0 eq) at 0° C. Then trimethylamine (0.88 mL, 6.3 mmol, 3.0 eq) was added dropwise. The solution turned clear within 1 min. After 1h, the solvent was evaporated to give crude compound S12, which was used in the next step reaction without further purification.
  • The above obtained crude compound S12 was dissolved in 10 mL of DMF, and sodium azide (275 mg, 4.2 mmol, 2.0 eq) was added. Then the reaction mixture was stirred at 60° C. for 5 h. After cooling to room temperature, the reaction was diluted in water and purified by HPLC with MeCN/H2O (0.1% TFA) to afford the compound S13 as a white solid (682 mg, 91% yield). UPLC-MS calculated for C18H22N5O3 [M+1]+: 356.17, found 356.29.
  • Figure US20210002289A1-20210107-C00474
  • Following the procedure for the synthesis of S7, S13 (682 mg, 1.92 mmol, 1.0 eq) was used in the reaction. Finally compound S14 was obtained as a white solid (704 mg, 76% yield). UPLC-MS calculated for C25H32N5O3Si [M+1]+: 478.23, found 478.24.
  • Following the procedure for the synthesis of S8, compound S14 (704 mg, 1.47 mmol, 1.0 eq) was used in the reaction. Finally compound S15 was obtained as a white solid (565 mg, 95% yield). UPLC-MS calculated for C22H24N5O3 [M+1]+: 406.19. found 406.26.
    • Example 29 Synthesis of 3-(4-((4-(4-ethynyl-1H-1,2,3-triazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00475
  • To a solution of PCC (7.29 g, 33.8 mmol, 1.2 eq) in 30 mL of DCM was added dropwise a solution of 4-chloro-1-butanol (3.06 g, 28.2 mmol, 1.0 eq) in 10 mL of DCM. The solution was stirred at room temperature for 1 h. Then the solution was filtered through celite and washed with ethyl ether. The combined organic layer was evaporated and the concentrated residue was purified by flash column chromatography with DCM to afford the desired product as colorless oil.
  • To a solution of lenalidomide (950 mg, 3.66 mmol, 1.0 eq) and 4-chloro-1-butanal (429 mg, 4.03 mmol, 1.1 eq) in 30 mL of DCE was added acetic acid (0.2 mL, 3.66 mmol, 1.0 eq) and sodium triacetoxyborohydride (1.55 g, 7.32 mmol, 2.0 eq). The suspended solution was stirred at room temperature for 12 h. The reaction mixture was quenched with brine and the product was extracted with DCM. The combined organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated to give the crude product, which was purified by flash column chromatography with DCM/MeOH to afford the desired product S16 as a white solid (128 mg, 10% yield). UPLC-MS calculated for C17H21C1N3O3 [M+1]+: 350.13, found 350.11.
  • To a solution of S16 (128 mg, 0.366 mmol, 1.0 eq) in 3 mL of DMF was added potassium iodide (6.1 mg, 0.037 mmol, 0.1 eq) and sodium azide (47.6 mg, 0.732 mmol, 2.0 eq). The solution was heat to 60° C. to stir for 2 h. After cooling to room temperature, the solution was diluted in water and purified by HPLC with MeCN/H2O (0.1% TEA) to afford the compound S17 as a white solid (117 mg, 90% yield). UPLC-MS calculated for C17H21N6O3 [M+1]+: 357.17, found 350.20.
  • Figure US20210002289A1-20210107-C00476
  • Following the procedure for the synthesis of S7, the reaction was conducted with 517 (117 mg, 0.33 mmol, 1.0 eq). The compound S18 was obtained as a white solid (71 mg, 45% yield). UPLC-MS calculated for C24H31N6O3Si [M+1]+: 479.22, found 478.97.
  • Following the procedure for the synthesis of S8, the reaction was conducted with 518 (71 mg, 0.15 mmol, 1.0 eq). The compound S19 was obtained as a white solid (57 mg, 95% yield). UPLC-MS calculated for C21H23N6O3 [M+1]+: 407.18, found 406.93.
    • Example 30 Synthesis of 3-(4-((4-(6-ethynylpyridin-3-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00477
  • To a solution of 5-bromopyridine-2-aldehyde (13.24 g, 71.2 mmol, 1.0 eq) in 200 ml of toluene was added TsOH monohydrate (677 mg, 3.56 mmol, 0.05 eq) and ethyleneglycol (8.0 mL, 142.4 mmol, 2.0 eq). The solution was heated to reflux with a Dean-Stark trap for 12 h. After cooling to room temperature, the solvent was evaporated and the residue was purified by flash column chromatography with DCM/MeOH to afford the compound S19 as colorless oil (14.74 g, 90% yield).
  • To a round-bottomed flask, compound S19 (5.95 g, 25.9 mmol, 1.0 eq), 4-butyn-1-ol (2.36 g, 33.6 mmol, 1.3 eq), Pd(PPh3)2Cl2 (909 mg, 1.295 mmol, 0.05 eq) and CuI (494 mg, 2.59 mmol, 0.1 eq) were mixed in 24 mL of DMF. The reaction mixture was sealed and filled with Nitrogen. 24 mL of triethylamine was added and the reaction mixture was heated to 80° C. to stir for 5 h. After cooling to room temperature, most of the solvent was evaporated and the residue was diluted in DCM and brine. The combined organic layer was dried and purified by flash column chromatography with DCM/MeOH to afford the final compound S20 as colorless oil (4.54 g, 80% yield). UPLC-MS calculated for C12H14NO3 [M+1]+: 220.10, found 220.09.
  • To the solution of S20 (4.54 g) in 100 mL of EtOH under nitrogen atmosphere was added 500 mg of Pd/C (10 wt %). Hydrogen was filled into the flask with three times. The solution was stirred at room temperature under 1 atm hydrogen atmosphere for 12 h. After consumption of the starting material, the solvent was evaporated and the residue was purified by flash column chromatography with DCM/MeOH to afford the desired product S21 as colorless oil (3.93 g, 85% yield). UPLC-MS calculated for C12H18NO3 [M+1]+: 224.13, found 224.14.
  • To the solution of S21 (1.84 g, 8.25 mmol, 1.0 eq) in 30 mL of THF was added 30 mL of 4N HCl (aq). The solution was heated to reflux for 6 h. After cooling to room temperature, the solvent was evaporated and diluted in ethyl acetate and saturated NaHCO3 aqueous solution. After extraction several times, the combined organic layer was dried and the concentrated residue was purified by flash column chromatography with DCM/MeOH to afford the compound S22 as colorless oil (3.0 g, 95% yield). UPLC-MS calculated for C10H14NO2 [M+1]+: 180.10, found 180.05.
  • To the solution of dimethyl (1-diazo-2-oxopropyl)phosphonate (25.14 mmol, 1.5 eq) and K2CO3 (2.0 eq) in 80 mL of methanol was added drop wise a solution of S22 (3.0 g, 16.76 mmol, 1.0 eq) in 20 mL of methanol. The resulting solution was stirred at room temperature for 2 h. The solvent was evaporated and the residue was diluted in ethyl acetate and brine. The combined organic layer was dried over anhydrous Na2SO4. After filtration and evaporation, the crude product was purified by flash column chromatography to afford the desired compound S23 as colorless oil (2.1 g, 72% yield). UPLC-MS calculated for C10H14NO [M+1]+: 176.11, found 176.01.
  • To a solution of S23 (1.1 g, 6 mmol, 1.0 eq) in 100 mL of DCM was added Dess-Martin Periodinane (4.6 g, 10.8 mmol, 1.8 eq). The reaction was stirred at room temperature for 2 h. 10 mL of water and 20 mL of saturated Na2S2O8 aqueous solution was added. After being stirred for 10 min, the reaction solution was filtered through celite and washed with DCM. After extraction for 3 times, the combined organic layer was dried over anhydrous Na2SO4. After filtration and evaporation, the crude product was purified by flash column chromatography to afford the desired compound S24 as colorless oil (680 mg, 65% yield). UPLC-MS calculated for C11H12NO [M+1]+: 174.09, found 174.08.
  • Figure US20210002289A1-20210107-C00478
  • To a solution of lenalidomide (1.01 g, 3.9 mmol, 1.0 eq) and compound S24 (680 mg, 3.9 mmol, 1.0 eq) in 50 mL of DCE was added acetic acid (0.23 mL, 3.9 mmol, 1.0 eq) and sodium triacetoxyborohydride (1.66 g, 3.9 mmol, 2.0 eq). The suspended solution was stirred at room temperature for 12 h. DCM and saturated NaHCO3 aqueous solution was added. After extraction, the combined organic layer was dried 974 mg, 60% yield). UPLC-MS calculated for C24H25N4O3 [M+1]+: 417.19, found 416.98.
    • Example 31 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(4-(6-ethynylpyridin-3-yl)butoxy)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00479
  • To a round-bottom flask, 3-hydroxyphthalic anhydride (1 g, 6.09 mmol) and 3-aminoperidine-2,6-dione hydrochloride (1.0 g, 6.09 mmol) were mixed in 50 mL of toluene. Triethyl amine (0.93 mL, 6.7 mmol) was added. The resulting reaction mixture was heated to reflux for 12 h with Dean-Stark trap equipment. After cooling to ambient temperature, evaporation of most of the solvent to give a crude product, which was purified by flash column chromatography with DCM:ethyl acetate to get the desired product as a slightly yellow solid S26 (1.5 g, 90% yield). 1H NMR (400 MHz, DMSO-d6) δ (ppm) 11.16 (s, 1H), 11.08 (s, 1H), 7.65 (t, J=7.6 Hz, 1H), 7.32 (d, J=7.2 Hz, 1H), 7.25 (d, J=8.4 Hz, 1H), 5.07 (dd, J=12.8 Hz, J=5.2 Hz, 1H), 2.93-2.84 (m, 1H), 2.61-2.46 (m, 1H), 2.05-2.01 (m, 1H).
  • To a solution of compound S23 (210 mg, 1.2 mmol, 1.0 eq) in 10 mL of DCM at 0° C. was added mesyl chloride (0.14 mL, 1.8 mmol, 1.5 eq) and triethyl amine (0.34 mL, 2.4 mmol, 2.0 eq) sequentially. The resulting solution was stirred at room temperature for 1 h. After evaporation of the solvent, the residue was purified by flash column chromatography with DCM/MeOH to afford the compound S27 as colorless oil (224 mg, 74% yield). UPLC-MS calculated for C12H16NO3S [M+1]+: 254.09, found 253.92.
  • To a solution of compound S27 (224 mg, 0.89 mmol, 1.0 eq) and S26 (243 mg, 0.89 mmol, 1.0 eq) in 4 mL of DMF was added KI (15 mg, 0.09 mmol, 0.1 eq) and KHCO3 (178 mg, 1.78 mmol, 2.0 eq). The resulting solution was stirred at room temperature for 5 h. After cooling to room temperature, the solution was diluted in water and purified by HPLC with MeCN/H2O (0.1% TFA) to afford the compound S28 as a white solid (290 mg, 75% yield). UPLC-MS calculated for C24H22N3O5 [M+1]+: 432.16, found 431.92.
    • Example 32 Synthesis of 3-(4-(4-((6-ethynylpyridin-3-yl)oxy)butyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00480
  • Following the procedure for the synthesis of compound S3, the reaction was conducted with S2 (1.29 g, 4.0 mmol, 1.0 eq). Finally, compound S29 was obtained as a slightly yellow solid (1.12 g, 90% yield). UPLC-MS calculated for C17H17N2O4 [M+1]+: 313.12, found 313.13.
  • Following the procedure for the synthesis of compound S11, the reaction was conducted with S29 (157 mg, 0.50 mmol, 1.0 eq). Finally, compound S30 was obtained as a white solid (148 mg, 94% yield). UPLC-MS calculated for C17H21N2O4 [M+1]+: 317.15, found 317.15.
  • Following the procedure for the synthesis of compound S4, the reaction was conducted with S30 (148 mg, 0.468 mmol, 1.0 eq). Finally, compound S31 was obtained as a white solid (175 mg, 95% yield). UPLC-MS calculated for C17H21N2O4 [M+1]+: 395.13, found 395.17.
  • Figure US20210002289A1-20210107-C00481
  • To a solution of 2-bromo-5-hydroxypyridine (1.04 g, 6.0 mmol, 1.0 eq) and trimethylsilylacetylene (1.7 mL, 12.0 mmol, 2.0 eq) in 30 mL of anhydrous THF were added Pd(PPh3)2Cl2 (420 mg, 0.6 mmol, 0.1 eq) and CuI (228 mg, 1.2 mmol, 0.2 eq) under nitrogen atmosphere. Then 8 mL of triethylamine was injected. The reaction flask was sealed and the reaction solution was stirred at 60° C. for 5 h. After cooling to room temperature, the solvent was evaporated and the residue was purified by flash column chromatography with DCM/MeOH to afford the compound S32 as colorless oil (803 mg, 70% yield). UPLC-MS calculated for C10H14NOSi [M+1]+: 192.08, found 191.98.
  • Following the procedure for the synthesis of compound S8, the reaction was conducted with S32 (803 mg, 4.2 mmol, 1.0 eq). Finally, the compound S33 was obtained as a white solid (400 mg, 80% yield). UPLC-MS calculated for C7H6NO [M+1]+: 120.04, found 119.93.
  • To a solution of compound S31 (175 mg, 0.44 mmol, 1.0 eq) and S33 (79 mg, 0.66 mmol, 1.5 eq) in 5.0 mL of DMF were added KI (7.3 mg, 0.044 mmol, 0.1 eq) and KHCO3 (88 mg, 0.88 mmol, 2.0 eq) sequentially. The resulted solution was stirred at 70° C. for 6 h. After cooling to room temperature, the reaction mixture was diluted in water and ethyl acetate. After extraction for 3 times, the combined organic layer was dried over Na2SO4. The concentrated residue was purified by reverse flash column chromatography with MeCN/H2O (0.1% TFA) to afford the compound S34 as a white solid (156 mg, 85% yield). UPLC-MS calculated for C24H24N3O4 [M+1]+: 418.18, found 418.20.
    • Example 33 Synthesis of 3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00482
  • Step 1: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.31 mmol), and 1-(pent-4-yn-1-yl)-1H-imidazole (50 mg, 0.37 mmol), DMF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 80° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (MeOH/DCM) to afford 3-(4-(5-(1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (42 mg, 36% yield). ESI-MS: 377.22.
  • Step 2: 3-(4-(5-(1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.26 mmol) in acetic acid (2 mL) was added NIS (56 mg). The reaction was stirred for 1 h prior to being concentrated. The residue was purified by HPLC to afford 3-(4-(5-(4-iodo-1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (39 mg, 30%). ESI-MS: 503.11.
  • Step 3: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-(5-(4-iodo-1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (101 mg, 0.2 mmol), and ethynyltrimethylsilane (39.2 mg, 0.4 mmol), THE (4 mL) and Et3N (1 mL). The reaction mixture was heated at 40° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (EtOAc) to afford crude product, which was dissolved in THE and a solution of TBAF in THE (1M, 0.2 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was subjected to HPLC purification to afford 3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (50 mg, 63% yield). ESI-MS: 401.17.
    • Example 34 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00483
  • Step 1: To a solution of 4-iodo-1H-pyrazole (2.4 g, 12 mmol) and triethylamine (1.85 mL, 13 mmol) in DCM (20 mL) at 0° C. was added MsCl (1 mL, 12.6 mmol). The reaction mixture was allowed to warm to r.t. and stirred for another 1 hour. The reaction mixture was quenched with saturated NH4Cl solution, extracted with DCM. The organic layer was separated, washed with brine, dried, and evaporated. The residue was dissolved in CH3CN (70 mL) and tert-butyl (4-hydroxybutyl)carbamate (1.89 g, 10 mmol) and Cs2CO3 (3.9 g, 12 mmol) was added. The reaction mixture was heated to reflux for 12 h. After the reaction was cooled, the mixture was filtered and the filtrate was evaporated. The residue was taken up in EtOAc and water. The organic layer was separated, washed with brine, dried, and evaporated. The residue was purified by chromatography (EtOAc/Hexanes: 1:2) to afford crude tert-butyl (4-(4-iodo-1H-pyrazol-1-yl)butyl)carbamate (2.3 g, 53%), which was treated with DCM (5 mL) and TEA (5 mL). The reaction mixture was stirred for 12 hours. All the volatiles were removed under vacuum and the residue was subjected to HPLC purification to afford 4-(4-iodo-1H-pyrazol-1-yl)butan-1-amine.
  • Step 2: To a solution of TEA salt of 4-(4-iodo-1H-pyrazol-1-yl)butan-1-amine (378 mg, 1 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (276 mg, 1 mmol) in DMF (1 mL) was added DIPEA (0.52 mL, 3 mmol). The reaction mixture was heated at 90° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was subject to HPLC purification to afford 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-iodo-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione (122 mg, 23% yield).
  • Step 3: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-iodo-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione (100 mg, 0.2 mmol), and ethynyltrimethylsilane (39.2 mg, 0.4 mmol), THE (4 mL) and Et3N (1 mL). The reaction mixture was heated at 40° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (EtOAc) to afford crude product, which was dissolved in THE and a solution of TBAF in THE (1M, 0.2 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was subjected to HPLC purification to afford compound L29 (50 mg, 60% yield). ESI-MS: 420.13.
    • Example 35 Synthesis of 3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00484
    Figure US20210002289A1-20210107-C00485
  • Step 1: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.31 mmol), and 1-(pent-4-yn-1-yl)-1H-pyrazole (50 mg, 0.37 mmol), DMF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 80° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (MeOH/DCM) to afford the desired product (82 mg, 70% yield). ESI-MS: 377.15.
  • Step 2: To a solution of the product from step 1 (100 mg, 0.266 mmol) in MeOH (2 mL) was added 10% Pd/C. The reaction was stirred under H2 balloon for 4 h prior to being filtered. The organic solvent was removed to afford 3-(4-(5-(1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (97 mg, 95%).
  • Step 3: 3-(4-(5-(1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100 mg, 0.26 mmol) in acetic acid (2 mL) was added NIS (56 mg). The reaction was stirred for 6 h prior to being concentrated. The residue was purified by HPLC to afford 3-(4-(5-(4-iodo-1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (118 mg, 90%). ESI-MS: 507.19.
  • Step 4: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 3-(4-(5-(4-iodo-1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (101 mg, 0.2 mmol), and ethynyl trimethyl silane (39.2 mg, 0.4 mmol), THE (4 mL) and Et3N (1 mL). The reaction mixture was heated at 40° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (EtOAc) to afford crude product, which was dissolved in THE and a solution of TBAF in THE (1M, 0.2 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was subjected to HPLC purification to afford compound L41 (44 mg, 55% yield). ESI-MS: 405.19.
    • Example 36 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(4-(4-ethynyl-1H-pyrazol-1-yl)butoxy)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00486
  • Step 1: To a suspension of 4-ethynyl-1H-pyrazole (920 mg, 10 mmol) and 4-chlorobutan-1-ol (216 mg, 20 mmol) in acetonitrile (25 mL) was added K2CO3 (4.1 g, 30 mmol, 3 eq) and KI (166 mg, 1 mmol, 0.1 eq). The mixture was stirred for 6 hours at 85° C. under N2 protection. The reaction mixture was quenched with water and extracted with EtOAc. The residue was purified by chromatography (DCM:MeOH 10:1) to afford to afford 1.3 g of 4-(4-ethynyl-1H-pyrazol-1-yl)butan-1-ol with 80% yield. ESI-MS m/z 165.02 [M+H]+.
  • Step 2: To a suspended solution of 4-(4-ethynyl-1H-pyrazol-1-yl)butan-1-ol (328 mg, 2 mmol, 1.0 eq) in 30 mL of DCM was added mesyl chloride (310 μL, 4 mmol, 2.0 eq) at 0° C. Then trimethylamine (0.77 mL, 6 mmol, 3.0 eq) was added dropwise. The solution turned clear within 1 min. After 1h, the solvent was evaporated to give crude 4-(4-ethynyl-1H-pyrazol-1-yl)butyl methanesulfonate, which was used in the next step reaction without further purification.
  • Step 3: To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (137 mg, 0.5 mmol), 4-(4-ethynyl-1H-pyrazol-1-yl)butyl methanesulfonate (61 mg, 0.25 mmol) in DMF (2 mL) was added KHCO3 (50 mg) and KI (10 mg). The reaction mixture was stirred at 70° C. for 12 hour prior to being taken up in ethyl acetate and water. The organic layer was separated, dried, and evaporated. The residue was purified by HPLC to afford 2-(2,6-dioxopiperidin-3-yl)-4-(4-(4-ethynyl-1H-pyrazol-1-yl)butoxy)isoindoline-1,3-dione (80 mg, 60%).
    • Example 37 Synthesis of (3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(4-((4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)butyl)carbamoyl)phenyl)-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamide
  • Figure US20210002289A1-20210107-C00487
    • Step 1: Synthesis of tert-butyl (4-oxobutyl)carbamate
  • To solution of tert-butyl 4-hydroxybutyl)carbamate (380 mg, 2 mmol) in 15 ml of DCM was added Dess-Martin periodinane reagent (1.7 g, 4 mmol). After stirring at room temperature for 1 h the reaction mixture was filtered by celite. The filtrate was then washed with brine, dried over Na2SO4, filtered, and the solvent evaporated in vacuo. The residue was purified by chromatography over silica gel, to yield tert-butyl (4-oxobutyl)carbamate as colorless oil.
    • Step 2: Synthesis of 3-(4-((4-aminobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • To tert-butyl (4-oxobutyl)carbamate (190 mg, 1 mmol) in 1,2-dichloroethane (15 mL) was added Lenalidomide (285 mg, 1.1 mmol), and the resulting solution was stirred at room temperature for 30 min. The solution was treated with Na(OAc)3BH (0.42 g, 2 mmol), and the resulting suspension was stirred overnight. The solvent was diluted with DCM and washed with sat. NaHCO3, brine, dried (Na2SO4), filtered, and concentrated. Then residue was diluted in 10 mL DCM then 2 mL trifluoroacetic acid was added to the reaction and stirred for 30 min. The solvent was removed by vacuo and the residue was purified by reverse phase chromatography over C18 column to yield 3-(4-((4-aminobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione as colorless oil.
    • Step 3: Synthesis of (3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(4-((4-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)butyl)carbamoyl)phenyl)-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamide
  • HATU (13.3 mg, 1.2 eq.) and N,N-Diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a solution of Cpd. A (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 3-(4-((4-aminobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (0.35 mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, re-dissolved in H2O, frozen and lyophilized to give title compound (TFA salt) as a white powder. LC-MS(ESI) m/z (M+H)+: 894.25, 4.96 min; calcd: 894.29; >98% purity.
    • Example 38 Synthesis of (3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(4-((5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-5-oxopentyl)carbamoyl)phenyl)-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamide
  • Figure US20210002289A1-20210107-C00488
    • Step 1: Synthesis of 5-amino-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentanamide
  • HATU (380 mg, 1 mmol) and N,N-diisopropylethylamine (0.44 mL, 2.5 mmol) were added to a solution of Boc-5-aminopentanoic acid (110 mg, 0.5 mmol) in 3 mL DMF and stirred. After 10 minutes, Lenalidomide (200 mg, 0.75 mmol) was added to the reaction. After 30 minutes, the solvent was removed and the crude was dissolved in 10 mL DCM and 2 mL trifluoroacetic acid. The reaction was stirred for 30 min and then the solvent was removed by vacuo. The residue was purified by reverse phase chromatography over C18 column to yield 5-amino-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentanamide as colorless oil.
  • Reaction 2: Synthesis of (3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(4-((5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-5-oxopentyl)carbamoyl)phenyl)-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamide
  • HATU (13.3 mg, 1.2 eq.) and N,N-diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a solution of Cpd. A (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 5-amino-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentanamide (0.35 mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, re-dissolved in H2O, frozen and lyophilized to give the title compound (TFA salt) as a white powder.
  • LC-MS(ESI) m/z (M+H)+:922.26, 5.39 min; calcd: 922.29; >98% purity. 1H NMR (400 MHz, MeOD) δ 7.77 (d, J=8.2 Hz, 2H), 7.74-7.67 (m, 2H), 7.63-7.57 (m, 3H), 7.54 (dd, J=8.2, 2.4 Hz, 1H), 7.47 (t, J=7.7 Hz, 1H), 7.39-7.31 (m, 1H), 7.17 (t, J=8.1 Hz, 1H), 7.11 (dd, J=8.2, 1.9 Hz, 1H), 6.79 (d, J=1.9 Hz, 1H), 5.38 (d, J=10.9 Hz, 1H), 5.12 (dd, J=13.3, 5.1 Hz, 1H), 4.98 (d, J=10.9 Hz, 1H), 4.45 (d, J=2.1 Hz, 2H), 3.40 (t, J=6.7 Hz, 2H), 3.02-2.79 (m, 2H), 2.78-2.66 (m, 1H), 2.57-2.30 (m, 3H), 2.21 (d, J=14.0 Hz, 1H), 2.17-2.07 (m, 1H), 2.06-1.88 (m, 3H), 1.81-1.63 (m, 6H), 1.60-1.46 (m, 1H), 1.24 (td, J=13.8, 3.9 Hz, 2H).
    • Example 38 Synthesis of (3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentyl)carbamoyl)phenyl)-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamide
  • Figure US20210002289A1-20210107-C00489
    • Step 1: Synthesis of tert-butyl (5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)carbamate
  • To a solution of tert-butyl pent-4-yn-1-ylcarbamate (236 mg, 1.29 mmol) and 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (400 mg, 1.29 mmol) in triethylamine (3 mL) and DMF (3 mL), CuI (50 mg, 0.25 mmol) and the Pd(Ph3P)2Cl2 (90 mg, 0.13 mmol) were added. The mixture was stirred at 80° C. under N2-atmosphere overnight. The reaction mixture was poured into a saturated aqueous solution of NH4Cl and after separation of the organic layer the aqueous layer was extracted with Ethyl Acetate. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography to afford tert-butyl (5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)carbamate as white solid.
    • Step 2: Synthesis of 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • To a solution of tert-butyl (5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-yn-1-yl)carbamate (210 mg, 0.5 mmol) in EtOH (5 mL) was added Pd/C (20 mg). The reaction was stirred under H2-atmosphere for 2 hr. Then the mixture was filtered by celite and the solvent was removed by vacuo. The residue was dissolved in 10 mL DCM and 2 mL trifluoroacetic acid. The reaction was stirred for 30 min and then the solvent was removed by vacuo. The residue was purified by reverse phase chromatography over CIS column to 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione as colorless oil.
    • Step 3: Synthesis of (3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(4-((5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentyl)carbamoyl)phenyl)-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamide
  • HATU (13.3 mg, 1.2 eq.) and N,N-diisopropylethylamine (0.026 mL, 0.15 mmol) were added to a solution of Cpd. A (20 mg, 0.029 mmol) in 0.5 mL DMF and stirred. After 10 minutes, 3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (0.35 mL, 0.1 M in DMSO) was added to the reaction. After 30 minutes, the solvent was removed and the crude was dissolved in 3:1 methanol/water, acidified with trifluoroacetic acid and purified by reverse-phase preparative HPLC. The purified fractions were combined, concentrated in vacuo, re-dissolved in H2O, frozen and lyophilized to give the title compound (TLA salt) as a white powder.
  • LC-MS(ESI) m/z (M+H)+: 893.19, 6.12 min; calcd (M+H)+: 893.30; >98% purity. 1H NMR (400 MHz, MeOD) δ 7.78-7.66 (m, 3H), 7.66-7.56 (m, 3H), 7.53 (dd, J=8.2, 2.5 Hz, 1H), 7.47-7.38 (m, 2H), 7.38-7.32 (m, 1H), 7.17 (t, J=8.1 Hz, 1H), 7.11 (dd, J=8.2, 2.0 Hz, 1H), 6.79 (d, J=1.9 Hz, 1H), 5.29 (d, J=10.7 Hz, 1H), 5.14 (dd, J=13.3, 5.2 Hz, 1H), 4.97 (d, J=10.8 Hz, 1H), 4.46 (dd, J=5.7, 2.5 Hz, 2H), 3.41-3.33 (m, 2H), 2.96-2.64 (m, 5H), 2.50 (qdd, J=13.3, 4.6, 2.5 Hz, 1H), 2.22-2.09 (m, 2H), 2.02-1.84 (m, 3H), 1.79-1.48 (m, 7H), 1.48-1.35 (m, 2H), 1.22 (td, J=13.7, 4.0 Hz, 2H).
    • Example 40 Synthesis of 3-(4-(5-(4-(((S)-4-(4-chlorophenyl)-3,6,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl)ethynyl)-1H-1,2,3-triazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00490
  • To a solution of S10 (14.1 mg, 0.03 mmol, 1.0 eq), S8 (18.1 mg, 0.045 mmol, 1.5 eq), Pd(PPh3)4 (3.5 mg, 0.003 mmol, 0.1 eq) and CuI (1.2 mg, 0.006 mmol, 0.2 eq) in 2 mL of DMF under nitrogen was added 1.0 mL of trimethylamine. The resulting reaction mixture was stirred at 60° C. for 5 h. After cooling to room temperature, the mixture was purified by HPLC to afford 3-(4-(5-(4-(((S)-4-(4-chlorophenyl)-3,6,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl)ethynyl)-1H-1,2,3-triazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione as a white solid (16 mg, 70% yield). 1HNMR (400 MHz, CD3OD) δ (ppm) 8.35 (s, 1H), 7.71 (d, J=7.2 Hz, 1H), 7.59 (d, J=7.6 Hz, 1H), 7.52-7.44 (m, 5H), 5.15 (dd, J=13.2 Hz, J=5.2 Hz, 1H), 4.65 (t, J=7.2 Hz, 2H), 4.53 (d, J=17.6 Hz, 1H), 4.46 (d, J=17.6 Hz, 1H), 4.39 (q, J=6.7 Hz, 1H), 2.95-2.86 (m, 1H), 2.81-2.75 (m, 1H), 2.75 (s, 3H), 2.58 (t, J=6.8 Hz, 2H), 2.57-2.50 (m, 1H), 2.30-2.21 (m, 2H), 2.20-2.17 (m, 1H), 2.01 (d, J=6.8 Hz, 3H), 1.86 (s, 3H); UPLC-MS calculated for C39H33ClN9O3S [M+1]+: 742.21, found 742.17.
    • Example 41 Synthesis of 3-(4-(5-(4-((4-(4-chlorophenyl)-3,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl)ethynyl)-1H-1,2,3-triazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
  • Figure US20210002289A1-20210107-C00491
  • To a solution of S9 (14.1 mg, 0.03 mmol, 1.0 eq), S15 (18.2 mg, 0.045 mmol, 1.5 eq), Pd(PPh3)4 (3.5 mg, 0.003 mmol, 0.1 eq) and CuI (1.2 mg, 0.006 mmol, 0.2 eq) in 2 mL of DMF under nitrogen was added 1.0 mL of trimethylamine. The resulting reaction mixture was stirred at 60° C. for 5 h. After cooling to room temperature, the mixture was purified by HPLC to afford 3-(4-(5-(4-((4-(4-chlorophenyl)-3,9-dimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl)ethynyl)-1H-1,2,3-triazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione as a white solid (14 mg, 63% yield). 1H NMR (400 MHz, CD3OD) δ (ppm) 8.26 (s, 1H), 7.65-7.63 (m, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.48-7.44 (m, 4H), 5.36 (d, J=13.2 Hz, 1H), 5.16 (dd, J=13.6 Hz, J=5.2 Hz, 1H), 4.52-4.42 (m, 4H), 4.35 (d, J=13.2 Hz, 1H), 2.96-2.87 (m, 1H), 2.82-2.80 (m, 1H), 2.76 (s, 3H), 2.71 (t, J=7.6 Hz, 2H), 2.59-2.48 (m, 1H), 2.23-2.17 (m, 1H), 1.99-1.96 (m, 2H), 1.92 (s, 3H), 1.76-1.68 (m, 2H), 1.40-1.30 (m, 2H); UPLC-MS calculated for C38H35ClN9O3S [M+1]+: 732.23, found 732.17.
    • Example 42 Synthesis of 4-((3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)amino)-7-(3,5-dimethylisoxazol-4-yl)-N-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3-oxopropoxy)ethoxy)ethoxy)ethyl)-6-methoxy-9H-pyrimido[4,5-b]indole-2-carboxamide
  • Figure US20210002289A1-20210107-C00492
  • To a round-bottom flask, N,N-diisopropylethylamine (50 mg) were added to a solution of 4-((3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)amino)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2-carboxylic acid (20 mg), HATU (20 mg), and 3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propanamide (50 mg) in DMF (1 mL) at room temperature. The mixture was stirred for 30 min and purified by HPLC to yield 17 mg of 4-((3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)amino)-7-(3,5-dimethylisoxazol-4-yl)-N-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3-oxopropoxy)ethoxy) ethoxy)ethyl)-6-methoxy-9H-pyrimido[4,5-b]indole-2-carboxamide as a TFA salt. ESI-MS calculated for C47H54NnO10 [M+H]+=932.4; Observed: 932.5.
    • Example 43 Synthesis of 4-((2-(4-(((S)-3-benzyl-6,9-dimethyl-4H,6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,4]oxazepin-2-yl)ethynyl)-1H-pyrazol-1-yl)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
  • Figure US20210002289A1-20210107-C00493
  • Step 1: To a solution of 4-iodo-1H-pyrazole (2.4 g, 12 mmol) and triethyl amine (1.85 mL, 13 mmol) in DCM (20 mL) at 0° C. was added MsCl (1 mL, 12.6 mmol). The reaction mixture was allowed to warm to r.t. and stirred for another 1 hour. The reaction mixture was quenched with saturated NH4Cl solution, extracted with DCM. The organic layer was separated, washed with brine, dried, and evaporated. The residue was dissolved in CH3CN (70 mL) and tert-butyl (4-hydroxybutyl)carbamate (1.89 g, 10 mmol) and Cs2CO3 (3.9 g, 12 mmol) was added. The reaction mixture was heated to reflux for 12 h. After the reaction was cooled, the mixture was filtered and the filtrate was evaporated. The residue was taken up in EtOAc and water. The organic layer was separated, washed with brine, dried, and evaporated. The residue was purified by chromatography (EtOAc/Hexanes: 1:2) to afford crude tert-butyl (4-(4-iodo-1H-pyrazol-1-yl)butyl)carbamate (2.3 g, 53%), which was treated with DCM (5 mL) and TEA (5 mL). The reaction mixture was stirred for 12 hours. All the volatiles were removed under vacuum and the residue was subject to HPLC purification to afford the 4-(4-iodo-1H-pyrazol-1-yl)butan-1-amine.
  • Step 2: To a solution of TEA salt of 4-(4-iodo-1H-pyrazol-1-yl)butan-1-amine (378 mg, 1 mmol) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (276 mg, 1 mmol) in DMF (1 mL) was added DIPEA (0.52 mL, 3 mmol). The reaction mixture was heated at 90° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was subject to HPLC purification to afford 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-iodo-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione (122 mg, 23% yield).
  • Step 3: To a Schlenk tube was added CuI (5.3 mg), Pd(Ph3P)2Cl2 (20 mg), 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-iodo-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione (100 mg, 0.2 mmol), and ethynyltrimethylsilane (39.2 mg, 0.4 mmol), THF (4 mL) and Et3N (1 mL). The reaction mixture was heated at 40° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was purified by chromatography (EtOAc) to afford crude product, which was dissolved in THF and a solution of TBAF in THF (1M, 0.2 mL) was added. After 5 minutes, the reaction mixture was evaporated and the residue was subjected to HPLC purification to afford 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione (50 mg, 60% yield). ESI-MS: 420.13.
  • Step 4: To a Schlenk tube was added CuI (3.8 mg), Pd(Ph3P)2Cl2 (7 mg), (S)-3-benzyl-2-bromo-6,9-dimethyl-4H,6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,4]oxazepine (20 mg, 0.05 mmol), and 2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione (42 mg, 0.1 mmol), THF (2 mL) and Et3N (0.5 mL). The reaction mixture was heated at 70° C. for 12 hours. The reaction mixture was cooled and treated with EtOAc and brine. The organic layer was separated, dried, and evaporated. The residue was subjected to HPLC purification to afford the title compound (14 mg, 38% yield). 1H NMR (400 MHz, MeOD) δ 7.95 (s, 1H), 7.67 (s, 1H), 7.53 (t, J=7.2 Hz, 1H), 7.31 (t, J=7.7 Hz, 2H), 7.23-7.18 (m, 3H), 7.02-6.98 (m, 2H), 5.05 (dd, J=12.3, 5.2 Hz, 1H), 4.82 (d, J=15.6 Hz, 1H), 4.66-4.61 (m, 1H), 4.60 (d, J=15.6 Hz, 1H), 4.23 (t, J=6.7 Hz, 2H), 4.14 (d, J=15.7 Hz, 1H), 4.04 (d, J=15.4 Hz, 1H), 3.38-3.33 (m, 2H), 2.93-2.60 (m, 6H), 2.14-2.09 (m, 1H), 2.06-1.91 (m, 2H), 1.64-1.59 (m, 5H). ESI-MS: 729.20.
  • It is to be understood that the foregoing embodiments and exemplifications are not intended to be limiting in any respect to the scope of the disclosure, and that the claims presented herein are intended to encompass all embodiments and exemplifications whether or not explicitly presented herein
  • All patents and publications cited herein are fully incorporated by reference in their entirety.

Claims (38)

1. A compound having Formula I:
Figure US20210002289A1-20210107-C00494
and the salts or solvates thereof,
wherein:
X is selected from the group consisting of —C≡C—, —O—, —N(R2a)—, —OC(═O)—,
Figure US20210002289A1-20210107-C00495
wherein the —N(R2b)— of
Figure US20210002289A1-20210107-C00496
is attached to L; the —O— of
Figure US20210002289A1-20210107-C00497
is attached to L; the —C(═O)— of —OC(═O)— is attached to L;
and the carbon atom of
Figure US20210002289A1-20210107-C00498
is attached to L;
L is selected from the group consisting of heteroalkylenyl, -A-(CH2)m—W—(CH2)n—, and —(CH2)r—W—(CH2)u—O—(CH2)v—;
A is absent; or
A is heteroarylenyl;
W is selected from the group consisting of phenylenyl, heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
m is 0, 1, 2, 3, 4, 5, 6, or 7;
n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
r is 0, 1, 2 or 3;
u is 0, 1, 2, or 3;
v is 1, 2, 3, or 4;
Y is selected from the group consisting of —C≡C—, —CH═CH—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
Y is absent;
wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
R2a, R2b, R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
B is selected from the group consisting of:
Figure US20210002289A1-20210107-C00499
A1 is selected from the group consisting of —C(R16a)═ and —N═;
A2 is selected from the group consisting of —C(R16b)═ and —N═;
A3 is selected from the group consisting of —C(R16c)═ and —N═;
G is selected from the group consisting of —C(R16d)═ and —N═;
Z is selected from the group consisting of —CH2 and —C(═O)—;
R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
R16d is selected from the group consisting of hydrogen, halo, and C1-4 alkyl,
with the proviso the compound is not any one of the compounds of Table 6.
2. The compound of claim 1, and the salts or solvates thereof, wherein;
X is selected from the group consisting of —C≡C—, —O—, —N(R2a)—,
Figure US20210002289A1-20210107-C00500
wherein the —N(R2b)— of
Figure US20210002289A1-20210107-C00501
is attached to L; the —O— of
Figure US20210002289A1-20210107-C00502
is attached to L; and
B is selected from the group consisting of B-1a, B-2, and B-3.
3. The compound of claim 1, wherein X is —C≡C—.
4. The compound of claim 1, wherein X is —N(H)—.
5. The compound of claim 1, wherein X is selected from the group consisting of
Figure US20210002289A1-20210107-C00503
wherein the carbon atom of
Figure US20210002289A1-20210107-C00504
is attached to L.
6. (canceled)
7. (canceled)
8. The compound of claim 1, wherein L is 3- to 12-membered heteroalkylenyl.
9. The compound of claim 8, or a pharmaceutically acceptable salt or solvate thereof, wherein;
L is —(CH2)oO—(CH2CH2O)p—(CH2)q—;
o is 1, 2, or 3;
p is 0, 1, 2, 3, 4, or 5; and
q is 1, 2, or 3.
10. (canceled)
11. The compound of claim 1, wherein;
L is -A-(CH2)m—W—(CH2)n—; and
A is absent.
12. (canceled)
13. (canceled)
14. The compound of claim 11, wherein W is 5-membered heteroarylenyl.
15. (canceled)
16. The compound of claim 11, wherein W is 6-membered heteroarylenyl.
17. (canceled)
18. The compound of claim 11, wherein W is heterocyclenyl.
19-21. (canceled)
22. The compound of claim 1, wherein;
L is -A-(CH2)m—W—(CH2)n—; and
A is selected from the group consisting of 5-membered heteroarylenyl and 6-membered heteroarylenyl.
23-40. (canceled)
41. The compound of claim 1, wherein Y is selected from the group consisting of —C≡C—, —CH2—, —O—, and —N(R2c)—.
42-45. (canceled)
46. The compound of claim 1, wherein B is B-1a.
47-54. (canceled)
55. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, having Formula II:
Figure US20210002289A1-20210107-C00505
56-65. (canceled)
66. The compound of claim 55, or a pharmaceutically acceptable salt or solvate thereof, wherein L is 3- to 20-membered heteroalkylenyl.
67. (canceled)
68. (canceled)
69. The compound of claim 55, or a pharmaceutically acceptable salt or solvate thereof, wherein L is —(CH2)m—W—(CH2)n—.
70-73. (canceled)
74. The compound of claim 69, or a pharmaceutically acceptable salt or solvate thereof, wherein;
L is selected from the group consisting of:
Figure US20210002289A1-20210107-C00506
Q3 is selected from the group consisting of —O—, —S—, and —N(R6)—; and
R6 is selected from the group consisting of hydrogen and C1-4 alkyl.
75. (canceled)
76. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, selected from the group consisting of;
2-(2,6-dioxopiperidin-3-yl)-4-((3-(2-(2-(3-(piperidin-4-ylamino)propoxy)ethoxy)ethoxy)propyl)amino)isoindoline-1,3-dione;
4-((2-(2-(2-(2-(4-aminophenoxy)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-((7-aminoheptyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
5-amino-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pentanamide;
N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide;
N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide;
4-((3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
4-((3-aminopropyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-((4-aminobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-((5-aminopentyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-((6-aminohexyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-((2-(2-aminoethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-((2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-((3-(4-(3-aminopropoxy)butoxy)propyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-((23-amino-3,6,9,12,15,18,21-heptaoxatricosyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(4-((2-(2-aminoethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((14-amino-3,6,9,12-tetraoxatetradecyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
4-((3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)amino)-2-(3-fluoro-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(4-(3-(2-aminoethoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(3-(2-(2-aminoethoxy)ethoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
4-((4-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)butyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(4-((4-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((3-(4-amino-1H-imidazol-1-yl)propyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(4-amino-1H-imidazol-1-yl)butyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((2-(4-(aminomethyl)-1H-imidazol-1-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(3-(4-(aminomethyl)-1H-imidazol-1-yl)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((3-(1-(2-aminoethyl)-1H-imidazol-4-yl)propyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((3-(1-(3-aminopropyl)-1H-imidazol-4-yl)propyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((3-(4-(3-aminopropyl)-1H-imidazol-1-yl)propyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(4-(3-aminopropyl)-1H-imidazol-1-yl)butyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((3-(5-(2-aminoethyl)-1H-imidazol-2-yl)propyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(5-(2-aminoethyl)-1H-imidazol-2-yl)butyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(4-(aminomethyl)-1H-imidazol-1-yl)butyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
4-(4-(4-(aminomethyl)-1H-imidazol-1-yl)butyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(4-((3-(4-(2-aminoethyl)-1H-imidazol-1-yl)propyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((3-(4-(aminomethyl)-1H-imidazol-1-yl)propyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(4-(2-aminoethyl)-1H-imidazol-1-yl)butyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
4-(4-(4-(2-aminoethyl)-1H-imidazol-1-yl)butyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(4-(((1-(3-aminopropyl)-1H-imidazol-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((2-(4-(3-aminopropyl)-1H-imidazol-2-yl)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(2-(1-(3-aminopropyl)-1H-imidazol-4-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
4-(2-(1-(3-aminopropyl)-1H-imidazol-4-yl)ethyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(4-(3-((1-(3-aminopropyl)-1H-imidazol-4-yl)methoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
4-(3-((1-(3-aminopropyl)-1H-imidazol-4-yl)methoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(4-(3-(4-(3-aminopropyl)-1H-imidazol-2-yl)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
4-(3-(4-(3-aminopropyl)-1H-imidazol-2-yl)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-(5-aminopentyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-(3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-(3-(2-aminoethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(2-(2-aminoethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propanamide;
3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)propanamide;
4-((2-(2-(2-aminoethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
3-(4-((4-aminobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((2-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((2-(2-(3-aminopropoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(1-amino-3,6,9,12-tetraoxapentadecan-15-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)prop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
4-(3-(2-(2-aminoethoxy)ethoxy)propyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
4-(((1-(3-aminopropyl)-1H-imidazol-4-yl)methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
(2S,4R)-1-((S)-2-(5-aminopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide;
(2S,4R)-1-((S)-2-(3-(2-(2-aminoethoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide;
N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide;
2-(2,6-dioxopiperidin-3-yl)-4-((2-(prop-2-yn-1-yloxy)ethyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(prop-2-yn-1-yloxy)ethoxy)ethyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(2-(prop-2-yn-1-yloxy)ethoxy)ethoxy)ethyl)amino)isoindoline-1,3-dione;
4-((3,6,9,12-tetraoxapentadec-14-yn-1-yl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxonineridin-3-yl)-4-(((5-ethynylpyridin-2-yl)methyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-(4-ethynyl-1H-pyrazol-1-yl)ethoxy)ethyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((3-(4-ethynyl-1H-pyrazol-1-yl)propyl)amino)isoindoline-1,3-dione;
3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(5-(5-ethynyl-1H-imidazol-2-yl)pent-1-yn-1-yl)isoindoline-1,3-dione;
3-(4-((4-(4-ethynyl-1H-imidazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(5-(4-ethynyl-1H-pyrazol-1-yl)pent-1-yn-1-yl)isoindoline-1,3-dione;
3-(4-(5-(5-ethynyl-1-methyl-1H-imidazol-2-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)isoindoline-1,3-dione;
3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(4-ethynyl-1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(5-(4-ethynyl-1H-imidazol-1-yl)pent-1-yn-1-yl)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(5-(4-ethynyl-1H-imidazol-1-yl)pent-1-yn-1-yl)isoindoline-1,3-dione;
2-(2,6-dioxonineridin-3-yl)-4-(4-(4-ethynyl-1H-pyrazol-1-yl) butoxy)isoindoline-1,3-dione;
3-(4-(5-(4-ethynyl-1H-1,2,3-triazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(4-ethynyl-1H-1,2,3-triazol-1-yl)pentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((4-(4-ethynyl-1H-1,2,3-triazol-1-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4(4-((6-ethynylpyridin-3-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(4-(6-ethynylpyridin-3-yl)butoxy)isoindoline-1,3-dione;
3-(4-(4-((6-ethynylpyridin-3-yl)oxy)butyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(6-ethynylpyridin-3-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(6-ethynylpyridin-3-yl)oxy)but-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((4-(5-ethynylpyridin-2-yl)butyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(5-ethynylpyridin-2-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(5-ethynyl-1H-imidazol-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(4-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione;
3-(4-(4-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(4-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione;
3-(4-((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(2-(1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)methoxy)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)methyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(2-(1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)ethyl)isoindoline-1,3-dione;
3-(4-((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(2-(1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)methoxy)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)methyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(2-(1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)ethyl)isoindoline-1,3-dione;
3-(4-((1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(2-(1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)methoxy)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(((1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)methyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(2-(1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)ethyl)isoindoline-1,3-dione;
3-(4-((1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(2-(1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)methoxy)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(((1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)methyl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(2-(1-((6-ethynylpyridin-3-yl)methyl)piperidin-4-yl)ethyl)isoindoline-1,3-dione;
3-(4-((4-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperazin-1-yl)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((4-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperazin-1-yl)methyl)isoindoline-1,3-dione;
3-(4-((4-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperazin-1-yl)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((4-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperazin-1-yl)methyl)isoindoline-1,3-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)methyl)isoindoline-1,3-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)methyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)methyl)isoindoline-1,3-dione;
3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-5-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(4-ethynyl-1H-pyrazol-1-yl)pentyl)-7-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(4-ethynyl-1H-pyrazol-1-yl)butoxy)-5-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(4-ethynyl-1H-pyrazol-1-yl)butoxy)-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(4-ethynyl-1H-pyrazol-1-yl)butoxy)-7-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)-5-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((4-(4-ethynyl-1H-pyrazol-1l-yl)buyl)amino)-7-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)amino)isoindoline-1,3-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)isoindoline-1,3-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H-imidazol-4-yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H-imidazol-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H-imidazol-4-yl)methoxy)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H-imidazol-4-yl)methyl)amino)isoindoline-1,3-dione;
3-(4-((4-((4-ethynyl-1H-pyrazol-1-yl)methyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((4-((4-ethynyl-1H-pyrazol-1-yl)methyl)benzyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((4-((4-ethynyl-1H-pyrazol-1-yl)methyl)benzyl)oxy)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((4-((4-ethynyl-1H-pyrazol-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione;
3-(4-(4-(4-ethynyl-1H-pyrazol-1-yl)butoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(5-((4-(4-ethynyl-1H-pyrazol-1-yl)butyl)amino)-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)piperidin-4-yl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)amino)isoindoline-1,3-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(4-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperazin-1-yl)isoindoline-1,3-dione;
3-(4-(((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H-imidazol-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(4-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)piperazin-1-yl)isoindoline-1,3-dione;
3-(4-((4-((4-ethynyl-1H-pyrazol-1-yl)methyl)benzyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H-imidazol-5-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-(4-(4-(4-ethynyl-1H-pyrazol-1-yl)butyl)piperazin-1-yl)isoindoline-1,3-dione;
3-(4-(((1-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)-1H-imidazol-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-((5-ethynylpyridin-2-yl)methyl)piperidin-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-((6-ethynylpyridin-3-yl)methyl)azetidin-3-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)oxy)isoindoline-1,3-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H-imidazol-4-yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)piperidin-4-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)piperidin-4-yl)oxy)isoindoline-1,3-dione;
3-(4-((1-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)-1H-imidazol-4-yl)methoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(4-(4-ethynyl-1H-pyrazol-1-yl)butyl)piperidin-4-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
2-(2,6-dioxopiperidin-3-yl)-4-((1-(4-(4-ethynyl-1H-pyrazol-1-yl)butyl)piperidin-4-yl)oxy)isoindoline-1,3-dione;
3-(4-(((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)-1H-imidazol-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)-1H-imidazol-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-(4-(4-ethynyl-1H-pyrazol-1-yl)butyl)-1H-imidazol-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((4-((4-ethynyl-1H-pyrazol-1-yl)methyl)cyclohexyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((3-((4-ethynyl-1H-pyrazol-1-yl)methyl)cyclobutyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)piperidin-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)azetidin-3-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(2-(4-ethynyl-1H-pyrazol-1-yl)ethyl)azetidin-3-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)azetidin-3-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-(3-(4-ethynyl-1H-pyrazol-1-yl)propyl)piperazin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(3-aminopropyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-aminobutyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(1-oxo-4-(piperidin-4-ylamino)isoindolin-2-yl)piperidine-2,6-dione;
3-(4-(azetidin-3-ylamino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(1-oxo-4-((piperidin-4-ylmethyl)amino)isoindolin-2-yl)piperidine-2,6-dione;
3-(4-((azetidin-3-ylmethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(2-aminoethyl)piperidin-4-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(2-aminoethyl)azetidin-3-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-(2-aminoethyl)piperidin-4-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1-(2-aminoethyl)azetidin-3-yl)methyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(2-(4-aminocyclohexyl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(1-oxo-4-(2-(piperidin-4-yl)ethyl)isoindolin-2-yl)piperidine-2,6-dione;
4-(4-(2-aminoethyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione;
(2S,4R)-1-((S)-2-(5-aminopentanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N—((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide;
(2S,4R)-1-((S)-2-(3-(2-(2-aminoethoxy)ethoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N—((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide;
(2S,4R)-1-((S)-1-amino-14-(tert-butyl)-12-oxo-3,6,9-trioxa-13-azapentadecan-15-oyl)-4-hydroxy-N—((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide;
3-(5-(5-aminopent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(6-(5-aminopent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-26-dione;
3-(5-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(6-(5-aminopentyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(((1r,4r)-4-aminocyclohexyl)ethynyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((Z)-2-((1r,4r)-4-aminocyclohexyl)vinyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(2-((1r,4s)-4-aminocyclohexyl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(6-(4-aminopiperidin-1-yl)-6-oxohex-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(5-(4-aminopiperidin-1-yl)-5-oxopent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
N-((1r,4r)-4-aminocyclohexyl)-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-ynamide;
N-((1r,4r)-4-aminocyclohexyl)-5-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)pent-4-ynamide;
3-(4-(3-(2-(2-aminoethoxy)ethoxy)prop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(3-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)prop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(4-aminobutoxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(3-aminopropyl)-1H-pyrazol-4-yl)ethynyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(2-(1-(3-aminopropyl)-1H-pyrazol-4-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(3-aminopropyl)-1H-imidazol-5-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(2-(1-(3-aminopropyl)-1H-imidazol-5-yl)ethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((1-(3-aminopropyl)piperidin-4-yl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-(7-(4-aminopiperidin-1-yl)hept-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
3-(4-((17-amino-3,6,9,12,15-pentaoxaheptadecyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione;
1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-oic acid;
14-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecanoic acid;
2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)acetamide;
1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxapentadecan-15-oic acid;
3-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)propanoic acid;
(2S,4R)-1-((S)-1-amino-17-(tert-butyl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-oyl)-4-hydroxy-N—((S)-1-(4-(4-methylthiazol-2-yl)phenyl)ethyl)pyrrolidine-2-carboxamide; and 1-amino-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-3,6,9,12-tetraoxapentadecan-15-amide.
77. (canceled)
78. A method of preparing a compound having Formula IX:
Figure US20210002289A1-20210107-C00507
or pharmaceutically acceptable salt or solvate thereof,
the method comprising:
(1) condensing a compound having Formula I:
Figure US20210002289A1-20210107-C00508
wherein;
B is selected from the group consisting of:
Figure US20210002289A1-20210107-C00509
X is selected from the group consisting of —C≡C—, —O—, —N(R2a)—,
Figure US20210002289A1-20210107-C00510
wherein the —N(R2b)— of
Figure US20210002289A1-20210107-C00511
is attached to L and the —O— of
Figure US20210002289A1-20210107-C00512
is attached to L
L is selected from the group consisting of alkylenyl, heteroalkylenyl, -A-(CH2)m—W—(CH2)n—, and —(CH2)r—W—(CH2)u—O—(CH2)v—;
A is absent; or
A is heteroarylenyl;
W is selected from the group consisting of phenylenyl, heteroarylenyl, heterocyclenyl, and cycloalkylenyl;
m is 0, 1, 2, 3, 4, 5, 6, or 7;
n is 0, 1, 2, 3, 4, 5, 6, 7, or 8;
r is 0, 1, 2 or 3;
u is 0, 1, 2, or 3;
v is 1, 2, 3, or 4;
Y is selected from the group consisting of —C≡C—, —CH2—, —O—, —N(R2c)—, —C(═O)N(R2d)—, —N(R2e)C(═O)CH2O—, and —N(R2e)C(═O)CH2N(R2f)—; or
Y is absent;
wherein the carboxamide nitrogen atom of —N(R2e)C(═O)CH2O— and —N(R2e)C(═O)CH2N(R2f)—, and the carbon atom of —C(═O)N(R2d)— is attached to L;
R2a, R2b, R2c, R2d, R2e, and R2f are each independently selected from the group consisting of hydrogen and C1-4 alkyl;
B is selected from the group consisting of:
Figure US20210002289A1-20210107-C00513
A is selected from the group consisting of —C(R16a)═ and —N═;
A2 is selected from the group consisting of —C(R16b)═ and —N═;
A3 is selected from the group consisting of —C(R16c)═ and —N═;
Z is selected from the group consisting of —CH2 and —C(═O)—;
R5 is selected from the group consisting of hydrogen, methyl, and fluoro;
R16a is selected from the group consisting of hydrogen, halo, and C1-4 alkyl;
R16b is selected from the group consisting of hydrogen, halo, and C1-4 alkyl; and
R16c is selected from the group consisting of hydrogen, halo, and C1-4 alkyl, with proviso that the compound having Formula I is not any of the compounds of Table 6,
with compound having Formula X;

T-X3X
wherein;
T is a monovalent radical of a target protein inhibitor;
X3 is selected from the group consisting of —C(═O)OH and -LG; and
LG is a leaving group,
(2) isolating the compound having Formula IX.
79-81. (canceled)
US17/007,191 2016-04-06 2020-08-31 Monofunctional intermediates for ligand-dependent target protein degradation Abandoned US20210002289A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/007,191 US20210002289A1 (en) 2016-04-06 2020-08-31 Monofunctional intermediates for ligand-dependent target protein degradation

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201662318974P 2016-04-06 2016-04-06
US201662321499P 2016-04-12 2016-04-12
US201662393874P 2016-09-13 2016-09-13
US201662393888P 2016-09-13 2016-09-13
US201662393935P 2016-09-13 2016-09-13
US201662409571P 2016-10-18 2016-10-18
US201662409592P 2016-10-18 2016-10-18
PCT/US2017/026275 WO2017176958A1 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation
US201816091544A 2018-10-05 2018-10-05
US17/007,191 US20210002289A1 (en) 2016-04-06 2020-08-31 Monofunctional intermediates for ligand-dependent target protein degradation

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US16/091,544 Continuation US10759808B2 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation
PCT/US2017/026275 Continuation WO2017176958A1 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation

Publications (1)

Publication Number Publication Date
US20210002289A1 true US20210002289A1 (en) 2021-01-07

Family

ID=58549317

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/091,544 Active US10759808B2 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation
US17/007,191 Abandoned US20210002289A1 (en) 2016-04-06 2020-08-31 Monofunctional intermediates for ligand-dependent target protein degradation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/091,544 Active US10759808B2 (en) 2016-04-06 2017-04-06 Monofunctional intermediates for ligand-dependent target protein degradation

Country Status (7)

Country Link
US (2) US10759808B2 (en)
EP (1) EP3440082A1 (en)
JP (2) JP7001614B2 (en)
CN (1) CN109311900A (en)
AU (2) AU2017246453A1 (en)
CA (1) CA3020281A1 (en)
WO (1) WO2017176958A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113788818A (en) * 2016-04-06 2021-12-14 密执安大学评议会 MDM2 protein degrading agent
UA123168C2 (en) * 2016-04-12 2021-02-24 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган VET PROTEIN DESTRUCTORS
CN109641874A (en) 2016-05-10 2019-04-16 C4医药公司 C for target protein degradation3The glutarimide degron body of carbon connection
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109790143A (en) 2016-05-10 2019-05-21 C4医药公司 The C of amine connection for target protein degradation3Glutarimide degron body
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
US11466028B2 (en) * 2016-09-13 2022-10-11 The Regents Of The University Of Michigan Fused 1,4-oxazepines as BET protein degraders
CA3036841A1 (en) * 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
EP3535265A4 (en) * 2016-11-01 2020-07-08 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11046709B2 (en) 2017-02-03 2021-06-29 The Regents Of The University Of Michigan Fused 1,4-diazepines as BET bromodomain inhibitors
CN110769822A (en) 2017-06-20 2020-02-07 C4医药公司 N/O-linked degron and degron bodies for protein degradation
TWI793151B (en) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN109422751B (en) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 Compound with activity of degrading tyrosine protein kinase JAK3
EP3679028A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
CN111315735B (en) 2017-09-04 2024-03-08 C4医药公司 Dihydrobenzimidazolones
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
IL295603B2 (en) 2017-09-22 2024-03-01 Kymera Therapeutics Inc Protein compounds and their uses
CN111542318A (en) 2017-11-10 2020-08-14 密歇根大学董事会 ASH1L degraders and methods of treatment therewith
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
US11485743B2 (en) 2018-01-12 2022-11-01 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019160890A1 (en) * 2018-02-13 2019-08-22 Dana-Farber Cancer Institute, Inc. Cyclin-dependent kinase degraders and methods of use
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CN110357850A (en) * 2018-03-26 2019-10-22 广东东阳光药业有限公司 A kind of preparation method of sulfur heterocyclic compound
WO2019196812A1 (en) * 2018-04-09 2019-10-17 上海科技大学 Protein degradation targeting compound, anti-tumor application, intermediate thereof and use of intermediate
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2019242625A1 (en) * 2018-06-20 2019-12-26 上海科技大学 Method for preparing lenalidomide derivatives
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADING AGENTS AND THEIR USES
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
DK3820573T3 (en) * 2018-07-10 2023-10-23 Novartis Ag 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
CN112912376A (en) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 Proteolytic targeted chimeric (PROTAC) compounds with E3 ubiquitin ligase binding activity and targeting alpha-synuclein for the treatment of neurodegenerative diseases
IL280984B2 (en) 2018-08-22 2025-02-01 Cullgen Shanghai Inc Tropomyosin receptor kinase (trk) degradation compounds and methods of use
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
CN110963958B (en) * 2018-09-30 2025-10-10 上海长森药业有限公司 An MDM2 inhibitor, and its preparation method, pharmaceutical composition and application
WO2020064002A1 (en) 2018-09-30 2020-04-02 中国科学院上海药物研究所 Isoindoline compound, preparation method, pharmaceutical composition and use thereof
SG11202103282YA (en) * 2018-10-08 2021-04-29 Univ Michigan Regents Small molecule mdm2 protein degraders
CN111018857B (en) 2018-10-09 2023-06-02 嘉兴优博生物技术有限公司 Targeted Protease Degradation Platform (TED)
CA3119343C (en) 2018-11-13 2024-01-16 Biotheryx, Inc. Substituted isoindolinones
TWI750539B (en) * 2018-11-23 2021-12-21 大陸商蘇州亞盛藥業有限公司 Novel pharmaceutical composition and its use
EP3886904A4 (en) 2018-11-30 2022-07-13 Kymera Therapeutics, Inc. IRAQ-TYPE KINASE DEGRADING AGENTS AND THEIR USES
CN111285850B (en) * 2018-12-06 2022-04-22 中国科学院上海药物研究所 Isoindoline compounds, preparation method thereof, pharmaceutical composition and application thereof
CN120698985A (en) 2018-12-20 2025-09-26 C4医药公司 Targeted protein degradation
US20230073777A1 (en) * 2019-02-27 2023-03-09 Cullgen (Shanghai), Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
CA3135802A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
US20230069104A1 (en) 2019-06-28 2023-03-02 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN119954801A (en) 2019-07-17 2025-05-09 阿尔维纳斯运营股份有限公司 TAU protein targeting compounds and related methods of use
US20220313829A1 (en) * 2019-08-05 2022-10-06 Shanghaitech University Egfr protein degradant and anti-tumor application thereof
WO2021032935A1 (en) * 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
CN119019369A (en) 2019-10-17 2024-11-26 阿尔维纳斯运营股份有限公司 Bifunctional molecules containing an E3 ubiquitin ligase binding moiety linked to a BCL6 targeting moiety
EP4048668A4 (en) * 2019-10-21 2024-03-13 Celgene Corporation METHOD FOR TREATING BLOOD CANCER AND USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDINE-3-YL)-4-((2-FLUORINE-4-((3-MORPHOLINOAZETIdine-1-YL)METHYL)BENZYL)AMINO) ISOINDOLIN-1,3-DIONE
CA3161497A1 (en) * 2019-12-12 2021-06-17 Kyle W.H. Chan Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
TW202136251A (en) 2019-12-17 2021-10-01 美商凱麥拉醫療公司 Irak degraders and uses thereof
US11850239B2 (en) 2019-12-19 2023-12-26 Ascentage Pharma (Suzhou) Co., Ltd. MDM2 inhibitor and a platinum compound for cancer treatment
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CA3162502A1 (en) 2019-12-23 2021-07-01 Yi Zhang Smarca degraders and uses thereof
CN113149998B (en) * 2020-01-23 2024-05-31 苏州亚盛药业有限公司 Amorphous or crystalline forms of 2-indoline spiroketones or salts, solvates thereof
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2021170021A1 (en) * 2020-02-25 2021-09-02 上海科技大学 Glutarimide skeleton-based compounds and application thereof
EP4110772A4 (en) 2020-02-26 2024-04-03 Cullgen (Shanghai), Inc. TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE
MX2022011602A (en) * 2020-03-19 2023-01-04 Kymera Therapeutics Inc MINUTE MOUSE HOMOLOGOUS 2 (MDM2) PROTEIN DEGRADERS AND USES THEREOF.
WO2021198966A1 (en) * 2020-03-31 2021-10-07 Orum Therapeutics, Inc. Conjugates
CN113509557A (en) * 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 Targeted protease degradation platform (TED)
TW202210483A (en) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Crystalline forms of irak degraders
WO2022042707A1 (en) * 2020-08-27 2022-03-03 Cullgen (Shanghai) , Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
US20230313313A1 (en) 2020-08-27 2023-10-05 Otsuka Pharmaceutical Co., Ltd. Biomarkers for cancer therapy using mdm2 antagonists
JP2023539663A (en) 2020-08-28 2023-09-15 アルビナス・オペレーションズ・インコーポレイテッド Rapidly Progressive Fibrosarcoma Proteolytic Compounds and Related Methods of Use
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
AR124547A1 (en) 2020-12-30 2023-04-05 Kymera Therapeutics Inc IRAQ DEGRADERS AND THEIR USES
MX2023008296A (en) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc ISOINDOLINONE COMPOUNDS.
CN112979657A (en) * 2021-02-03 2021-06-18 福建医科大学 Compound for targeted degradation of Hsp90 protein and preparation method and application thereof
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2022221673A1 (en) 2021-04-16 2022-10-20 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
EP4328219A4 (en) 2021-04-23 2024-11-27 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. SOS1 DEGRADATION AGENTS AND MANUFACTURING PROCESSES THEREFOR AND APPLICATION THEREOF
TW202309030A (en) 2021-05-07 2023-03-01 美商凱麥拉醫療公司 Cdk2 degraders and uses thereof
TW202317546A (en) 2021-07-09 2023-05-01 美商普萊克斯姆公司 Aryl compounds and pharmaceutical compositions that modulate ikzf2
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
JP2024540080A (en) 2021-10-29 2024-10-31 カイメラ セラピューティクス， インコーポレイテッド IRAK4 degraders and their synthesis
JP2025504059A (en) 2022-01-31 2025-02-06 カイメラ セラピューティクス， インコーポレイテッド IRAK Degrader and its Use
EP4499148A1 (en) * 2022-03-30 2025-02-05 Ohio State Innovation Foundation Cyclin-dependent kinase 9 (cdk9) degraders and methods of using thereof
US20250270202A1 (en) * 2022-06-24 2025-08-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted 4-aminoisoindoline compound, preparation method therefor, pharmaceutical composition thereof, and use thereof
JP2025522795A (en) * 2022-06-27 2025-07-17 ピン セラピューティクス、インコーポレイテッド Compounds and methods for degrading casein kinase 1 alpha - Patents.com
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2024051766A1 (en) * 2022-09-08 2024-03-14 标新生物医药科技(上海)有限公司 Molecular glue compound based on cereblon protein design and use thereof
WO2024064316A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
TW202502779A (en) 2023-06-30 2025-01-16 美商金橘生物科技公司 Substituted heteroaromatic amines and uses thereof
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
TW202523291A (en) 2023-11-02 2025-06-16 美商金橘生物科技公司 Degraders and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291562A1 (en) * 2014-04-14 2015-10-15 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US10464925B2 (en) * 2015-07-07 2019-11-05 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
PT989131E (en) 1996-09-13 2003-03-31 Mitsubishi Pharma Corp COMPOUNDS OF TRIENOTRIAZOLODIAZEPINA AND ITS USES FOR MEDICAL PURPOSES
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
RU2305095C2 (en) 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Cis-2,4,5-triphenylimidazolines and pharmaceutical composition based on thereof
JP4361798B2 (en) 2001-12-18 2009-11-11 エフ．ホフマン−ラ ロシュ アーゲー Cis-imidazoline as an MDM2 inhibitor
WO2003106384A2 (en) 2002-06-01 2003-12-24 Johns Hopkins University Novel boronic chalcone derivatives and uses thereof
WO2004043371A2 (en) 2002-11-08 2004-05-27 Irm Llc Methods and compositions for modulating p53 transcription factor
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
EP1633749A4 (en) 2003-02-13 2011-03-02 Us Gov Health & Human Serv DEAZAFLAVIN COMPOUNDS AND METHODS OF USE
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US7829742B2 (en) 2003-12-22 2010-11-09 Johns Hopkins University Boronic acid aryl analogs
US8598127B2 (en) 2004-04-06 2013-12-03 Korea Research Institute Of Bioscience & Biotechnology Peptides for inhibiting MDM2 function
CN1953965B (en) 2004-05-18 2012-07-04 霍夫曼-拉罗奇有限公司 Novel cis-imidazolines
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
DK1809622T3 (en) 2004-09-22 2010-11-08 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and P53
SG176463A1 (en) 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
US7579368B2 (en) 2005-03-16 2009-08-25 Hoffman-La Roche Inc. Cis-imidazolines
TWI447120B (en) 2005-05-30 2014-08-01 Mitsubishi Tanabe Pharma Corp Thienotriazolodiazepine compound and a medicinal use thereof
US7576082B2 (en) 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
EP1919892B1 (en) * 2005-08-31 2013-08-14 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
EP2001868B1 (en) 2006-03-22 2013-07-17 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
BRPI0716092A2 (en) * 2006-08-30 2013-09-17 Celgene Corp compound or a salt, solvate, or stereoisomer thereof, pharmaceutical composition, method for treating, controlling or preventing a disease or disorder, and, single unit dosage form.
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
DK2076260T3 (en) * 2006-09-15 2011-06-27 Celgene Corp N-methylaminomethyl-isoindole compounds and compositions containing them, and methods for their use
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
JPWO2008072655A1 (en) 2006-12-14 2010-04-02 第一三共株式会社 Imidazothiazole derivatives
JP5236664B2 (en) 2007-02-01 2013-07-17 レスバーロジックス コーポレイション Compounds for preventing and treating cardiovascular disease
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
AR065860A1 (en) 2007-03-29 2009-07-08 Novartis Ag 3-IMIDAZOLIL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
AU2008300483B2 (en) 2007-09-21 2013-01-10 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and p53
KR101600634B1 (en) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 Antitumor agent
WO2009151069A1 (en) 2008-06-12 2009-12-17 第一三共株式会社 Imidazothiazole derivative having 4,7-diazaspiro[2.5]octane ring structure
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
NZ586440A (en) 2008-06-26 2011-07-29 Resverlogix Corp Methods of preparing quinazolinone derivatives
AU2010239266B2 (en) 2009-04-22 2015-01-22 Resverlogix Corp. Novel anti-inflammatory agents
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
DK2496582T3 (en) 2009-11-05 2016-03-21 Glaxosmithkline Llc Benzodiazepine-BROMDOMAeNEINHIBITOR.
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
JP2013510860A (en) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン Spiro-oxindole MDM2 antagonist
LT3202460T (en) * 2010-02-11 2019-10-10 Celgene Corporation ARILMETOXI-ISOINDOLINE DERIVATIVES AND COMPOSITIONS INCLUDING THEIR USES
EP2569429A4 (en) 2010-05-14 2013-09-25 Dana Farber Cancer Inst Inc COMPOSITIONS AND METHOD OF METABOLIC MODULATION
MX354217B (en) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Compositions and methods for treating leukemia.
PL2571503T3 (en) 2010-05-14 2015-06-30 Dana Farber Cancer Inst Inc Compositions and their use in treating neoplasia, inflammatory disease and other disorders
WO2011161031A1 (en) 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
TWI535723B (en) 2010-11-12 2016-06-01 密西根大學董事會 Spiro-oxindole mdm2 antagonists
AR084070A1 (en) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc BROMODOMINIUM INHIBITORS AND USES OF THE SAME
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
WO2012116170A1 (en) 2011-02-23 2012-08-30 Ming-Ming Zhou Inhibitors of bromodomains as modulators of gene expression
WO2012151512A2 (en) 2011-05-04 2012-11-08 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
SG194873A1 (en) 2011-05-11 2013-12-30 Sanofi Sa Spiro-oxindole mdm2 antagonists
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2013033268A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bivalent bromodomain ligands, and methods of using same
DE102011082013A1 (en) 2011-09-01 2013-03-07 Bayer Pharma AG 6H-thieno [3,2-f] [1,2,4] triazolo [4,3-a] [1,4] diazepines
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
US20130281399A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
CA2870931A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Isoindolone derivatives
WO2013185284A1 (en) 2012-06-12 2013-12-19 Abbott Laboratories Pyridinone and pyridazinone derivatives
US9675697B2 (en) 2013-03-11 2017-06-13 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
US20160282354A1 (en) * 2013-11-08 2016-09-29 The Broad Institute, Inc. Compositions and methods for selecting a treatment for b-cell neoplasias
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
PL3214081T3 (en) * 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
WO2016105518A1 (en) * 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291562A1 (en) * 2014-04-14 2015-10-15 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US10464925B2 (en) * 2015-07-07 2019-11-05 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof

Also Published As

Publication number Publication date
US10759808B2 (en) 2020-09-01
CA3020281A1 (en) 2017-10-12
CN109311900A (en) 2019-02-05
AU2017246453A1 (en) 2018-11-08
WO2017176958A1 (en) 2017-10-12
JP7001614B2 (en) 2022-02-03
AU2021232732A1 (en) 2021-10-14
EP3440082A1 (en) 2019-02-13
JP2019513746A (en) 2019-05-30
US20190119289A1 (en) 2019-04-25
JP2022050469A (en) 2022-03-30

Similar Documents

Publication Publication Date Title
US10759808B2 (en) Monofunctional intermediates for ligand-dependent target protein degradation
US9187464B2 (en) TRPV4 antagonists
US12209081B2 (en) Heterocycle derivatives for treating TRPM3 mediated disorders
US20060247439A1 (en) Mchir antagonists
EP1487822B1 (en) Pyrrole-2,5-dione derivatives and their use as gsk-3 inhibitors
JP6412102B2 (en) Cycloalkylnitrile pyrazolopyridones as Janus kinase inhibitors
CN100455586C (en) pyrimidothiophene compounds
TW200819443A (en) An imidazole derivative
CN111944012B (en) Aromatic amine targeting AR and BET protein degradation chimeric compound and application thereof
US9556159B2 (en) Renin inhibitor
BR112015011010B1 (en) BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS, THEIR USES, THEIR PREPARATION PROCESSES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM
US9302988B2 (en) Fluoromethyl-substituted pyrrole carboxamides
TW201125864A (en) Novel compounds as casein kinase inhibitors
US11286252B2 (en) Alkene spirocyclic compounds as farnesoid X receptor modulators
EP2976341A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
CN105308046A (en) Kinase inhibitors
TW200533656A (en) Therapeutic agents
WO2016098793A1 (en) Thiazole derivative having cyclic guanidyl group
WO2013024427A1 (en) Novel urea derivatives as tec kinase inhibitors and uses thereof
US10335402B2 (en) Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders
US8318749B2 (en) Quinazoline derivatives as NK3 receptor antagonists
KR20050016991A (en) Mchir antagonists

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION